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Abstract 
Although bone has an intrinsic capacity for self repair, the healing of large bone 
defects that typically present in humans often involves complications which can result 
in failure to heal, leading to delayed union or non-union of the defect. Due to limitations 
of current therapeutic approaches of autografting and allografting, the use of tissue 
engineered scaffolds has emerged. Despite some success with this approach, a major 
limitation is creating functionally vascularised constructs. In addition, scaffolds often 
require an additional stimulus such as a growth factor (GF) to fully heal large fractures. 
However, current GF factor delivery approaches are often associated with limited 
success due to uncontrolled protein release. These issues arise due to the high 
concentrations of protein required to elicit healing which, in turn, is due to the result of 
the short half-life of proteins in vivo. These shortcomings have led to the emergence of 
scaffolds integrated with polymeric carriers which encapsulate, protect and control the 
release of GFs.  
In the context of producing superior bone graft substitutes, this thesis focused on 
fabricating a new generation of scaffolds by functionally enhancing collagen-
hydroxyapatite (CHA) and collagen-glycosaminoglycan (CG) scaffolds, optimised 
specifically for bone repair in our laboratory, in order to make them capable of coupling 
both angio- and osteogenesis for promoting enhanced regeneration. Specifically, this 
research aimed to investigate the potential for controlled release of bone morphogenetic 
protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) encapsulated in 
alginate and poly (lactic-co-glycolic acid) (PLGA) microparticles (MPs) and 
subsequently, to investigate whether a series of functionalised scaffolds incorporating 
this system could promote enhanced bone repair in a critical size defect in vivo model. 
As a GF-free alternative approach, a final aim of this research was to develop and 
characterise a collagen-based scaffold incorporating pro-angiogenic and pro-osteogenic 
cobalt-bioactive glass (BG) and to assess the in vitro ability of the material to promote 
these processes.   
In the study shown in Chapter 2 of this thesis, feasible preparation methods for 
GF-eluting MPs were established. It was shown that PLGA MPs fabricated by double 
emulsion and spray dried alginate MPs were capable of not only controlling and 
prolonging the release of two of the main GFs pertinent to bone repair but also retaining 
their bioactivity. Additionally, it was demonstrated that the release kinetics of GFs can 
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be tailored by using different polymers for encapsulation. In Chapter 3 it was shown 
that with an optimised fabrication process, it was possible to develop GF-releasing CHA 
scaffolds containing MPs without interfering with the structural properties of the 
scaffold previously optimised for bone repair. Additionally, sustained release of 
bioactive GFs from the optimised scaffolds was demonstrated with kinetics resembling 
the in vivo condition: the early expression of VEGF from alginate MPs and sustained 
release of BMP-2 from PLGA MPs. Hence, functionalised scaffolds were capable of 
eliciting a pro-angiogenic and pro-osteogenic response in vitro. Having demonstrated 
the functionality of these materials in vitro, VEGF and/or BMP-2-eluting scaffolds were 
implanted in a rat calvarial defect model where they enhanced healing compared to non-
eluting scaffolds as well as non-treated animals. Ultimately, VEGF-releasing CHA 
scaffolds accelerated healing to the greatest extent offering an ideal platform to promote 
both vasculogenesis and bone repair. In Chapter 5 a GF-free biomaterial alternative, a 
novel scaffold was successfully fabricated by the incorporation of cobalt-eluting BG 
particles into a CG scaffold. This material was capable of stimulating angiogenesis in 
vitro via the release of cobalt, a known hypoxia mimic, as well as osteogenesis via the 
dissolution of osteoinductive BG particles. This study indicated that an angiogenic and 
osteogenic response may be achievable exclusively through a GF-free biomaterials 
based approach. 
Collectively, the research presented in this thesis has led to the development of a 
new generation of functionally enhanced collagen-based scaffolds. Specifically, 
polymeric MPs were developed that were capable of controlling the release of bioactive 
GFs pertinent to bone repair. Functionalised scaffolds containing MPs were capable of 
the sustained release of bioactive concentrations of VEGF and BMP-2 from MPs within 
the matrix. The alginate-VEGF scaffold emerged as the GF-eluting scaffold which 
promoted the most accelerated neovascularisation and bone repair in vivo. Furthermore 
this thesis has shown that novel cobalt-BG containing CG scaffolds enhanced cell-
mediated osteogenesis and angiogenesis representing a desirable, economical, 
alternative to GF-based delivery for the regeneration of bone tissue. These novel 
functionalised scaffolds offer the advantage of off-the-shelf availability and lack the 
need to for in vitro cell culture. In addition, the delivery systems developed in this thesis 
have enormous potential in regenerative medicine, as they could be tuned in terms of 
the composition of the collagen-based scaffold and released therapeutic to promote 
healing of a diverse range of tissues and organs in addition to bone.  
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Chapter 1: Introduction and Literature Review 
 
1.1 Tissue engineering and regenerative medicine 
The term “tissue engineering” (TE) emerged in the 1980’s when the US 
National Science Foundation’s (NSF) scientific review panel convened and suggested 
the name to identify proposals that sought to grow tissue in the laboratory.  It was later 
expanded to the interdisciplinary approach of exploiting living cells to regenerate 
diseased, damaged or lost tissues inside the patient’s body.  This definition also 
encompasses the initiative of growing structures outside the body for the purpose of 
drug discovery or diagnostics, or alternatively, that can then be re-implanted in order to 
replace tissues. This then led to the coining of the term “regenerative medicine” (RM)  
in 1998 which refers to the approach of re-establishing the structure and function of 
tissues and organs as opposed to the repair of damaged tissue [13]. The terms tend to be 
used interchangeably and occasionally together- (TERM). Traditional approaches for 
replacing damaged tissue include the use of autografting and allografting. Autografting 
involves tissue transplantation from one part of the body to another within the same 
individual and is regarded as the gold standard for treatment [14]. However, there are 
problems associated with this approach including lack of donor availability and risk of 
infection [15]. Allografting involves the grafting of tissue obtained from a donor.  
However, such grafting procedures present various problems such as donor tissue 
shortages, rejection by the patient’s immune system, risk of infection and disease 
transmission from donor to patient and graft-versus-host-disease [16]. Another approach 
for the restoration of organ function is the use of prosthesis, commonly used in hip, 
knee and heart valve replacement. The use of titanium implants for hip and knee 
replacement has a number of inherent shortcomings such as the induction of an 
inflammatory response causing scar tissue formation, loosening of the prosthesis and a 
reduction in joint mobility [17].  
There is a widening gap between tissue/organ donors and recipients which can 
be primarily attributed to increased life expectancy. In the United States alone, it has 
been reported that approximately 120,000 people died in 2010 from kidney failure and 
597,000 died from heart disease [18].  Hence, the field of TE aims to address this issue 
by developing new substitutes or scaffolds as alternative treatment prospects. The 
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global market for TE is estimated at $59.8 billion dollars and is expected to grow to 
$89.7 billion by 2016 [19].  There are three main requirements typically described for 
the development of a successful TE construct: 1) cells to facilitate required tissue 
formation, 2) a biomaterial or scaffold that provides structural, morphological and 
biological cues or 3) growth factors or biophysical stimuli to direct cell growth and 
differentiation on the scaffolds (Fig. 1.1).  
 
Fig. 1.1 The tissue engineering triad. The three traditional requirements of a successful TE 
construct consisting of cells, biomaterials and signalling molecules, adapted from O’Brien [20]. 
 
 
1.2 Bone formation and repair 
The development and repair of bone tissue involves a myriad of molecular, 
cellular, biochemical and mechanical cues working in concert. This is due to the 
dynamic nature of bone, coupled with its strength and remodelling capacity. It provides 
biomechanical support, permitting locomotion, forming new blood cells and promoting 
calcium homeostasis. Bone is a composite material primarily consisting of an organic 
phase of collagen fibres that make up one third of bone mass and are strong in response 
to tension allowing bone to tolerate twisting and bending. This organic matrix 
comprises of 95 % collagen type I and 5 % proteoglycans and non-collagenous proteins. 
The inorganic hydroxyapatite (HA) phase occupies the majority of the remainder and 
imparts a high compressive modulus to bone, consisting of nanoHA mineral and salts 
such as sodium, magnesium, fluoride and calcium carbonate. Although HA is brittle, the 
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combination of both phases results in a protein-crystal interaction which results in a 
stabilised framework of collagen fibres to yield a strong, somewhat flexible material 
that is highly resistant to impact loading [21].  
1.2.1 The cellular component of bone 
Cells form a small but obviously essential 2 % of the bone mass. 
Osteoprogenitors or preosteoblasts are immature progenitor cells derived from 
mesenchymal cells with the potential to differentiate into osteoblasts [22]. During the 
process of bone formation fully differentiated osteoblasts are responsible for laying 
down new matrix and depositing collagen type I or osteoid. NanoHA crystals align on 
collagen or osteoid, a nucleation site forms which leads to mineralisation, bone 
formation and maturation. Mature bone cells, or osteocytes, comprising the majority of 
the bone cell population, are derived from osteoblasts incorporating into the bone 
matrix. They play a mechanosensory role in bone with a pivotal role in functional 
adaptation of bone and bone turnover [23]. Osteoclasts are multinucleated cells derived 
from the differentiation of monocytes/macrophage precursor cells located near the bone 
surface. They are the main resorptive cell of bone governing skeletal formation and 
skeletal mass [24]. During fracture repair, inflammatory cells, vascular cells, 
osteochondral progenitors, and osteoclasts play a key role [25].  
1.2.2 Osteogenesis  
The process of osteoblast differentiation and bone formation is referred to as 
osteogenesis. Essentially, there are two types of bone formation: intramembranous 
ossification and endochondral ossification. The process of intramembranous ossification 
begins with mesenchymal stem cells (MSCs) which undergo osteogenesis during 
embryonic development and is the process responsible for the formation of the flat 
bones e.g. skull [26]. During endochondral ossification the MSCs first condense to form 
a temporary cartilage model onto which bone is formed. This process forms the 
majority of bones including the bones of the axial and appendicular system [27]. 
Osteoblast differentiation and maturation in vitro occurs in a developmental sequence 
involving 3 distinct stages: 1) proliferation, 2) extracellular matrix (ECM) deposition 
and 3) mineralisation [27]. Each stage of osteoblast differentiation is characterised by a 
stage-specific gene expression profile [27]. This process involves a number of 
physiological mediators including cytokines, growth factors (GFs) and hormones which 
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can modify or abrogate bone-cell phenotype. Osteoblast differentiation during both 
intramembranous and endochondral ossification is transcriptionally regulated by the 
Cbfa1/Runx2 pathway [27, 28] which is essential but not sufficient to support 
maturation of osteoblasts [29, 30]. It is upregulated by GFs such as bone morphogenetic 
protein (BMP), transforming growth factor (TGF), basic fibroblast growth factor 
(bFGF) and insulin-like growth factor (IGF). 
Osteoblasts express various phenotypic markers during osteogenesis (Fig. 1.2) 
such as high alkaline phosphatase (ALP) activity, an early marker of ECM production 
expressed following the downregulation of cell proliferation. At a later point ALP 
declines and late stage markers of mineralisation and maturation such as osteopontin 
(OP) and osteocalcin (OC) are expressed. These non-collagenous proteins play a role in 
regulating osteoclast attachment, matrix resorption and bone remodelling (OP) [31] 
whereas OC, a marker of mature osteoblasts, regulates the mineral phase in bone and 
promotes osteoclast differentiation [1].  
 
Fig. 1.2 Expression of phenotypic markers of bone formation with time, taken from Stein and 
Lian [1]. AP-1, H4 and COL I are markers of cell proliferation. AP-1 represents c-fos and c-jun 
which are cell growth regulated genes. H4 histone is a cell cycle gene reflecting DNA synthesis. 
COL I is type 1 collagen. Alkaline Phosphatase (AP) is expressed during matrix maturation. 
Osteopontin (OPN) and osteocalcin (OCN) are expressed and Ca2+ deposited during matrix 
mineralisation.  
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1.2.3 Bone fracture repair 
The fracture healing process is a combination of bone formation (anabolic) and 
bone resorption (catabolic) responses performed by the previously discussed osteoblasts 
and osteoclasts respectively. Therefore, maintaining a balance between these processes 
is fundamental in conserving healthy bone. Bone fracture repair (Fig. 1.3) by callus 
production is initiated as a result of disruption to blood vessels resulting in bleeding 
from the bone and soft tissue. This is followed by haematoma formation and an 
inflammatory response [32]. The development of a fibrinous blood clot plays a role in 
the release of GFs and cytokines such as platelet-derived growth factors (PDGF) and 
BMPs. These biomolecules provide the necessary signals to initiate progenitor cell 
recruitment and migration triggering differentiation of osteoprogenitor cells into osteoid 
forming osteoblasts. The periosteum undergoes intramembranous ossification or direct 
bone formation to form an external callus to stabilise the fracture, which is eventually 
replaced with a hard callus of woven bone. The overall process consists of the 
remodelling of the soft callus by osteoblasts and osteoclasts and remodelling of the hard 
callus to lamellar bone over a period of 6-8 weeks [33]; the size of the callus reverts 
back to that of existing bone at the defect site and the vascular supply returns back to 
normal. However, fracture repair is only successful if the blood supply and cellular 
components of the endosteum and periosteum are intact. 
 
Fig. 1.3 Events and time course of a bone fracture repair [21]. Initially a blood clot or fracture 
haematoma forms. The internal and external callus form to stabilise the edges of the defect. The 
external callus is then replaced by bone and areas of the bone around the defect are remodelled. 
The initial location of the fracture is remodelled over time. 
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1.2.4 The role of angiogenesis in bone repair 
Angiogenesis precedes bone formation and is an essential process in 
endochondral bone formation and homeostasis. The role of angiogenesis in bone repair 
was recognised as early as 1763 by Albrecht von Haller who suggested that ‘the origin 
of bone is the artery carrying the blood and in it the mineral elements’ [34]. These early 
predictions have led to the identification of numerous factors involved in this complex 
process and inspired a search for the genetic and molecular mechanisms of blood vessel 
formation. The mechanism of angiogenesis is coordinated by genes encoding for 
cytokines and GFs such as vascular endothelial growth factor (VEGF165) which initiates 
vessel formation. Next, basic fibroblast growth factor (bFGF), a mitogen for fibroblasts 
and endothelial cells (ECs), and angiopoietin-2 (Ang-2) act to disrupt pre-existing 
vessels and promote cell proliferation and migration leading to immature vessel 
formation. Angiopoietin-1 and platelet derived growth factor (PDGF) initiate vessel 
maturation and stabilisation and lead to the formation of new vascular networks [35]. 
The presence of microvascular networks support and nourish the chondrogenic, 
mesenchymal and osteogenic cells necessary for bone repair. When blood vessels are 
lacking in and around bone the result is decreased bone formation and bone mass. 
Consequently 5-10 % of the 6 million bone fractures per year in the U.S fail to heal 
normally due to lack of vascularisation. Induction of this process is therefore a desirable 
achievement for successful bone repair. Therefore, the success of any TE based strategy 
for repair thus requires the ability to produce and/or support functional vasculature that 
can metabolically provide for these cells as well as fully integrate with the host tissue. 
1.3 Biomaterials for bone tissue engineering 
Although bone has an intrinsic capacity for self repair, the healing of large bone 
defects that typically present in humans often involves complications. This can result in 
failure to heal, leading to delayed union or non-union of the defect which then requires 
surgical intervention. Bone thus holds second place for most common transplanted 
tissue next to blood. Over 2.2 million bone grafting procedures are carried out 
worldwide every year [36]. Grafts are used in a variety of procedures including 
maxillofacial reconstruction, spinal fusion operations, replacing diseased bone and as 
bone void fillers for non-union fractures. Bone grafts offer mechanical support, fill 
defect areas and accelerate bone healing [37, 38]. Specifically, for the treatment of non-
union fractures, the preferred choice of a bone substitute remains the autograft. As well 
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as the problems with autografts described above, the failure rates associated with this 
approach are as high as 30 % [39]. Allografts are a common alternative to autografts but 
also have limitations. Given the complications with the current clinical gold standards, 
the bone TE field aims to address these issues typically using TE scaffolds which mimic 
the natural ECM by serving as templates for tissue formation. They should provide sites 
for cell attachment, mechanical stability within the defect site, ideally have a porous and 
interconnected pore network for interaction with the host that encourages cell migration, 
nutrient and waste movement [40] and vascularisation by both seeded cells and the host 
tissue. The significance of these properties will be described in further detail below. 
Recently a series of collagen-based scaffolds have been developed in our 
laboratory for the purpose of bone repair. These include collagen, collagen 
glycosaminoglycan (CG) and collagen hydroxyapatite (CHA) scaffolds which have 
shown excellent healing capacity when implanted in critical size defects [41-43]. 
However, in order to treat large bone defects, an extra agent in the form of a therapeutic 
biomolecule is often combined with the scaffold. Scaffolds may therefore actively 
participate in the regenerative process by serving as matrices for the release of drugs, 
genes, GFs and other therapeutic biomolecules. As such, the overall aim of this thesis 
was to generate a new generation of scaffolds for bone repair applications capable of 
coupling both angio- and osteogenesis via the controlled delivery of the pro-angiogenic 
and pro-osteogenic biomolecules described in the following sections. 
In order to facilitate adequate tissue formation, the ideal scaffold must possess a 
number of macro and microstructural properties [44]. These properties are known to 
affect cell signalling, survival, growth, organisation, propagation, and differentiation. 
The biocompatibility and cytocompatibility of the scaffold itself and the by-products of 
its degradation are important factors which must be considered in scaffold design. Cells 
must be able to adhere to and proliferate throughout the material before depositing new 
matrix. In vivo, the scaffold must elicit a negligible immune reaction so as not to impair 
healing or be rejected by the body. In addition architecture is an important property of 
scaffolds for bone repair. It is generally agreed that a highly porous, interconnected 
structure and a large surface area are conducive to cell infiltration as well as the 
diffusion of nutrients, oxygen and waste [45]. Without a sufficiently porous structure, 
core degradation of scaffolds due to a lack of vascularisation, which leads to inefficient 
transfer of waste and nutrients in the centre of the scaffold, can occur. This is because 
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cells at the centre of the scaffold rely on the limits of diffusion of nutrients and oxygen 
[46].  
Another important consideration is scaffold pore size which may need to be 
varied depending on the cell type used. Cell interaction with scaffolds is dependent on 
ligands on the material surface. Collagen for example naturally possesses these ligands 
in the form of Arg-Gly-Asp or RGD binding sequences. The ligand density of the 
material is critically dependant on the surface area which is in turn influenced by pore 
size. A smaller mean pore size leads to a higher surface area of the material allowing 
more cells to bind. On the other hand the pores need to be large enough to allow cells to 
penetrate and migrate through the material [47-50]. 
In relation to the repair of load-bearing defects, scaffolds should be designed to 
have sufficient mechanical strength to maintain the spaces required for cell infiltration 
and matrix metabolism during in vitro culture. This structural integrity should continue 
from the point of cell seeding to remodelling by the host tissue in vivo. As such, the 
scaffolds must be able to withstand the hydrostatic pressures in vivo, especially with 
load-bearing tissue such as bone and articular cartilage. In addition, the rate of 
biodegradation should coincide with the rate of tissue formation in vivo such that the 
scaffold will persist for a sufficient time until the ingrowing tissue can support itself 
whilst replacing the degrading scaffold [51]. Furthermore, to allow for commercial and 
clinical viability, scaffold production should be easily and cost effectively scaled up to 
batch production to the standard of good manufacturing practice (GMP). Ideally the 
clinicians preferred choice of material will be available ‘off-the-shelf’ without the 
requirement for prior in vitro engineering.  
Biomaterials used in bone TE fall into three main categories including: 1) 
synthetic bioceramics, 2) synthetic polymers and 3) natural polymers, formulated into a 
variety of structures. These include porous scaffolds for tissue repair based on the 
natural polymer collagen and microparticles designed for therapeutic drug delivery 
based on natural and synthetic polymers, which will both be described further in this 
thesis. 
1.3.1 Ceramic constructs 
Bioceramics are inorganic bioactive materials that possess osteoconductive and 
in some instances osteoinductive properties as well as high compressive strength, 
making them attractive for bone replacement. The most common bioceramics generally 
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contain calcium phosphate (CaP). These CaP ceramics are used extensively by surgeons 
as bone substitute materials and include calcium sulphate, tricalcium phosphate (β-
TCP), synthetic HA or biphasic calcium phosphate (a mixture of TCP and HA) [52]. 
HA and related CaPs have excellent biocompatibility due to their close resemblance to 
bone mineral structure as well as the ability to directly bind to bone. Indeed, a large 
body of in vitro and in vivo studies have shown that CaPs (particularly those 
incorporating HA), support attachment, proliferation, infiltration and differentiation of 
MSCs and osteoblasts. However,  there are a number of drawbacks associated with 
CaPs, including rapid degradation (in the case of TCP and calcium sulphate) and slow 
degradation of HA in vitro and in vivo [53]. Therefore, a major challenge in bone TE is 
to generate a mechanically strong material that can degrade at an appropriate rate while 
stimulating the body’s natural regenerative ability. 
Glass ceramics including bioactive glasses (BG), which will be outlined in the 
next section, have also been utilised for bone repair and are excellent bioactive materials 
for the purpose of bone regeneration [54]. They have been shown to be capable of 
bonding to bone more rapidly than other bioceramics [55]. These materials however, 
tend to be brittle with poor tensile properties, both of which are limitations from a TE 
perspective [56]. Given the composition of bone, one of the most efficient ways of 
developing biomimetic and bioactive biomaterials is through the combination of 
osteoconductive bioceramics and ductile biopolymers. As such, several collagen 
composite materials including CaPs, HA and nHa-based materials have been developed 
in our Tissue Engineering Research Group at RCSI [57-59]. The bone regeneration 
capacity of a number of these composites specifically will be investigated as part of this 
thesis, including CHA and collagen-bioactive glass composite scaffolds both described 
below. 
1.3.1.1 Bioactive glass scaffolds 
Bioactive glasses (BGs) are inorganic, surface active bioceramics which have 
been fabricated as scaffolds (Fig. 1.4) for the purpose of in situ bone regeneration [6, 
60-62]. They are capable of stimulating osteoprogenitor cells via the release of soluble 
silica and calcium ions [6] the mechanisms of which will be discussed in more detail in 
Section 1.4.2. Furthermore, they are resorbable, osteoconductive and osteoinductive 
[63]. Exposure of BG to biological fluids initiates the formation of a hydroxyl carbonate 
apatite (HCA) layer on the surface of the glasses following glass dissolution [64]. It is 
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this layer that forms the bond between the BG and bone in a more rapid manner than 
other bioactive ceramics [6]. Moreover, the HCA layer may interact directly with 
collagen fibrils from the host bone via the production of nodules but may also recruit 
osteoprogenitor cells to the glass surface leading to the formation of bone matrix which 
can interact with collagen fibrils. A hybrid scaffold consisting of BG particles within a 
collagen-based scaffold will be explored later in this thesis for its in vitro osteogenic 
and angiogenic potential as a potential GF-free platform for enhancing bone repair. 
 
Fig. 1.4 Stages involved in the reaction sequence leading to HCA formation according to Hench 
and colleagues [54, 55]. The first three stages involve reactions between the silicate surface and 
the surrounding fluid as follows: (1) Calcium and H
+
 exchange and (2) breakage of Si–O–Si 
bonds, leading to the formation of Si–OH groups; (3) repolymerization: 2Si–OH→Si–O–
Si+H2O, (4) the formation of amorphous calcium phosphate (ACP) and (5) ACP→HCA 
crystallization that involves uptake of additional ions, e.g. OH
−
 and Na
+
 [65]. 
1.3.2 Synthetic polymers 
Synthetic polymers are excellent materials for TE applications since they can be 
manipulated and tailored in terms of their strength, porosity, architecture and stiffness. 
There has been extensive research into synthetic polymers such as polylactides (PLA), 
polyglycolides (PGA), co-polymers poly(lactide-co-glycolides) (PLGA), 
polycaprolactone (PCL) and polyethylene-glycol (PEG) for use in scaffolds as well as 
for drug delivery in TE [66, 67]. PLA and PLGA are often used to fabricate scaffolds 
with higher mechanical integrity than natural polymers. Although these materials are 
versatile and Food and Drug Administration (FDA) approved, they suffer in terms of 
their slow degradation and acidic byproducts, which can trigger an inflammatory 
response ultimately impeding tissue formation [68]. They also lack natural 
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osteoconductivity compared to allografts and for this reason are often combined with 
ceramics such as hydroxyapatite (HA) and calcium phosphate [69].  
1.3.3 Natural polymers 
Much TE research focuses on natural origin polymers since naturally-derived 
polymers offer numerous advantages due to their low cost, safety (in terms of minimal 
inflammatory response) and, for some materials, FDA approval [70-73]. Naturally-
derived polymers typically employed include collagen [41], chitosan [74, 75], alginate 
[76], fibrin [77] and glycosaminoglycans (GAGs) [78] which can allow cells to adhere, 
proliferate and differentiate without the drawbacks of cytotoxicity and inflammatory 
reactions, commonly associated with synthetic polymers. Although natural polymers 
can be difficult to process and lack the mechanical stability required to withstand the 
forces which exist in the bone environment they can be structurally reinforced through 
crosslinking techniques for example using calcium chloride [70, 79]. They offer several 
advantages related to their excellent biocompatibility and non-toxic degradation 
products. A number of scaffolds based on the natural polymer collagen have been 
fabricated and optimised in our laboratory for bone repair and these will be described in 
further detail below. 
1.3.3.1 Collagen-based scaffolds 
Collagen and collagen-based scaffolds have been shown to offer many 
advantages when used as biomaterials in TE [47, 80, 81]. In general, collagen type I is 
the most abundant protein in the human body as well as being a key element of the 
ECM where it offers strength to tissues such as blood vessels, tendon, cartilage and 
bone [48, 51]. Specifically, scaffolds comprised of this macromolecule have shown 
much potential as bone graft substitutes since it is the major organic component of bone. 
It has also been shown that type I collagen allows for osteoblastic differentiation in vitro 
and osteogenesis in vivo [82-84]. This scaffold forms the basis of commercially 
available products such as INFUSE® where it provides a matrix for protein delivery. In 
particular, highly porous collagen-based scaffolds offer excellent biocompatibility and 
biodegradability. Many hybrid composites exist in bone TE which show superior 
biological and physical properties compared with the single component (collagen). A 
number of these composite scaffolds will be used in this thesis and these will be 
described below. 
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1.3.3.2 Collagen-glycosaminoglycan scaffolds 
The functionality and regenerative capacity of collagen can be enhanced by the 
addition of linear polysaccharides in the form of GAGs. These are found within the 
ECM and on cell surfaces and are involved in cell-matrix interactions and wound 
healing. The most predominant GAG is chondroitin sulphate and in combination with a 
collagen scaffold can provide cells with an environment similar to the native ECM on 
which cells attach to, migrate, infiltrate and differentiate within [85]. The concept of 
using crosslinked CG scaffolds (Fig. 1.5) to regenerate skin tissue was first introduced 
by Prof. Ioannis Yannas, one of the initial pioneers in the field of TE [47]. This 
composite scaffold was later used for a number of other applications including nerve 
[86], cartilage [87] and, in our lab, bone regeneration [88]. These early studies have 
shown that in comparison to GAG-free collagen polymers which degrade rapidly, CG 
copolymers degraded over extended periods of time so that the level of tissue formation 
and scaffold degradation coincided with that of the innate healing process [89, 90]. 
More recently various studies have been conducted within our laboratory to further 
optimise the CG scaffold specifically for bone repair applications.  
 
 
Fig. 1.5 MicroCT image of collagen-glycosaminoglycan scaffold. Inset is an SEM image of 
scaffold microstructure [91]. Scale bar indicates 1 mm and inset is 100 µm. 
 
CG scaffolds offer several advantages over the collagen alone scaffold since 
chondroitin sulphate can be easily crosslinked to generate stable bonds with collagen, 
and varying the crosslinking density results in a CG scaffold with more improved 
mechanical properties. The primary methods for crosslinking involve: 1) physical 
crosslinking using dehydrothermal (DHT) crosslinking and 2) chemical crosslinking 
using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) and N-
hydroxysuccinimide (NHS) which will be used in this thesis [92]. Furthermore, CG 
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scaffold composition and pore size have previously been optimised in our lab for bone 
repair [49, 50, 78, 92, 93]. It has been shown that a cell-free CG scaffold and a MSC 
seeded scaffold can enhance bone formation [41-43] leading to the healing of minimally 
loaded calvarial defects in vivo [41, 48, 85, 92]. However, in order to facilitate bone 
repair in load bearing defects, collagen-based scaffolds which incorporate a ceramic 
phase have been developed with significant success in our group. 
1.3.3.3 Collagen-hydroxyapatite scaffolds 
Native bone consists of type I collagen and HA and these components make an 
excellent choice for a composite biomaterial capable of assisting and promoting bone 
regeneration [82]. As mentioned above, collagen has poor mechanical properties and 
ceramics such as HA tend to be brittle. Thus, the generation of a collagen-
hydroxyapatite (CHA) composite scaffold results in a superior material which maintains 
the beneficial properties of each component. Recent work in our laboratory has led to 
the development of a highly porous biomimetic CHA scaffold that has a high level of 
pore interconnectivity, enhanced mechanical strength, permeability and cellular 
bioactivity. This scaffold is produced using a patented fabrication process [94]. In a 
study by Gleeson et al. (2010), it was found that the addition of 200 weight percentage 
(wt %) HA relative to collagen content, resulted in an increase in scaffold stiffness and 
had a 10 fold increase in pore interconnectivity while also attaining 99 % porosity [57]. 
Furthermore, CHA has shown enhanced healing compared to CG scaffolds as a result of 
the calcium phosphate phase, which has previously been shown to produce an 
osteoinductive response [41, 95, 96]. 
All of the collagen-based scaffolds used in this thesis namely CHA, CG and BG 
scaffolds, were fabricated using a freeze drying-based lyophilisation technique. This 
involves the freezing of a collagen suspension, which traps the collagen fibres within 
the growing ice crystals to form a continuous network. The subsequent sublimation of 
ice during the drying phases leads to a highly porous material. The final freezing 
temperature largely determines the pore size of the resulting materials which can range 
from 85-325 µm [49, 91, 93]. Furthermore, crosslinking the material can enhance the 
mechanical properties and delay scaffold degradation. These scaffolds will be 
investigated throughout this thesis in combination with the therapeutic biomolecules 
outlined in the following sections. 
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1.4 Bioactive molecules for tissue engineering 
1.4.1 Growth factors 
GFs are signalling molecules which guide tissue formation by mimicking native 
reparative signalling cascades [97]. These signalling molecules are large polypeptides 
that complete their effects through binding to transmembrane receptors on target cells 
(Fig. 1.6). GFs are released during the post-injury tissue repair response where they 
provide instructive cues to cells involved in matrix production and organisation leading 
to angiogenesis, scar and tissue formation [98]. A number of external cues for 
increasing GF levels exist including the production of recombinant (rh) GFs, the 
delivery of genes to produce GFs and purification from cell extracts [99]. The most 
widely applied osteoinductive factors currently used in TE applications for the treatment 
of orthopaedic injuries are BMPs [100]. Furthermore, angiogenic factors such as VEGF 
are increasingly studied given the previously outlined role of VEGF in bone repair [101-
103]. However, soluble cytokine GFs such as BMP-2 and VEGF have considerably 
short half-lives in vivo (from minutes to hours) owing to their rapid degradation as a 
result of enzymatic, chemical or physical degradation. The concentration of GF, the 
duration of exposure to the GF, their chemical identity and cellular context all dictate 
the eventual fate of cells either developmentally or in the adult. Of relevance to this 
thesis, GF concentration can affect receptor synthesis. Very high concentrations can 
saturate GF receptors disrupting its signalling effect and in some instances causing 
embryonic lethality [104]. During developmental signalling FGF concentrations are 
involved in tissue fate determination whereby higher concentrations drive lung 
development and lower concentrations drive liver development [105]. Therefore, it is 
essential that a suitable delivery device is chosen to protect the integrity and bioactivity 
of the GF as well as delivering suitable concentrations locally. 
The effects of GFs are broad, multifunctional and can be classified as a 1) 
mitogenic effect – stimulating cell division, 2) chemotactic effect – inducing cell 
migration, 3) apoptotic effect – triggering cell death, 4) morphogenic effect – inducing 
cell differentiation, 5) metabolic effect – controlling cell metabolism and 6) 
combinations of the aforementioned effects [9, 106]. GFs can exert these effects through 
autocrine, paracrine, endocrine, intracrine, juxtracrine and pleitropic secretory pathways 
triggering these events by acting on the same cell type from which they were secreted, 
on adjacent cells, distant cells, when the GF/receptor complex is internalised, cells 
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directly opposite the complex and where multiple cells produce the same GF which can 
act on many cell types [107]. Collectively these processes illustrate the multitude of 
downstream signalling events and responses that can result from GF administration or 
secretion.  It is widely accepted that GFs applied or produced at a defect site can drive 
MSC differentiation and tissue regeneration, augmenting the self-healing capacity of an 
individual [108].  
 
Fig. 1.6 Signal transduction mechanism by growth factors (GFs) taken from Lee et al. [3]. GFs 
secreted by producer cells bind transmembrane receptors and the signal is translated by complex 
signal transduction machinery to elicit specific biological responses in the target cell such cell 
migration, differentiation and proliferation. The extracellular matrix can also influence this 
process by releasing GFs upon degradation or influencing cell migration towards gradients of 
GFs. 
 
1.4.1.1 Bone morphogenetic proteins 
Research related to osteogenesis has identified BMP as the most important GFs 
in bone formation and healing. It enables skeletal tissue formation during 
embryogenesis and throughout adulthood as well as bone growth and repair [109]. 
BMPs are member of the TGF-β superfamily [110]. The significance of BMPs was first 
discovered in 1965, when Urist revealed the formation of new ectopic bone from a 
demineralized bone matrix and suggested the presence of osteoinductive molecules that 
guided the formation of bone forming osteoblasts [111]. However, it was not until 1988 
that Johnson et al. found the possibility of the clinical application of BMP, where 
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endogenous bone was somewhat purified and utilised in human patients to heal long 
bone non-unions and segmental defects [112]. To date, there are more than 30 BMPs 
and among them BMP-2, -4, and -7 are each reported to stimulate new bone formation 
at ectopic sites in vivo in critical sized defects [110, 113]. In particular, BMP-2 is 
known as a primary GF in bone formation involved in the commitment of multipotent 
stem cells to the osteogenic lineage. Furthermore, preclinical and clinical studies have 
shown that BMP-2 can be utilized in various therapeutic situations such as bone defects, 
non-union fractures, spinal fusion, osteoporosis and root canal surgery. Additionally, 
recombinant human BMPs (rhBMP) have been isolated by purification and cloning and 
are widely available for preclinical applications [114]. Recently BMP-2 and BMP-7 
have been approved by the FDA for very specific indications. In particular, Medtronic’s 
INFUSE®, a collagen sponge soaked with recombinant BMP-2, is the market leader in 
the bone graft field with 44 % of the $1.9 billion market. However, it has been 
associated with numerous side effects and complications such as bone overgrowth due 
to uncontrolled release of BMP-2 [115] thus demonstrating the need for alternative drug 
delivery strategies capable of controlling GF release to particular sites. Current BMP 
release systems as well as emerging alternatives for the controlled delivery of BMP-2 
and other GFs will be discussed in more detail below and are the major focus of this 
thesis (Chapters 2-4). 
The effects of BMPs are mediated by signalling through BMP receptor I and II 
and other downstream molecules such as Smad 1, 5 and 8 proteins (Fig. 1.7). Following 
BMP receptor activation, the Smad proteins transmit the intracellular signal which 
stimulates the transcription of specific genes such as runx2 [116] and mediates bone 
formation. BMP function is extracellulary regulated by BMP-binding proteins such as 
noggin and chordin which can bind BMP, preventing them from interacting with their 
surface receptors. Alternatively the Smad protein, Smad 6 can bind to receptor I and 
prevent interaction with Smad 1, 5, and 8 [117]. Additionally, Smurf1, a ubiquitin 
ligase, functions to degrade Smad proteins. Indeed overexpression of Smurf1 has been 
shown to inhibit differentiation and bone formation postnatally [118]. Essentially, 
regulation of BMP signalling can significantly increase bone formation and this process 
can be controlled by an array of molecules in cells expressing BMP receptors.   
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Fig. 1.7 Bone morphogenetic protein (BMP) signalling mediated by BMP receptors I and II, 
taken from Liu et al. [4]. BMP-2 binds to its receptors I and II. BMPRII phosphorylates and 
activates BMPRI which subsequently phosphorylates receptor-activate Smad proteins (R-
Smads). The interaction of co-Smad then mediates entry to the nucleus initiating the induction 
of osteoblast specific genes. The Smad proteins positively or negatively control gene expression 
by the interaction with co-activators or co-repressors. Inhibitory (I-Smads) block BMP 
signalling by preventing R-Smad/co-Smad interaction. Noggin also blocks signalling by 
blocking BMP ligand/receptor interaction. 
 
1.4.1.2 Vascular endothelial growth factor 
Bone, as a highly vascularised tissue, requires the formation of new blood 
vessels for tissue to grow beyond 200 µm [46]. VEGF has been implicated as a critical 
regulator of neovascularisation involved in initiating new vessel formation and is also 
fundamental to the osteogenic response in fracture healing [119]. VEGF has been 
shown to be essential for intramembranous and endochondral bone formation [120]. 
The primary function of VEGF is the stimulation and migration of endothelial cells 
(ECs) (Fig. 1.8); however there is also strong evidence that VEGF modulates the 
recruitment, survival and activity of osteoblasts and osteoclasts with the discovery of 
VEGF receptors on osteoblast cells. VEGF also mediates the activity of osteoinductive 
factors such as insulin-like growth factor (IGF), FGF-2 and TGF-β1. Unfortunately, 
systemic delivery of VEGF has been associated with side effects in non-target sites such 
as hypotension, hyperpermeable vessels, tumor growth and uncontrolled 
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neovascularisation [99, 121-124]. As an alternative approach, VEGF can be used in TE 
to vascularise materials such as scaffolds since VEGF can induce vessel formation (Fig. 
1.8). Successful TE approaches incorporating rhVEGF should provide a sustained 
release VEGF profile (Fig. 1.8) for the formation of stable vasculature otherwise vessels 
regress. VEGF will be investigated in this capacity in Chapter 2, 3 and 4 of this thesis. 
 
Fig. 1.8 The use of VEGF for vascularising tissue engineered scaffolds, taken from Place et al. 
[5]. New blood vessels form by endothelial cells (ECs) organising into tubes which are 
stabilised by pericytes and smooth muscle cells. VEGF is involved in inducing this process in 
TE scaffolds through a number of material-based strategies. Growth factor delivery based 
approaches require a sustained VEGF release from the biomaterial as burst release results in 
unstable, leaky vessels. Platelet-derived growth factor BB (PDGF-B) may also be released as it 
favours vessel maturation. Next, gene transfer approaches can generate populations of VEGF-
expressing cells. Also the co-cultures of ECs and pericytes enhances angiogenesis by increasing 
the production of tissue inhibitor of metalloproteases TIMP-2 (ECs) and TIMP-3 (pericytes), 
which inhibit vessel regression. 
 
A number of other approaches outlined below can also be used to express GFs. 
Specifically VEGF gene transfer may generate cells that constitutively express VEGF or 
can stabilise hypoxia inducible factor-1 alpha (HIF-1α) activating genes involved in the 
upregulation of angiogenic GFs via the hypoxic response [125]. Furthermore, recent 
reports suggest that synergistic effects of combining osteogenic molecules with VEGF 
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can enhance osteogenesis. In addition, BMP has also been shown to be upregulated by 
VEGF [126]. 
1.4.2 Osteogenic and angiogenic ions  
Ions can be classified as therapeutics exerting similar effects to GFs detailed in 
Figure 1.9. It has been shown that silicon (Si
14
) and calcium (Ca
2+
) ions initiate 
osteogenesis when released in biologically relevant ranges (15-30 ppm for Si and 60-90 
ppm for Ca).  Ions are being considered as possible alternatives to GFs and genetic 
approaches in TE because they remain stable under typical scaffold processing 
techniques and at high temperatures and they are easily processed as well as being more 
cost-effective [12]. However, the controlled release of ions is essential to avoid cell 
toxicity associated with high concentrations. Bioactive glass such as PerioGlas®, a 
dental bone grafting material, can be used to release therapeutically relevant, non-
cytotoxic concentrations of ions such as calcium and silicon [127].  
 
 
Fig. 1.9 The biological responses of cells to the ionic dissolution products of bioactive glasses 
of various structures, taken from Hoppe et al. [6]. These responses include angiogenesis, 
osteogenesis and antibacterial activity. 
 
Specifically, to promote neovascularisation, ion-based approaches involve using 
cobalt which has been shown to promote the expression of genes encoding proteins 
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involved in angiogenesis [128]. Pro-angiogenic therapeutic ions may also eliminate the 
risk of blood vessel and bone formation at distant sites observed as a result of 
uncontrolled GF delivery, when delivered with a suitable carrier such as BG, 
stimulating the cells themselves to produce the required GFs. Cobalt ions are capable of 
producing an angiogenic response via the induction of the hypoxia-inducible factor 1α 
pathway (HIF-1α) pathway (Fig.1.10). This pathway responds to low oxygen 
concentration (hypoxia) resulting in the activation of numerous pro-vasculogenic genes 
involved in angiogenesis such as VEGF [129, 130]. It has been well documented that 
cobalt mimics hypoxia (<5 % O2), it artificially stabilises the transcription factor HIF-
1α, which then moves into the nucleus to stimulate a series of pro-regenerative 
responses including the upregulation of VEGF [131]. The beneficial effects of cobalt 
ions have been investigated in vitro [132] and in vivo. For instance, studies in a rat 
remnant kidney in vivo model have demonstrated enhanced angiogenesis via HIF-1 
activation when cobalt was subcutaneously injected [133, 134]. These hypoxia-
mimicking pro-angiogenic ions will be adopted in combination with the previously 
discussed CG scaffolds in Chapter 5 of this thesis, as an alternative approach to rhGF 
delivery.           
 
Fig. 1.10 The hypoxia-inducible factor 1α (HIF-1α) pathway, taken from Jaakkola et al. [7]. 
HIF-1α is stabilised under hypoxic conditions as it is hydroxylated by prolyl hydroxylases 
(PHD) as a result of an increase in reactive oxygen species (ROS) which alters the oxidation 
state of Fe
2+
 to Fe
3+
 and subsequently leads to transcriptional activation of angiogenic genes 
such as VEGF.  Cobalt inhibits degradation by sequestering iron a necessary cofactor in PHD 
mediated targeting of HIF-1α to the Von Hippel Lindau protein. 
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1.5 Growth factor delivery in tissue engineering 
There are three principle delivery strategies for GFs for clinical use as described 
by Kirker-Head et al including: 1) the delivery of GF encoding plasmid DNA, 2) 
systemic administration of GFs and 3) GF delivery on a carrier matrix [110]. The first 
avenue involves gene transfer approaches such that cells are transfected to constitutively 
express genes that produce, for example, VEGF and other proteins involved in the 
angiogenic cascade for instance, a stabilised version of HIF-1α. However, gene-based 
approaches have been associated with low transfection efficiencies as well as potential 
safety concerns within a clinical setting. The next route involves delivery of GFs by 
bolus injection which has shown efficacy to some extent at inducing new tissue 
formation in animal models. Promising results have been reported in some phase I 
clinical trials for coronary artery disease involving human FGF-1 infusions [135]. 
However, the systemic bolus injection or infusion of aqueous formulations of rhGFs is 
associated with problems due to the mode of delivery and duration of exposure (Fig. 
1.11) [99, 123, 124]. As such, the efficacy of bolus injection has not been realised in 
large controlled clinical trials which have thus far reported limited clinical success [121, 
122]. Systemic delivery of VEGF has been associated with side effects in non-target 
sites such as hypotension, hyperpermeable vessels, tumor growth and uncontrolled 
neovascularisation. This is largely due to the high doses which are generally 
administered in an attempt to increase the effects of GFs which generally possess short 
half-lives in vivo. Therefore, this form of non-targeted delivery may adversely damage 
tissue in off-target sites bearing these GF receptors. Hence the need for GFs to be 
delivered on biomaterials, that can release them in suitable concentrations and for an 
appropriate time period.  
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Fig. 1.11 Drug delivery kinetics, taken from Liechty et al. [8]. Shown is the burst 
release, pulsatile release, and controlled release of drugs or proteins relative to both 
toxic and therapeutic concentrations.  
 
Finally, the delivery of GFs from biomaterials has shown greater commercial 
promise than bolus injection of GFs largely due to the capability of delivering GF 
directly to a damaged microenvironment. For this reason, the use of naturally derived 
materials as GF delivery systems is currently being researched extensively as reviewed 
by Lee et al. [136]. One major theme guiding this approach is the delivery of rhGFs 
directly from TE scaffolds which are then implanted into the defect site to enhance 
tissue repair and regeneration. This approach will be discussed in further detail below 
and adopted in Chapters 3 and 4 of this thesis. 
1.5.1 Scaffolds as delivery vehicles for soluble growth factors in tissue engineering 
Chen et al have reviewed the number of possibilities with this kind of delivery 
approach (Fig. 1.12) including: the inclusion of GFs in particles and in the scaffolds or, 
just inside the particles as well as the potential to modulate the GF release profiles by 
altering scaffold architecture e.g., a multilayered scaffold [9]. However, a number of 
specific factors must be considered to successfully deliver GFs on a scaffold. Scaffolds 
should be able to: 1) present the GF in an active form, 2) at required continuous 
concentration to induce the specific GF-mediated bioactive response from cells, 3) 
localise GF delivery to target site to minimise toxic effects at non-target sites, 4) 
biodegrade within a short time frame to minimise interference with the innate healing 
response whilst retaining optimal factor retention and 5) be easily manufactured in a 
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cost-effective manner. In order to add osteoinductive capacity to these materials, 
osteoinductive cell mediators, the most widely studied of which are the BMPs, are often 
added. A sophisticated scaffold-based delivery approach was adopted by des Rieux et al 
whereby free-VEGF was loaded in a matrix of PLGA or Matrigel® or encapsulated in 
chitosan MPs and then loaded into the same matrix which allowed for a more sustained 
release [137].  
Recent therapeutic strategies for the incorporation of GFs within scaffolds can 
be broadly divided into two methods: 1) the chemical or physical attachment of GFs to 
the scaffold or 2) the physical inclusion of GFs within the scaffold. The former involves 
the immobilisation of GFs onto the surface via chemical crosslinking or the absorption 
of GFs onto the surface using physicochemical interactions between the polymer and 
GF [138]. Scaffold-based systems offer several advantages, due to their similarity to 
natural ECM, for example they posess inherent properties of biological recognition, 
they are susceptible to remodelling and proteolytic degradation and they present 
receptor-binding ligands [138]. Additionally, within the ECM, GFs can bind with 
GAGs, performing their function upon release and subsequent interaction with surface 
receptors (usually associated with cell migration, proliferation, differentiation and 
organization within tissues).  
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E
 
Fig. 1.12 Strategies for growth factor (GF) delivery for bone repair [9]. (A) 
Incorporation of GFs on a vehicle by bolus injection resulting in burst release 
(scaffolds, hydrogels). (B) Non-covalent immobilisation by encapsulation of GF into 
crosslinked microspheres resulting in sustained release (microspheres and nanoparticles 
etc.). (C) Non-covalent immobilisation by delivering GFs in microparticles and 
scaffolds resulting in pulse-like release (well designed composites, multifunctional 
vehicles etc.). (D) Covalent immobilisation or chemical modification (environment 
sensitive materials e.g. intelligent hydrogels, on-off delivery systems, etc.) resulting in 
pulsatile release. 
  
Currently, there are two scaffold-based products delivering either BMP-2 or 
BMP-7 that are approved by the FDA. Medtronics INFUSE® Bone Graft Kit (Fig. 
1.13), which consists of an absorbable collagen sponge impregnated with rhBMP-2, was 
approved for spinal fusion procedures in 2002 and for open tibial fractures in 2004 as 
well as alveolar ridge and sinus augmentations in 2007 [100]. It represents TERM’s 
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largest financial success and attracted nearly US$ 700 million sales in 2007 at the height 
of its success. OsigraftTM
 
(Olympus Biotech)
 
contains rhBMP-7, also known as OP-1 
(osteogenic protein-1) and was approved for long bone non-union fractures and also for 
use in patients requiring posterolateral lumbar spinal fusion [139-141].  
 
Fig. 1.13 Medtronics INFUSE® Bone Graft Kit adapted from Kearney and Mooney 
[10]. INFUSE® consists of an absorbable collagen sponge soak-loaded with rhBMP-2. 
Unfortunately, there are several problems surrounding these GF-releasing 
sponges including (but not limited to) poor GF release characteristics and limited 
control over the timing and concentration gradients of the released GF. Essentially up to 
30 % of protein can be lost as a result of the initial burst release phase reported with this 
kind of system. In order to circumvent this loss and the further loss of protein due to its 
subsequent degradation upon release, high doses are often administered to achieve 
therapeutic efficacy. The side-effects and complications resulting from these high doses 
are well documented, for example, heterotopic bone growth or bone overgrowth due to 
BMP-2 leakage with INFUSE® into other areas of the body as well as haematomas in 
soft tissue and para-implant bone resorption and osteolysis [115]. This product contains 
a BMP-2 dose 10-100 times higher than endogenous concentrations of the protein [142] 
since a smaller dose does not effectively trigger an adequate osteoinductive effect. 
Consequently, the reported sales of this controversial medical device have dropped from 
US$700 million in 2007 to US$468 million in 2013. More importantly, these safety 
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concerns are being translated into a lack of confidence by surgeons and the wider 
medical community. The shortcomings of conventional methods for delivering GFs thus 
demonstrate the need for the emergence of an alternative, more advanced drug delivery 
strategy in order to allow for control over the release kinetics of GF-based therapeutics 
and extend their duration at the defect site. 
1.5.2 Controlled release strategies for growth factor delivery 
The classical methods of GF delivery are therefore associated with numerous 
limitations in that they lack specific targeting, require high doses of expensive GFs and 
often result in transient responses at a defect site. With this in mind, a delivery system 
which controls the release of GFs is a desirable therapeutic approach to achieve an 
enhanced therapeutic response. Moreover GFs such as VEGF have been shown to be 
most effective based on the timing of their expression and at specific concentration 
gradients. A controlled release approach ideally maintains a constant gradient of GFs 
within the body following zero-order drug release kinetics whereby the rate of release 
does not change with time until no drug remains. There are several general requirements 
of an ideal carrier system for GFs as reviewed by Chen et al [9] including;  
 Feasible preparation method 
 Biocompatible and biodegradable carrier material 
 The ability to protect the protein from physical and chemical degradation 
 High loading efficiency 
 Controlled release profile 
 Retention of the carrier material at the defect site 
 Sufficient flexibility and degradation of the carrier 
 Ability to sequentially release several GFs as required mimicking the in vivo 
healing profile 
Below is an overview of some of the common designs for GF delivery devices. These 
releasing matrices have been adapted for some of the previously described biomolecules 
involved in bone repair.  
 
Polymeric microparticles 
Over the past few decades, biodegradable polymers have been employed as 
carriers for controlled delivery of proteins and drugs [143]. Polymer microcarriers have 
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been extensively explored as GF delivery devices in several forms to enhance the 
delivery of proteins. Some polymers can be cleaved into biocompatible degradation 
products via chemical or enzymatic hydrolysis and as a result do not require subsequent 
removal from the body once implanted, making them a desirable material for protein 
encapsulation. Polymer encapsulation serves to protect GFs from degradation by 
proteinases, proteolysis or oxidation prolonging and controlling the presence of the GF 
at the relevant site. Furthermore, the release rate from polymers can be controlled by the 
biodegradation kinetics of the polymer as well as the physicochemical properties of the 
proteins and polymers and the shape of the delivery devices formulated. Although 
maintenance of protein stability and thus bioactivity is often a critical concern, in vivo 
studies report enhanced GF effects following implantation due to the prolonged delivery 
after an initial burst release, followed by a sustained plateau of release for up to 30 days 
[144]. In addition, this mode of GF delivery may be exploited to deliver multiple GFs in 
unison by altering the composition or structure of the polymer. One example of such a 
material combines lyophilized VEGF followed by polymer encapsulated PDGF from 
PLG scaffolds to increase vessel density and maturation [145].  
Polymers can be formulated into a variety of shapes such as microspheres, 
nanoparticles and microparticles (MPs) using various manufacturing techniques to 
encapsulate a wide range of drugs. This allows for easy application at a variety of in 
vivo locations. A number of techniques exist for the effective microencapsulation of 
drugs within polymers, such as the double emulsion solvent evaporation method, spray 
drying, phase separation-coacervation, interfacial deposition, and polymerisation. A 
variety of both natural and synthetic polymers have been used to fabricate MPs [136, 
146] as described below. Some examples of natural and synthetic biodegradable 
polymers used in microparticle fabrication include polyesters, polyphosphazenes, 
polyanhydrides, poly (ortho esters) and polysaccharides. Specifically the use of alginate 
and PLGA for GF delivery will be examined in the research presented in this thesis. 
1.5.2.1 Alginate microparticles 
Drug delivery systems using natural polymers are primarily based on proteins 
such as gelatin, albumin and collagen as well as polysaccharides such as hyaluronic 
acid, chitosan and alginates. Polysaccharides are attractive drug carriers for a number of 
reasons: their natural abundance, commercial availability, low cost and ease of 
modification due to their simple chemistry which allows for ease of modification along 
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with their fundamental properties of biocompatibility, biodegradability and low 
immunogenicity.  
Alginate, a seaweed-derived polysaccharide, has well characterised 
biodegradability, biocompatibility and controlled release properties. Alginate consists of 
linear copolymers comprising blocks of (1,4)-linked  β- D-mannuronate (M) and α- L-
guluronate (G) residues [3] (Fig. 1.14). Alginates structural resemblance to the native 
ECM makes it relevant in wound healing and delivery of drugs, proteins and 
transplantation of cells [3]. Various factors such as the M/G ratio, the molecular weight 
and length of G-block have a huge influence on the physical properties of alginate and 
its hydrogels [147]. Alginate exhibits pH-dependent behaviour which is commonly 
exploited for protein and drug release and undergoes rapid dissolution at high pH, 
resulting in the burst release of protein drugs within a few hours, leading to their 
subsequent degradation by proteolytic enzymes. However, in low pH solutions, the 
release of biomolecules is considerably reduced as alginate shrinks and the encapsulated 
drugs are held within; a feature which is exploited to tailor release profiles and in the 
development of ‘smart’ delivery systems.  
Ca-alginate particles
Ca2+ buffer
Na-alginate (alginic acid, sodium salt)
 
Fig. 1.14 Alginate chemical structure and crosslinking technique. Alginates consist of (1→4) 
linked β-d- mannuronic acid (M) and α-l-guluronic acid. When sodium alginate is placed in a 
solution of divalent cations (calcium ions), the divalent cations cooperatively interact with 
blocks of G monomers to form ionic bridges. Each calcium ion can attach to two of the polymer 
strands leading to crosslinking. 
 
This polymer lends itself well to the encapsulation of unstable water-soluble 
macromolecules creating a hydrophilic environment to protect the encapsulated protein 
from degradation. Furthermore, GFs can be added into alginate under mild conditions 
51 
 
which would have a low effect on their denaturation shielding proteins from 
degradation until their release [3]. Alginate carries a negative charge and molecules that 
do not ionically interact with the alginate network are rapidly released. VEGF and 
BMP-2, for example, reversibly binds to alginate at physiological pH through 
electrostatic interactions. In order to efficiently encapsulate GFs and permit a sustained 
release, alginate requires ionic cross-linking with divalent cations [148]. Release of the 
GF from MPs then occurs via two methods: 1) diffusion of the protein out of the 
particles and 2) release of protein due to ion exchange, causing the removal of the 
divalent cation calcium used to crosslink the particles by the monovalent cations present 
in the physiological environment (e.g., potassium and sodium). This leads to swelling of 
alginate particles, increased porosity of the alginate matrix and its subsequent erosion. 
Alginate MPs can be fabricated using various methods including emulsion dispersion, 
ionotropic pregelation [149] and spray drying [150]. 
1.5.2.2 PLGA microparticles 
Synthetic polymers offer several advantages for GF delivery since they can be 
modified, functionalised and configured into a range of structures [66]. In addition, they 
are less immunogenic and more predictable in terms of their chemical and mechanical 
properties than natural polymers [136]. Consequently, a range of synthetic polymers 
have been used to encapsulate GFs including the aforementioned PGA, PLA and PLGA 
[123, 151, 152]. Synthetic polymeric MPs are typically fabricated by solvent extraction, 
whereby the GF is dispersed in organic/aqueous solvent emulsion [66]. The solvent is 
subsequently evaporated to yield MPs of various sizes. 
PLGA represents the most widely used polyester for the delivery of drugs, 
proteins and various macromolecules such as DNA, RNA and peptides over the past 
two decades [152-157]. This is largely due to the possibility of tuning its degradation 
rates and mechanical properties and its sustained release properties which have led to its 
immense clinical use [152, 155, 158, 159]. PLGA degradation rates can be tuned by 
varying the ratio of lactic acid/glycolic acid in its structure (Fig. 1.15), polymer 
molecular weight and drug concentration which in turn affects the release profiles of the 
encapsulated drug. The degradation of PLGA occurs by hydrolysis or cleavage of the 
backbone esters into glycolic acid and lactic acid [152].  
GF entrapment in PLGA is dependent on hydrophobic-hydrophobic or 
hydrophilic-hydrophilic interactions between the GF and polymer. The subsequent 
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release of GF from PLGA is biphasic consisting firstly of an initial diffusion-dependant 
burst release of proteins from the particle surface due to water penetrating the matrix. 
This is followed by diffusion/erosion-dependant drug release following hydrolysis of 
the polymer by water inside the matrix into soluble oligomers and monomers [160]. 
Given the variables which affect PLGA degradation rates, the protein release kinetics 
can often be unpredictable. PLGA-based particles prepared by double emulsion/solvent 
evaporation are widely used for GF delivery and have been adopted as the PLGA MP 
fabrication method in this thesis [161]. For instance, PLGA MPs encapsulating and 
sustaining the release of VEGF have previously been used to promote angiogenesis in 
the intestine [162]. Additionally, BMP-2 has been encapsulated in PLGA in numerous 
studies for sustained release purposes resulting in faster and more complete bone 
healing in vivo [163-165]. 
 
Fig. 1.15 Chemical structure of poly lactic-co-glycolic acid (PLGA). PLGA degradation 
products consist of glycolic acid and lactic acid. 
 
Ultimately, a material system loaded with different GFs is a desirable 
therapeutic strategy which can be modified to display a sequential delivery of factors to 
target sites at the appropriate time during the bone repair cascade. This could be 
achieved by adding the relevant proteins encapsulated in different polymers with 
distinct release kinetics spatially distributed throughout the same scaffolds or within 
different levels of a layered scaffold. For example, three-dimensional patterning of the 
primary GFs involved in angiogenesis namely, VEGF, Ang-1, Ang-2, bFGF and PDGF 
on composite scaffolds may significantly enhance the therapeutic potential of a scaffold 
thereby allowing an element of control over this complex biological process. The 
delivery of BMP-2 and/or VEGF from a controlled release system may thus lead to the 
chemo-attraction of cells residing along the delivery device and subsequently cell 
proliferation and infiltration to promote tissue regeneration throughout the scaffold. By 
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incorporating MPs into scaffolds, a spatial localization of the GF would be achieved 
enabling control not only over the extent of bone tissue formation but the pattern, the 
importance of which has been reported [123, 166].  
Consequently, the development of a controlled release delivery system will be 
explored as the major theme guiding this thesis. Chapters 2-4 of this thesis will 
investigate the use of GFs encapsulated in polymeric MPs and subsequently delivered 
on a scaffold as a GF delivery system to potentially negate the negative side-effects of 
off-target delivery seen with Medtronics INFUSE®. As an alternative strategy to this 
GF-based approach, Chapter 5 of this thesis will focus on the development and in vitro 
assessment of the functionality of a CG scaffold containing osteoinductive BG particles 
for the controlled release of pro-angiogenic cobalt ions. 
1.6 Objectives 
The overall goal of this research was to synthesise a new generation of scaffolds 
by functionally enhancing collagen-based scaffolds specifically optimised for bone 
repair in order to make them capable of coupling both angio- and osteogenesis and thus 
enhance their regenerative capacity.  Specifically, this study aimed to investigate the 
potential for controlled release of BMP-2 and VEGF encapsulated in alginate and 
PLGA microparticles (Chapter 2) and subsequently, to investigate whether a series of 
functionalised scaffolds incorporating this system (Chapter 3) could promote enhanced 
bone repair in a critical size defect in vivo model (Chapter 4). A final aim of this thesis 
was to examine the potential of a cobalt-bioactive glass microparticle-containing 
scaffold to promote endogenous growth factor production via the release of pro-
angiogenic and osteogenic ions in the development of a growth factor-free based 
approach for bone regeneration (Chapter 5). 
 
The specific aims of this thesis were: 
1) To develop and characterise PLGA and alginate microparticles for the 
encapsulation and controlled release of bioactive growth factors rhBMP-
2 and rhVEGF (Chapter 2) 
2) To develop a functionalised collagen-hydroxyapatite scaffold by the 
incorporation of the controlled release GF delivery systems optimised in 
Chapter 2 and to characterise the resulting scaffold in terms of 
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microarchitecture, growth factor release kinetics and  in vitro bioactivity 
(Chapter 3) 
3) To assess the ability of the optimal functionalised scaffolds to induce 
bone healing following implantation in a critical size defect in rat 
calvaria in vivo (Chapter 4) 
4) To develop and characterise a growth factor-free collagen-based scaffold 
incorporating pro-angiogenic and pro-osteogenic cobalt-bioactive glass 
microparticles and to assess the in vitro ability of the scaffold to promote 
osteogenesis and angiogenesis (Chapter 5) 
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Chapter 2: Polymeric alginate and PLGA microparticles as carriers for 
the controlled release of BMP-2 and VEGF in bone tissue engineering 
 
2.1 Introduction 
The success of any tissue engineering (TE) based strategy for repair of defects of 
substantial size lies in the ability of the engineered construct to produce functional 
vasculature that can metabolically provide for cells as well as fully integrate with the 
host tissue [167]. Addressing the requirement for angiogenesis and neovascularisation 
in TE constructs is one of great importance to enable sufficient engraftment and 
integration once implanted in the host [69, 103]. This is because the diffusion distance 
for nutrients and oxygen implicit to cell survival is limited to 150-200 µm and a lack of 
this often leads to necrosis in the centre of the construct [168]. One potential solution to 
this nutrient limitation is to encourage the rapid development of vasculature within 
engineered matrices by delivering molecules such as growth factors (GFs) pertinent to 
this process. Due to the need for efficient sustained delivery devices for these growth 
factors, over the past few decades there has been expanding interest in developing 
efficient drug delivery vehicles for proteins (Fig. 2.1) as reviewed by Lee et al  given 
the vast array of recombinant proteins under investigation for therapeutic applications 
[3, 99].  
 
Fig. 2.1 Schematic representation of a drug delivery vehicle in the form of a polymeric 
microparticle. The microparticle is shown to encapsulate and sustain the release of the 
therapeutic factor over time. 
 
In relation to TE specifically, several studies have shown that bone formation is 
also an angiogenesis-dependant process with angiogenesis preceding osteogenesis in the 
bone repair cascade [169]. Bone morphogenetic proteins (BMPs), considered the most 
potent stimulators of bone formation are a family of GFs associated with the growth and 
maturation of bone [99, 170]. In this sense, numerous factors have been identified in the 
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search for the genetic and molecular mechanisms of blood vessel formation. Namely, 
vascular endothelial growth factor (VEGF) has been implicated as a critical potent 
regulator of neo vascularisation in vivo [119]. Additionally, VEGF is also an inducer of 
osteoblast differentiation serving to promote cell recruitment by acting as a chemo 
attractant for MSCs and BMP-2 suggesting a role for VEGF in coupling angiogenesis 
and osteogenesis [171-173]. Therapeutically, the release of these factors should mimic 
the natural bone repair cascade which involves the spatial and temporal presentation of 
GFs at the appropriate time interval during bone fracture repair [123, 166].  
Traditional therapeutic strategies involving GF delivery relies on systemic 
delivery by simple bolus injection or infusion of aqueous formulations of these proteins 
or on their surface-adsorption onto carriers resulting in high burst release characteristics 
and generally poor control over the delivery.  However, VEGF and other angiogenic 
factors have been shown to be most effective based on the timing of their expression 
and at specific concentration gradients. GFs are also susceptible to rapid degradation 
[174]; VEGF has a half-life of 30 mins when infused intravenously and is thus required 
in large doses which can lead to non-specific pathological vessel formation [175]. 
Additionally, as described in detail in Chapter 1, studies have suggested that the 
inability to control the delivery of BMP-2 from the collagen sponges clinically 
approved for this purpose necessitates supraphysiological GF doses which can lead to 
serious clinical complications including bone tissue overgrowth, ectopic bone 
formation, inflammation and carcinogenicity [115, 176]. Also, intravenous and 
intracoronary injections of VEGF [177] and FGF-2 [135] have shown limited clinical 
success in phase II clinical trials for the treatment of cardiovascular disease possibly 
owing to the mode of delivery. These classical methods of GF delivery lack specific 
targeting, require high doses of these expensive proteins and often result in transient 
responses at a defect site. Given the poor clinical outcome observed, the development of 
biomaterials with the ability to mimic in vivo spatiotemporal control over delivery is 
thus a desirable therapeutic strategy.  
The controlled release of proteins from a variety of microparticle (MP) 
formulations has been reported. In the current study, the natural polymer alginate and 
the synthetic polymer PLGA were investigated for protein encapsulation because they 
are biodegradable, biocompatible and classified as generally regarded as safe (GRAS) 
by the FDA [147]. Furthermore, these polymers have many possible applications in the 
area of drug delivery and controlled release [73, 152, 178]. Alginate gels have shown 
57 
 
potential in bone regeneration for delivery of osteoinductive factors such as BMP [73]. 
In a study by Kolambkar and colleagues (2011) the use of alginate hydrogel injected 
inside an electrospun nanofiber mesh tube was investigated to deliver rhBMP-2 for the 
repair of critically-sized segmental bone defects in a rat model [179]. Furthermore, 
alginate matrices have proven a viable option for the slow delivery of several 
angiogenic factors such as VEGF which reversibly binds to alginate at physiological pH 
through electrostatic interactions as well as for the co delivery of multiple GFs [172, 
180]. PLGA has been used for the encapsulation of a wide range of GFs including 
BMP-2 [165, 181, 182]. 
The scientific literature describes an array of methodologies for encapsulating 
drugs in a variety of matrix materials including ionotropic pregelation [149], emulsion 
dispersion [66] and spray drying [150] - the latter two will be detailed in the following 
study. Specifically the double emulsion process, commonly employed for the 
fabrication of PLGA MPs, is best suited for the encapsulation of water-soluble drugs 
like proteins [157, 183]. Protein encapsulation by double emulsion (water-oil-water) is a 
well regarded, robust technique [11, 66, 184, 185]. This method is more difficult to 
scale up and involves the use of organic solvents compared to the use of spray-drying. 
Spray-drying is a well established methodology currently used in the food and 
cosmetics industry as well as the pharmaceutical industry for the production of drug 
powders and therapeutics [186]. This easily scalable method provides a means of 
producing alginate MPs of about 5um [150, 187]. Additionally, the principal advantages 
of the spray-drying method include ease of control over particle size, distribution and 
shape and also the dispersability of the product and high encapsulation efficiencies 
obtainable. It has previously been determined that particle size is linked to the 
concentration and composition of the feed solution, morphology is governed by the 
drying rate and yield is affected by the process parameters [188]. With this in mind, in 
this study spray-drying was chosen as the method of alginate MP fabrication while 
PLGA particles were fabricated by the commonly used double emulsion technique. The 
current study describes for the first time to our knowledge, the use of spray-drying as a 
method for the encapsulation of GFs relevant to bone repair within alginate MPs for the 
purpose of sustaining their release. 
It is hypothesized that the incorporation of MPs with scaffolds specifically 
designed for bone repair would result in a scaffold-based delivery system capable of 
sustained GF elution and thus enhanced regenerative capacity. The work presented in 
58 
 
this chapter focuses on the development of MP delivery systems while that presented in 
Chapter 3 focuses on the development and characterization of a functionalised scaffold 
incorporating these delivery systems with the purpose of enhancing osteogenesis and 
angiogenesis in vitro and promoting bone healing in vivo. 
2.1.1 Objectives 
The overall objective of this chapter was to develop a polymeric microparticulate 
controlled release system for the delivery of vascular endothelial growth factor (VEGF) 
and bone morphogenetic protein (BMP-2). With this purpose, spray-drying and double 
emulsion methods were used to fabricate alginate and PLGA microparticles respectively 
for encapsulating, protecting and sustaining the release of therapeutic growth factors 
pertinent to bone repair.   
 
The specific aims were:  
1) To assess the characteristics of the polymeric microparticles in terms of size and 
yield following the fabrication process, protein distribution, encapsulation 
efficiency within the polymer matrix and microparticle morphology. 
 
2) To determine the kinetics of protein release from the alginate and PLGA 
microparticles and to evaluate the potential for prolonged release of rhBMP-2 
and rhVEGF. 
 
3) To assess the biological activity of the growth factors following encapsulation in 
and delivery from alginate and PLGA microparticles as well as to determine the 
effects of the encapsulation process on protein integrity and bioactivity. 
 
2.2 Materials and Methods 
2.2.1 Fabrication of microparticles 
Alginate microparticle fabrication  
Alginate (Sigma, Ireland, low viscosity alginic acid sodium salt from 
Macrocystis pyrifera) MPs were manufactured by a spray-drying method. Fluorescently 
labelled BSA-Fluorescein Isothiocyanate (BSA-FITC-Sigma, Ireland) was initially 
incorporated as a model drug to determine the effects of the spray-drying process on the 
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loaded protein in terms of the protein distribution within the particles. A 0.5 % w/v 
alginate feed solution was mixed with a fluorescently labelled model protein BSA-FITC 
used as an alternative during characterisation studies prior to the encapsulation of the 
therapeutic proteins of interest (1 µg/mg) namely rhBMP-2 or rhVEGF VEGF (R&D 
Systems, UK). This mixture was subsequently spray-dried using a Buchi Mini Spray-
Dryer B290 (Fig. 2.2) according to the following previously established parameters for 
fabricating particles of an appropriate size range for the intended application [150]: 
compressed air 5-8 bar, air flow rate 400-600 L/h, inlet temperature 140° C, aspirator at 
80 % of maximum capacity, and pump flow rate at 15 %. Unloaded MPs (blank) were 
used as controls for later experiments. By this process, the protein and alginate feed 
solution was spray-dried and collected in the form of dried alginate spherical MPs. 
Briefly, this involves transformation of a feed solution from a fluid state into dried 
particulate form by feeding into an atomiser to increase the surface area of the solution 
for subsequent vaporisation of the solvent (water).  
 
 
Fig. 2.2 Primary components of a spray dryer. A dry powder is produced from a feed solution or 
slurry containing the substance to be encapsulated (the load) and a carrier (polymer) in water by 
feeding through an atomiser to create small drops which are rapidly dried with a hot gas as they 
pass through the drying chamber. The carrier forms a hardened shell around the load. 
 
The MPs were collected and cross-linked to allow for gelation, increased 
resistance to degradation and better controlled release properties by first suspending 
them in acetonitrile to disperse them under sonication [187]. The suspension was then 
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poured into 1.2 % (w/v) calcium chloride solution under magnetic stirring for 10 min to 
allow particle crosslinking (Fig. 2.3). The particles were filtered on 0.45 µm nylon filter 
paper, washed twice with distilled water to remove any remaining solvent and dried at 
room temperature overnight. The recovered MPs were stored at 4º C in a dessicator 
until further use.  
 
Fig. 2.3 Alginate MP crosslinking technique. When sodium alginate is placed in a solution of 
calcium ions, the calcium ions replace sodium ions in the polymer. Each calcium ion can attach 
to two of the polymer strands to crosslink them. 
 
 
PLGA microparticle fabrication  
PLGA (50:50) MPs were synthesized by a water-oil-water (W/O/W) emulsion method 
(Fig. 2.4) adapted from a previously described method [11]. Briefly, 0.5 mL of an 
aqueous solution of 16 µg of growth factor was added to 125 µL of Physiogel® (80 
mg/mL of succinylated gelatin) from Braun Medical (Emmenbrucke, Switzerland) 
which has been reported to protect proteins from degradation (W1-Phase) [189]. PLGA 
(375 mg) was dissolved in 5 mL of dichloromethane (O-Phase). After mixing the W1-
Phase with the O-Phase, the mixture was immediately ultrasonicated to obtain the 
primary W1/O emulsion. This W1/O emulsion was diluted by adding it dropwise while 
sonicating to 30 mL of an aqueous solution containing 1 g of polyvinyl alcohol (PVA) 
and 1.13 g of NaCl. The resulting W1/O/W2 emulsion was dispersed into 70 mL of the 
same aqueous solution. This emulsion was stirred for 4 h at room temperature and the 
resulting microparticles were collected by centrifugation (5000 rpm, 10 mins). The 
particles were washed three times with 1.13 % (w/v) NaCl and freeze-dried at -56°C 
overnight. 
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Fig. 2.4 Fabrication of PLGA microparticles by solvent evaporation from a water-in-oil-in-
water dispersion for growth factor delivery, adapted from Wang et al. [11]. 
2.2.2 Microparticle characterisation 
The mass yield of product after spray-drying and crosslinking was determined 
according to the following equation; 
 
Equation 2.1 
 
 
PLGA mass yield was similarly recorded following the freeze-drying process. The 
mean particle size and size distribution of the MPs were determined by dynamic light 
scattering (DLS) with a Malvern MasterSizer Sirocco 2000 by suspending the particles 
in water prior to analysis.  
 
Scanning electron microscopy and microscopic images 
Surface morphology of the protein-loaded and unloaded MPs was characterized 
using a scanning electron microscope (SMU SEM, Japan) and an optical microscope 
(Olympus CX-41). SEM images were recorded by mounting the samples on metallic 
studs coated with thermoplastic adhesive, later sputtered with gold ions and captured at 
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a voltage of 5 kV using secondary electron mode, taken at a working distance between 
12-18 mm. 
 
Confocal microscopy 
The presence of BSA-FITC encapsulated in alginate or PLGA MPs was 
confirmed using Confocal Laser Scanning Microscopy (CLSM) using a LSM 510 Axio 
plan 2 upright confocal microscope (Carl Zeiss, Germany) at original magnification 
63X. Fluorescently labelled protein (BSA-FITC) was employed for this study [190]. 
 
Encapsulation efficiency 
To determine the content of protein encapsulated in alginate, 5 mg of dried 
crosslinked protein loaded MPs were dissolved in 10 mL of 0.1 M sodium citrate under 
magnetic stirring for 30 min and the protein content analysed by ELISA as described 
below. Sodium citrate breaks the polymer cross-links by saturation of the medium with 
positive ions. The amount of protein recovered from each formulation was divided by 
the total mass of the amount added in the formulation to calculate protein loading 
efficiency according to the below equation;  
 
Equation 2.2 
 
 
The content of protein encapsulated in PLGA was determined by adding 20 mg of MPs 
to 3 mLs of a 0.1M NaOH 5 % w/v SDS solution in water. The particles were digested 
at 37º C while shaking (50 rpm for 2 h) following centrifugation for 2 mins at 10,000 
rpm. The supernatant was used to analyse protein content similarly as above by ELISA. 
2.2.3 In vitro growth factor release kinetics from microparticles 
In order to examine protein release kinetics, 20 mg of protein-loaded MPs were 
dispersed in 2 mLs of PBS (20 mM sodium phosphate and 150 mM sodium chloride, 
pH 7.4), placed in a waterbath and shaken at 37º C. The release medium was removed 
and replaced by fresh PBS at the following timepoints for analysis of protein content 
using an enzyme-linked immunosorbent assay (ELISA); 4 h, day 1, 3, 7, 14, 21, 28, 32. 
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RhBMP-2 was quantified using the rhBMP-2 ELISA (R&D Systems UK) according to 
the manufacturer’s instructions. VEGF was quantified using a rhVEGF DuoSet® 
ELISA Development kit (R&D Systems UK) according to the manufacturer’s 
instructions. Briefly, this involved adding 50 L of assay diluent to each well followed 
by 200 L of samples or standards diluted in the calibrator diluent, the plate was 
incubated for 2 h at room temperature, the wells were then washed 4 times with wash 
buffer followed by the addition of 200 L VEGF/BMP-2 conjugate, the plate was then 
incubated for a further 2 h at room temperature. The plate was washed another 4 times 
with the wash buffer, 200 L of substrate solution was added and the plate incubated for 
30 min in the dark. Finally, 50 L of stop solution was added to each well and the plate 
was read at abs 450 nm and corrected for at 570 nm (Varioskan, Fisher Scientific, 
Ireland). 
 
2.2.4 Bioactivity of protein loaded microparticles 
2.2.4.1 Analysis of BMP-2 bioactivity  
Cell culture & seeding 
To analyse the ability of the BMP-2 released from MPs to promote cell 
differentiation down the osteogenic lineage, MC3T3-E1 cells, a murine pre-osteoblastic 
cell line, were cultured to confluence in standard α-MEM. Cells were seeded onto 6 
well plates at a density of 30,000 cells per well and cultured for 24 h in standard growth 
media followed by osteogenic differentiation media thereafter containing; α-MEM 
supplemented with ascorbic acid 2-P 50 uM, dexamethasone 100 nM, β-
glycerophosphate 10 mM, FBS 10 %, 100 U/mL penicillin, 100 ug/mL streptomycin. 
  
DNA quantification 
In order to assess the effects of BMP-2 released from MPs on cell numbers 
DNA was quantified from MC3T3 cells cultured in the presence of osteogenic 
differentiation media containing BMP-2 previously released from MPs and diluted to 50 
ng/mL. Media without BMP-2 supplement was used as a control as well as non-
encapsulated rhBMP-2 (50 ng/mL) added directly to the media as a bioactivity 
benchmark control.  To convert DNA content into cell number, a cell standard curve 
was also generated where known numbers of cells were treated in the same manner as 
the cell seeded scaffold and assayed as below.  
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Alkaline phosphatase quantification 
In order to assess the ability of BMP-2 released from MPs to enhance 
osteogenesis, alkaline phosphatase (ALP) was quantified from MC3T3 cells cultured in 
the presence of various BMP-2 supplements for 7 days as a measure of the bioactivity 
of BMP-2 since this is an early marker for osteoblasts differentiation. At the endpoint of 
the study, MC3T3-E1 cells were washed in PBS and lysed according to the 
manufacturer’s protocol (SensoLyte pNPP Alkaline Phosphatase Assay Kit). Briefly, 
cells were homogenised in the lysis buffer provided in the kit and incubated at 4º C. The 
supernatant was collected for quantification of ALP or DNA. This method utilized p-
nitrophenyl phosphate (pNPP) that is hydrolysed by ALP to produce a yellow product. 
The amount of coloured product is proportional to the amount of enzyme in the 
reaction. 
2.2.4.2 Analysis of VEGF bioactivity 
Endothelial cell culture and seeding 
In order to examine the ability of VEGF released from MPs to promote 
angiogenic differentiation, Human Umbilical Vein Endothelial Cells (HUVECs) were 
employed and cultured in complete endothelial media (Millipore) in T175 flasks 
(Sarstedt, Dublin, Ireland) under standard conditions (37
o 
C, 5 % CO2) and similarly 
cultured in 6 well plates. For all angiogenic assays VEGF was removed as a supplement 
from the complete endothelial media. 
 
DNA quantification 
As a measure of VEGF bioactivity, HUVECs were cultured in the presence of 
VEGF, which is a potent inducer of endothelial cell (EC) proliferation. Cell number was 
used as a surrogate marker of cell growth at 3 days post seeding after an initial seeding 
density of 30,000 cells per well of a 6 well plate. HUVECs were cultured in complete 
EC growth media for 24 h (Millipore) after which endothelial media containing VEGF 
previously released from alginate and PLGA MPs and diluted to 50 ng/mL was added. 
Endothelial media (minus VEGF) was used as a control as well as non-encapsulated 
VEGF (50ng/mL) added directly to the media as a bioactivity benchmark control. At the 
end of the study wells were washed in PBS, lysed using cell lysis buffer (SensoLyte 
pNPP Alkaline Phosphatase Assay Kit) and analysed for dsDNA content using the 
PicoGreen assay (Quanti-iT TM PicoGreen dsDNA Molecular Probes, OR, USA). 
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Fluorescent PicoGreen binds to double stranded DNA; the amount of fluorescence 
corresponds to the amount of DNA in the sample. The fluorescence of the samples was 
measured at 538 nm after excitation at 485 nm on a plate reader (Varioskan, Fisher 
Scientific, UK).  
 
Matrigel tubule formation assay 
In order to further assess the ability of VEGF released from MPs to enhance 
angiogenesis, Matrigel™, a basement membrane matrix commonly used to observe in 
vitro angiogenesis was placed in a 48 well plate at 120 µL/well. HUVECs were then 
plated at 1x10
5
 cells per well. Plates were placed in an incubator for 20 min after which 
time endothelial media (1 mL) containing VEGF previously released from MPs and 
diluted to 50ng/mL was added. Endothelial media without VEGF supplement was used 
as a control as well as non-encapsulated rhVEGF added directly to the media (50 
ng/mL) as a bioactivity benchmark control. Matrigel cultures were imaged at 6 h, 12 h 
and 24 h post-seeding with a Leica DMIL microscope (10x objective, DFC420C digital 
camera) with 5 images taken and analysed for each group using ImageJ. The length of 
tubule network formation by ECs in response to the various culture conditions was used 
as a surrogate marker of angiogenesis.   
2.2.5 Statistical analysis 
The data are represented as means ± standard deviations (SD). Statistics were 
carried out using GraphPad Prism software using a general linear model ANOVA with 
Tukey’s post hoc tests performed for multiple comparisons. All experiments were 
performed with a sample size of 3 per treatment group. Statistical significance was 
taken at P<0.05 unless otherwise stated. 
2.3 Results 
2.3.1 Particle yield, encapsulation efficiency, size and morphology  
The alginate MPs were fabricated by using a spray-drying technique. By this 
process, the protein and alginate feed solution was spray dried and collected in the form 
a dried alginate spherical MPs. The process yield for blank, BMP-2 loaded and VEGF 
loaded alginate MPs was 50-69 % while the yield for PLGA was reported at 50-60 %. 
Diameters of the alginate and PLGA microparticles distributed in the range of 1-10 and 
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1-8 µm respectively (Fig. 2.5). The content of encapsulated protein (Table. 2.1) as 
determined by ELISA was found to be 45 % for BMP-2 and 49 % for VEGF 
encapsulated in alginate while it was 84 % for BMP-2 and 85 % for VEGF of the 
original amount of GF incorporated in PLGA during the fabrication processes.  
 
Table 2.1. Encapsulation efficiencies (%) of PLGA and alginate microparticles. 
 
Polymer type BMP-2 VEGF 
PLGA 84 % 85 % 
Alginate 45 % 49 % 
 
Fig. 2.5 Polymeric microparticle size distributions. Size distribution of cross-linked spray-dried 
alginate (A) and PLGA microparticles fabricated by double emulsion (B) indicating particle 
diameters in the range of <10 µm for alginate and PLGA with average particle sizes (C) of 3.4 ± 
1.4 and 2.4 ± 0.5 µm respectively. 
 
Having obtained particles of an appropriate size for their intended purpose, SEM 
was used to investigate particle morphology. The micrographs showed smooth, 
spherical protein-loaded alginate MPs and spherical PLGA MPs with perforations 
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characteristic of this polymer. Both PLGA and alginate MPs had diameters < 10 µm in 
size (Fig. 2.6) for blank and both GF-loaded formulations. 
 
 
Fig. 2.6 Scanning electron micrographs of microparticles. Indicated are blank (A) alginate and 
(B) PLGA microparticles prepared by spray-drying and double emulsion methods respectively. 
Micrographs taken at 22000X magnifications. Scale bars represent 5 µm. 
 
Since the spatial distribution of the protein within the MPs can be affected by 
the particle size, confocal microscopy was used to examine the presence of 
fluorescently labelled BSA-FITC within both MP formulations. Results show spherical 
structures indicating the accumulation of protein within the polymer (Fig. 2.7) 
confirming the ability of the spray-drying and double emulsion techniques to 
encapsulate the model protein. Results also confirmed the particle sizes were in a range 
similar to the results previously obtained with SEM and DLS. 
 
Fig. 2.7 Confocal laser scanning microscopy (CLSM) images of alginate and PLGA 
microparticles, indicating the presence of BSA-FITC (green) in the polymer. 
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2.3.2 In vitro growth factor release kinetics from alginate and PLGA 
microparticles 
2.3.2.1 BMP-2 release  
Having fabricated alginate MPs with an appropriate size for encapsulation of 
therapeutic GFs as well as combining with a scaffold, we next sought to study the 
release kinetics of GFs from the MPs over a 28 day time period. The release profile of 
BMP-2 from alginate was characterised by an initial slow release followed by a 3-fold 
increase from day 1 to day 4 as seen in Figure. 2.8. This correlated to 6 % protein 
release within the first 24 hours and a subsequent increase to 14 % was observed on day 
4 and 13 % on day 7 followed by a decrease thereafter. Cumulative release was 
quantified from the MPs and within 14 days 45 % of the incorporated BMP-2 was 
released from alginate. Additionally, a sustained pattern of protein release (0.5 %) was 
evident from 21 to 28 days corresponding to a total release of 2000 ng/mL at day 28 
(Fig. 2.8A).  
After 30 days the remaining particles were digested and found to still contain 20 
% of the originally loaded BMP-2. In contrast, the concentration of BMP-2 released 
from PLGA was significantly lower than alginate from day 1 to day 7. After an initial 
burst release of a similar percentage of protein to alginate (6 %), BMP-2 release from 
PLGA decreased 2-fold at 24 h (Fig. 2.8B) and protein release was subsequently 
sustained at low concentrations thereafter. Within 14 days 13 % of the incorporated 
BMP-2 was released and the final cumulative release of protein at day 28 was 14 %, 
corresponding to a total release of 500 ng/mL. 
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Fig. 2.8 Release kinetics of rhBMP-2 from polymeric microparticles. (A) In vitro cumulative 
release, as a percentage of the theoretically loaded amount of rhBMP-2 showing a higher, steady 
state increase in BMP-2 from alginate for up to 7 days compared to lower release from PLGA. 
(B) RhBMP-2 release at the respective timepoints as a percentage of total protein loaded which 
was significantly higher (***P<0.001). A low burst release from alginate is seen at 4 h with an 
increase for up to 7 days compared to the burst release from PLGA which was sustained at 
lower concentrations from 24 h onwards. 
2.3.2.2 VEGF release  
Figure 2.9 displays the release profiles of rhVEGF from the MPs which 
followed a similar cumulative release pattern to that of BMP-2 although the 
concentrations released were much higher. The protein release rate from alginate was 
shown to be continuous and sustained (Fig. 2.9A) at high levels for up to 4 days (>6 % 
per timepoint) after which time the release rate dropped at 7 days to 5 % (Fig. 2.9B). A 
decrease in VEGF release was seen thereafter from day 10 to day 28 where low 
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concentrations were recorded. The cumulative release of VEGF at the endpoint of the 
assay was 28 % (Fig. 2.9A) corresponding to a release of 1300 ng/mL, well above the 
limits for supporting enhanced sprouting of ECs in vitro [191, 192]. When the alginate 
particles were digested at the endpoint of the study they were shown to contain 20 % of 
the initially incorporated protein. On the other hand, PLGA released a significantly 
lower concentration of VEGF overall (Fig. 2.9A) with a burst release of 2 % seen in the 
first 4 h followed by a decrease in VEGF release thereafter. Within 28 days the 
cumulative release of VEGF was 5 % (Fig. 2.9B) corresponding to a release of 280 
ng/mL.  
 
Fig. 2.9 Release kinetics of rhVEGF from polymeric microparticles. (A) In vitro cumulative 
release, as a percentage of the theoretically loaded amount of VEGF showing a higher, sustained 
cumulative release from alginate compared to lower VEGF release from PLGA. (B) VEGF 
release at the respective timepoints as a percentage of total protein loaded showing the sustained 
released of significantly higher concentrations (**P<0.01, ***P<0.001) of VEGF from alginate 
(4 h up to 7 days) compared to the lower release observed from PLGA after a low burst release 
at 4 h. 
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Taken together, Figure 2.8 and 2.9 demonstrate that the amount of GF released 
from alginate MPs was higher when compared to PLGA although both polymers 
released concentrations well above the lower limits required for in vitro differentiation 
of preosteoblasts [193] and endothelial cells [191, 192]. Additionally, the kinetics of GF 
release differed depending on the polymer of choice. Alginate displayed high, early 
concentrations of GF release. In contrast, PLGA displayed an initial burst release profile 
and a lower sustained pattern of release was seen thereafter. PLGA is capable of the 
long term, sustained release of bioactive concentrations of GF whereas alginate is more 
suited to achieving higher concentrations at earlier timepoints. 
 
2.3.3 Bioactivity of growth factor released from microparticles 
2.3.3.1 Bioactivity of BMP-2 encapsulated and released from microparticles 
Having determined the release kinetics of proteins from the alginate MPs the 
next step was to examine how the process of MP preparation affects protein bioactivity. 
The clonal osteogenic cell line MC3T3-E1 was chosen for this purpose since they 
exhibit similar properties to pre-osteoblasts; high activity of ALP and the ability to 
differentiate into osteoblasts and mineralize in vitro [194]. BMP-2 was released from 
MPs and diluted to a concentration (50 ng/mL), a bioactive concentration capable of 
inducing an osteogenic response from these cells [193]. As a control, non-encapsulated 
rhBMP-2 was added directly to the media (50 ng/mL) as a bioactivity benchmark 
control. The protein released from MPs was shown to enhance osteoblast 
differentiation. When cultured in the presence of media retained from blank alginate 
MPs, a decrease in cell number was detected compared to all other groups owing to the 
reduction in pH in this group (**P<0.01). Importantly, cell number was maintained at 
relatively similar levels to controls (Fig. 2.10) in the presence of BMP-2 released from 
the alginate and PLGA MPs. There was no significant difference in cell numbers 
between alginate and PLGA, or between these groups and the controls.  
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Fig. 2.10 Cell numbers in response to media containing BMP-2 from different sources. Cell 
numbers of MC3T3 cells cultured for 7 days in cell growth media (cells alone), media 
containing non-encapsulated rhBMP-2 (50 ng/mL) as a bioactivity benchmark control and 
rhBMP-2 released from particles for 4 h (50 ng/mL) at an original seeding density of 30,000 
cells/well. (***P<0.001) denotes a significant increase vs blank alginate.  
 
Alkaline phosphatase (ALP) activity, an early phase marker for osteoblast 
differentiation, was significantly enhanced, 2 fold and 3.5 fold, in the presence of BMP-
2 released from alginate and PLGA MPs respectively relative to cells alone (Fig. 2.11) 
following 8 days culture. The control, media supplemented with rhBMP-2 (50 ng/mL) 
which was not encapsulated in MPs, increased ALP activity >4 fold compared to cells 
alone.  Although BMP-2 released from alginate MPs had reduced bioactivity with 
respect to non-encapsulated rhBMP-2, the bioactivity benchmark control and PLGA-
BMP-2, the results indicated the ability of released BMP-2 from both polymers to 
induce cellular differentiation down the osteogenic lineage compared to cells alone. 
These results suggest the pro-osteogenic effect of BMP-2 released from PLGA and to a 
lesser extent alginate. 
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Fig. 2.11 Alkaline phosphatase activity of MC3T3 cells cultured in media containing BMP-2 
from different sources. ALP was significantly enhanced following 8 days culture in growth 
media supplemented with non-encapsulated rhBMP-2 (***P<0.001) at 50 ng/mL and media 
supplemented with BMP-2 released and collected from alginate and PLGA MPs following 
4days incubation compared with BMP-2 free growth media. (**P<0.01denotes significance in 
PLGA-BMP-2 vs alginate-VEGF). 
 
2.3.3.2 Bioactivity of VEGF encapsulated and released from microparticles 
The bioactivity of VEGF released from the MPs was assessed by determining 
the proliferative capacity of endothelial cells (ECs) after VEGF treatment (50 ng/mL) as 
shown in Figure. 2.12. EC proliferation was enhanced in the presence of VEGF 
compared to the group without VEGF (**P<0.01 control VEGF and *P<0.01 released 
VEGF vs cells alone) confirming the bioactivity of the protein. The results demonstrated 
that cells exposed to VEGF released from alginate MPs showed a significantly 
increased rate of proliferation to a similar extent as the control containing non-
encapsulated rhVEGF (*P<0.01 VEGF (50 ng/mL) vs alginate-VEGF (50 ng/mL)). 
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Fig. 2.12 Endothelial cell number in response to VEGF (50 ng/mL) released from various 
sources. The proliferative capacity of the cells was significantly enhanced in the presence of 
media supplemented with non-encapsulated rhVEGF (**P<0.01) as the bioactivity benchmark 
control and VEGF encapsulated and released from alginate MPs (*P<0.05) compared to cells in 
the absence of VEGF (cells alone). 
 
As further evidence of the bioactivity of the encapsulated and subsequently 
released VEGF, the capacity of ECs to form tubule-like structures was evaluated in a 
tubule formation assay (Fig. 2.13A). Compared to the group without VEGF, cells 
exposed to VEGF released from alginate MPs (for 4 h) were more effective at forming 
tubules than VEGF added directly to the media at the 6 and 12 h timepoints of exposure 
(Fig. 2.13B). Similarly VEGF released from PLGA (for 4 h) was more effective at 
forming tubules than the direct addition of VEGF at the 12 h timepoint. This positive 
result suggests that the angiogenic factor released from alginate and PLGA MPs has 
retained its bioactivity to a similar extent as non-encapsulated rhVEGF added directly to 
the cells suggesting the feasibility of spray-drying and double emulsion as methods of 
VEGF-eluting MP fabrication. Importantly the processing parameters for MP 
fabrication had no detrimental effect on VEGF bioactivity and at 12 h polymeric 
encapsulation enhanced VEGF activity compared to non-encapsulated protein. These 
results suggest the pro-angiogenic effect of VEGF released from alginate and PLGA 
MPs. 
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Fig. 2.13 Bioactivity of VEGF released from microparticles. (A) Optical images of tubule 
formation by human endothelial cells (ECs) cultured in VEGF from different sources after 6 h. 
Scale bar represents 100 µm. (B) Quantification of tubule length after 6, 12 and 24 h cultured in 
the same conditions. After 6 h increased tubule length is recorded in the presence of 50 ng/mL 
of the non-encapsulated VEGF control (**P<0.01), VEGF encapsulated and released from 
alginate for 4 h (***P<0.001) and PLGA (*P<0.05) MPs compared to cells alone. After 12 h 
ECs exhibit increased tubule length relative to cells in the presence of VEGF released from 
alginate MPs only (**P<0.01 denotes significant increase vs. cells alone).  
 
2.4 Discussion 
The focus of this current study was to fabricate and characterise a polymeric 
microparticulate controlled release system for the delivery of vascular endothelial 
growth factor (VEGF) and bone morphogenetic protein (BMP-2). With this in mind, 
polymeric microparticles (MPs) were fabricated with the aim of sustaining the dose and 
duration of GF release by the non-covalent immobilization or physical entrapment of 
these factors in the polymer. It was hypothesised that encapsulating proteins, namely 
BMP-2 and VEGF, within alginate and/or PLGA matrices fabricated by spray-drying 
and double emulsion methods respectively, may serve not only to increase the half-life 
but also to increment the mean residence time of these growth factors (GFs) within the 
area of damage. In summary, this chapter showed that it is possible to encapsulate 
BMP-2 and VEGF in alginate and PLGA MPs respectively. Importantly, this chapter 
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describes, for the first time, that spray-dried alginate MPs may effectively encapsulate 
and sustain the release of bioactive BMP-2 and VEGF, GFs pertinent to bone repair. 
Characterisation of spray-dried alginate and PLGA MPs prepared by double 
emulsion confirmed these methods as a feasible means of fabricating a controlled 
release platform for the delivery of therapeutic BMP-2 and VEGF. When considering 
formulation processes for encapsulating therapeutics a successful process requires the 
production of a stable, safe product and must be reproducible and scalable to produce 
industrial quantities. The formulation parameters chosen in this study were based on the 
previous literature and MPs were characterised in terms of a number of these properties 
[66, 152, 187]. The mass yield of the VEGF and BMP-2 loaded alginate MPs of 60-69 
% collected was determined to be above the typical range reported from bench-top 
spray dryers of 60 % maximum of the initial solids concentration in the feed [188]. Any 
loss is due to alginate polymer depositing on the vessel, cyclone walls, filter and 
exhaust. Encapsulation efficiencies of 45 % were reported for protein loaded alginate 
MPs, a level which has previously been reported from insulin-loaded MPs prepared by 
spray-drying. This is perhaps due to the difference in molecular weight between BMP-2 
(13 kDa), VEGF (19.2 kDa) and alginate which has a higher molecular weight of 147 
kDa potentially pulling protein out with water during MP drying [195]. Similar to 
alginate, a yield of 50-60 % is typically reported from PLGA MPs which was within the 
range reported in this study. In contrast to alginate, PLGA MPs had higher 
encapsulation efficiencies >85 % which is at the higher limits of the range reported 
previously of 42-100 % [189, 196, 197]. 
The alginate and PLGA MPs fabricated in this study had similar size ranges of 
1-10 µm, a size considered appropriate for facilitating their incorporation into collagen-
based scaffolds. Size can also affect the spatial distribution of the encapsulated 
compound within the MPs while also facilitating better dispersion, greater mechanical 
strength, easier implantation, and potential access to a new implantation site [198]. 
Previous studies have shown that MP size greatly influences the release profiles, with 
an increase in sphere size causing a decrease in the rate of drug release. Materials with 
large surface area to volume ratio such as small diameter particles will react with fluids 
at much faster rates than monolithic materials due to the larger surface area available for 
reaction. The morphology of both particle sets was shown to be spherical, smooth and 
homogenous. In addition, the distribution pattern of the protein in the MPs was shown to 
homogenously distribute from the centre of the particle outwards. This is expected since 
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the feed solution is a neat solution of protein and polymer dissolved in water [150]. 
Protein distribution can have a significant effect on the release profiles. If the protein is 
heterogeneously distributed throughout the polymer a triphasic pattern of release results 
with an initial burst release as a result of protein on the particle surface being released 
upon contact with dissolution media [190]. A homogenous pattern of protein 
distribution often results in a biphasic pattern of release based on diffusion initially 
followed by polymer degradation [190, 195]. 
The release studies demonstrated that alginate and PLGA MPs are capable of 
sustaining the release of rhBMP-2 for the duration of the study with different release 
kinetics achieved depending on the MP formulation. The release kinetics of any agent is 
related to three processes; polymer degradation, diffusion through the polymer and 
dissolution of the dispersed factor. Low molecular weight MPs, such as those fabricated 
herein, show a diffusion dependant steady controlled release after the initial burst 
release [198]. As such, the main factors affecting protein release profiles from 
polymeric MPs revolve around the chemical properties of the encapsulated protein as 
well as the properties and structure of the polymer MPs, explaining the different release 
kinetics achieved with either polymer. Typically, MPs deliver a burst release of drug 
within the first 24 h [199, 200] however, it is hypothesised that the burst release effect 
was minimised from alginate MPs as a result of calcium chloride crosslinking. This 
process may have washed away any protein located on the periphery of the MPs. 
Protein may also have been released during crosslinking and lost during the washing 
steps leading to a lower release as opposed to a high burst release which was seen with 
PLGA. The burst release reported from PLGA may have a therapeutic benefit since 
products such as INFUSE® (Medtronic) rely heavily on burst delivery of protein. 
Interestingly, at the final timepoint of the study, MPs were still found to contain some of 
the originally loaded GF suggesting that these particles are capable of further long-term 
release of low concentrations of protein beyond durations of 28 days in vitro. The 
release from PLGA is slow compared to alginate releasing 14 % by day 28 in 
comparison to 45 %. However based on this release rate, only 5 mg of PLGA MPs will 
release on average 250 ng of BMP-2 within 28 days whereas the same volume of 
alginate MPs will release 1000 ng. This is a beneficial result for alginate and PLGA 
since these concentrations are well above the lower limits shown to induce ALP 
expression in preosteoblast cells [193] and well below the BMP-2 concentrations loaded 
in such products as INFUSE®.  
78 
 
Similar to BMP-2, VEGF released from alginate showed a similar trend of 
cumulative release however, the concentration released was lower than for BMP-2 with 
a cumulative release of 28 % by day 28. The molecular weight of the active agent may 
be affecting release, since drugs with a smaller molecular weight could be more easily 
removed during evaporation compared to larger molecules [198]. Unlike for BMP-2 
released from alginate, a steady state release profile of 8 % VEGF was achieved at each 
timepoint with high release rates observed until day 4 after which the release decreased 
to the endpoint of the study. A similar pattern of release was observed from VEGF 
released from PLGA as BMP-2 released from PLGA. Additionally, a smaller burst 
release of VEGF was observed for PLGA in comparison to BMP-2. Taken together, 
these data demonstrate the different release rates which can be achieved from alginate 
and PLGA MPs encapsulating numerous different active agents. The results of release 
studies revealed the potential to release high concentrations of BMP and VEGF at 
timepoints and concentrations relevant to the in vivo expression profiles for this GF in 
animal models undergoing fracture healing for up to 21 days [201]. Furthermore, by 
combining different populations of these MPs, in terms of size and composition, it may 
also be possible to further manipulate the release profile of the GFs. 
Obviously an essential consideration during the MP fabrication process is to 
maintain the bioactivity of the load pre- and post-processing. Although spray-drying 
and double emulsions are conventional MP fabrication methods they can compromise 
protein integrity via shear, interfacial, and thermal stresses following atomization of the 
feed solution and the high drying temperatures in the case of spray-drying and 
mechanical stirring and sonication incurred by double emulsions. In this study, it was 
shown that BMP-2 when exposed to preosteoblasts maintained its bioactivity after it 
was released from MPs suggesting that alginate and PLGA encapsulation provided 
protection to degradation. This is in agreement with previous reports which show 
maintenance of spray-dried protein integrity and secondary conformational structure 
[202]. Cell numbers were maintained in the presence of released BMP-2 similar to that 
of the control. A significant enhancement in ALP enzymatic activity in cells exposed to 
BMP-2 released from alginate and PLGA MPs strongly suggests maintenance of protein 
bioactivity but to a lesser extent than non-encapsulated rhBMP-2 added directly to the 
media relative to cells alone. This result may be attributed to the relatively short half-
life of BMP-2 which was released and retained in PBS for 4 h prior to its dilution and 
subsequent use as a media supplement. Interestingly, GF-free alginate dissolution media 
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seems to be more conducive to ALP activity than the normal growth media (cells alone 
group). A possible explanation may lie in the dissolution products of alginate MPs. 
Ionically cross-linked alginate MPs dissolve by releasing divalent Ca
2+
 ions into the 
surrounding media as a result of cation exchange with monovalent sodium ions [73]. 
This calcium release may be affecting cell differentiation versus the cells alone controls.  
VEGF was also shown to retain its bioactivity after being released from MPs as 
demonstrated by the ability to act as a mitogen for endothelial cell (EC) proliferation. 
As confirmation of VEGF functionality, the ability of ECs to form tubules was 
significantly enhanced following exposure to alginate and to a lesser extent PLGA 
released VEGF. Angiogenic sprouts of ECs are a critical regulator of the angiogenic 
process as they continue to extend, branch and anastamose to form capillary networks. 
The results showed that the presence of VEGF released from MPs triggered an 
enhanced tubule formation in ECs after 6 and 12 h versus cells alone. Additionally, 
when compared with rhVEGF (which was not encapsulated and released from MPs) 
added to the media (bioactivity benchmark control), tubule formation was enhanced at 
these timepoints. Importantly, this result suggests that the angiogenic factor released 
from alginate and similarly PLGA MPs is effective at triggering an angiogenic response 
from ECs. Specifically for alginate, VEGF activity is possibly being enhanced via its 
interaction with alginate due to an ionic interaction stabilising the GF from degradation 
compared to the VEGF control, as previously reported [203]. A unique and desirable 
property of alginate as a delivery polymer is its ability to promote enhanced bioactivity 
of GFs. It has been suggested that alginate dissolving from particles into the release 
media may be altering the binding of VEGF to VEGF receptors on ECs thereby 
prolonging the effects. 
Taken together, these encouraging results suggest a feasible preparation method 
for drug loaded-MPs composed of non-cytotoxic, biodegradable carrier materials. With 
this in mind, the mode of GF delivery developed in this study has considerable potential 
for the delivery of GFs with different temporal profiles. This can be achieved by 
altering either the fabrication parameters or regulating the local availability of GFs 
through combinations of protein-loaded MPs with other bioactive materials such as 
scaffolds.  
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2.5 Conclusion 
In this chapter VEGF and BMP-2 loaded alginate and PLGA  microparticles 
have been successfully fabricated and characterised using well established methods 
which allows a process of fabricating microparticles from stable, safe, GRAS classified 
and FDA approved natural and synthetic origin polymers. These polymers were capable 
of not only controlling the release of two of the main GFs pertinent to bone repair for 
prolonged periods of time, but also retaining the integrity and bioactivity of the 
encapsulated proteins within following delivery and release from the microparticles. 
Following on from these results, it is further hypothesized that a combination of 
optimised microparticles with scaffolds designed for tissue regeneration would create a 
GF eluting “smart” scaffold capable of supporting cell growth and inducing both 
angiogenesis and osteogenesis in vitro. This will be explored in Chapter 3. 
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Chapter 3: Functionalisation of a collagen-hydroxyapatite scaffold via 
the delivery of BMP-2 and VEGF from polymeric microparticles 
 
A patent has been filed based on the delivery system optimised in this work: 
O'Brien, F.J., Lopez-Noriega, A, Quinlan, E, Partap, S, Kelly, H, Cryan, S.A, A 
composite scaffold for use as a tissue engineering implant, 2014, WO2014060443 A2: 
Royal College of Surgeons in Ireland.  
 
The work has been adapted for the release of other therapeutic biomolecules which is 
the subject of the following publications: 
A. López-Noriega, E. Ruiz-Hernández, E. Quinlan, G. Storm, W.E. Hennink and F.J. 
O’Brien, Thermally triggered release of a pro-osteogenic peptide from a functionalized 
collagen-based scaffold using thermosensitive liposomes, Journal of Controlled 
Release, 187: 158-166, 2014. 
 
A. López-Noriega, E. Quinlan, N. Celikkin and F.J. O’Brien, Incorporation of 
polymeric microparticles into collagen-hydroxyapatite scaffolds for the delivery of a 
pro-osteogenic peptide in bone tissue engineering, APL Materials Special Issue 
Biomaterials and Bioelectronics. Invited paper - Submitted. 
 
3.1 Introduction  
The direct intramuscular injection of angiogenic growth factor (GF) into tissues 
for treatment of ischemic disease has shown promising results [204]. However, as 
previously mentioned in Chapter 2, bolus delivery of VEGF into the diseased site 
necessitates multiple high doses that can result in aberrant, highly permeable, 
structurally abnormal and unstable vessel formation. One reason for this is the inability 
to retain the GF efficiently at the desired site. Thus, the design of a multifunctional 
biomaterial tailored to release the appropriate signals at the desired site, at a sufficient 
dose and for the optimal duration to facilitate a therapeutic effect represents a highly 
desirable therapeutic strategy [99, 123]. With this in mind, the general concept in this 
chapter is to use a biomaterial scaffold designed for tissue regeneration to control the 
release of the GFs in order to promote vascularisation [205, 206] as well as to enhance 
osteogenesis. 
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Collagen-based scaffolds may serve as the delivery vehicle for these proteins by 
acting as a biological reservoir for GFs serving to enhance the bioavailability of the 
protein, allowing for a sustained release and enhanced activity compared to traditional 
methods of GF delivery [172, 195, 207]. A common approach for the delivery of GFs 
consists of the direct incorporation of proteins within the scaffold matrix [123, 208]. 
However, GF-releasing scaffolds have several drawbacks including poor release 
characteristics, lack of control over the timing and concentration gradients of proteins 
and compromised protein bioactivity [209]. One example of such a commercially 
available product is Medtronic’s INFUSE® bone graft as previously described. Whilst 
this product has been shown to be a viable alternative to autologous bone graft, the side-
effects and complications are well documented and include heterotopic bone growth or 
bone overgrowth due to BMP-2 leakage into other areas of the body as well as 
carcinogenicity [115]. Work in our laboratory has led to the development of a hybrid 
composite collagen-hydroxyapatite (CHA) scaffold which shows superior regenerative 
performance to currently available bone graft substitutes. It combines the 
biodegradability and biocompatibility properties of collagen, with the high mechanical 
stiffness characteristics of the naturally occurring bone mineral hydroxyapatite; 
representing the major organic and inorganic component of bone respectively [57]. 
Furthermore, the presence of the HA phase imparts osteoinductivity to the scaffold by 
encouraging rapid mineralization of new bone matrix [57, 197, 210]. In order to 
enhance the regenerative capacity of this commercially available CHA scaffold (trading 
as HydroxyColl™, SurgaColl Technologies™, Ireland), the current study focuses on 
material functionalisation through the delivery of therapeutic GFs - namely VEGF and 
BMP-2 to improve vascularisation and bone repair respectively.  
In an attempt to overcome the previously mentioned shortcomings associated 
with GF-releasing scaffolds, technologies such as microparticles (MPs) are increasingly 
integrated with scaffolds [123] in order to facilitate controlled release of therapeutics. 
MPs composed of numerous materials such as ceramics and polymers can protect 
proteins from degradation. Among them, poly (lactic-co-glycolic acid) (PLGA) and 
alginate, which were studied in Chapter 2, can be used to protect proteins as well as 
controlling and sustaining their release during tissue development. One example of a 
biologically functionalized material developed by Kempen et al employed PLGA 
microspheres loaded with BMP-2 in a poly(propylene) scaffold surrounded by a gelatin 
hydrogel loaded with VEGF to successfully repair an ectopic defect via the sequential 
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release of the GFs [211]. Also, Huang et al employed a dual scaffold capable of 
releasing plasmid DNA encoding for BMP-4 from the PLGA scaffold itself and plasmid 
DNA encoding for VEGF from alginate within the scaffold which also showed superior 
bone repair. These studies demonstrate the considerable therapeutic potential of GF-
releasing materials incorporating materials for controlled release [173]. Since impaired 
vascular structure can inhibit the transport of nutrients which eventually leads to failure 
to form bone and as angiogenesis precedes bone formation in vivo, the initial release of 
VEGF is desired followed by slower release of BMP-2 from the scaffolds [69, 119, 171-
173].  Figure 3.1 portrays the concept explored in this study, with the aim of using a 
biomaterial scaffold to control the kinetics of availability of polymer encapsulated GFs, 
i.e. the microparticulate delivery system developed in Chapter 2, for the delivery of 
BMP-2 and/or VEGF, is combined with a CHA scaffold.  Incorporation of BMP-2 and 
VEGF in the appropriate polymer within the CHA scaffold was tested either separately 
or in combination in a dual GF-loaded scaffold.  The ability of these systems to promote 
local bone healing in vivo was then explored in Chapter 4.  
 
Fig. 3.1 Scheme of a collagen-hydroxyapatite scaffold (HydroxyColl™) functionally activated 
with BMP-2 and VEGF encapsulated in polymeric microparticles. This material may facilitate 
cell recruitment and attachment at the site of injury allowing for activation of angiogenesis and 
osteogenesis. 
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3.1.1 Objectives 
The overall objective of this chapter was to develop and characterise a functionalised 
collagen-hydroxyapatite scaffold capable of the sustained release of VEGF and/or 
BMP-2 to promote vascularisation and bone repair. 
 
The specific aims were: 
1) To combine alginate and PLGA MPs developed in Chapter 2, for the 
encapsulation and sustained release of BMP-2 and VEGF in different 
combinations, with the CHA scaffold previously optimised for bone repair. 
 
2) To characterise the resulting scaffold in terms of scaffold microarchitecture in 
order to determine if the materials meet the specific requirements of scaffolds 
for tissue engineering. 
 
3) To determine the kinetics of BMP-2 and/or VEGF protein release from the 
scaffold in order to achieve a sustained and controlled pattern of release at 
bioactive concentrations. 
 
4) To assess the in vitro biological activity of BMP-2 and/or VEGF following their 
individual or dual incorporation into the scaffold and to determine the GF 
release kinetics from the materials. 
3.2 Materials and Methods 
3.2.1 Scaffold fabrication  
A CHA slurry was fabricated by mixing bovine type I collagen (1.8 g) in 400 
mL aqueous 0.5 M glacial acetic acid solution, followed by the addition of 3.6 g of HA 
in 40 mL of 0.5 M aqueous acetic acid solution (200 wt %) followed by further 
homogenisation [57, 212]. The slurry was degassed under a vacuum to remove air 
bubbles. The final suspension was poured into a stainless steel tray and lyophilised in 
the freeze-dryer (VirTis). Briefly, the suspension was first placed at 20º C. The 
temperature of the freeze-dryer was then cooled at a constant rate to a final freezing 
temperature of -10º C [57, 213]. The shelf/chamber temperature was then held constant 
for 60 mins to complete the freezing process. The ice phase was sublimated under a 
vacuum (< 100 mTorr) at 0º C for 16 h to produce the final porous scaffold.   
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Fluorescently labelled BSA (FITC for alginate and Rhodamine for PLGA) 
loaded alginate and PLGA MPs were initially incorporated into the scaffold for the 
characterisation studies as well as blank polymeric MPs. In order to incorporate the 
MPs into the scaffold they were suspended in PBS and dispersed by stirring into the 
CHA slurry at four different MP: CHA slurry ratios; 0, 0.5, 1.1 and 2.2 % w/v (equating 
to 0, 1.5, 3.3 and 6.6 µg of protein) and freeze-dried as above. BMP-2 and VEGF 
ultimately replaced BSA-FITC as the loading cargo and were similarly incorporated 
into the slurry producing a GF-eluting scaffold. This optimised multistep process for 
functionalised scaffold fabrication has subsequently been patented (Fig. 3.1) [212]. 
These scaffolds incorporated the optimal MP dose as established in the characterisation 
studies in the range of 0.5 % w/v of alginate MPs and up to 2.2 % w/v of PLGA MPs 
corresponding to 1.3 and 2.8 µg of GF respectively. Scaffolds containing various MP 
compositions were fabricated based on the findings in Chapter 2 including; 1) blank 
alginate, 2) blank PLGA, 3) alginate-VEGF, 4) alginate-BMP-2, 5) PLGA-VEGF 6) 
PLGA-BMP-2 6) scaffolds incorporating both alginate-VEGF and PLGA-BMP-2 (‘dual 
loaded’) and 7) scaffolds containing blank alginate and blank PLGA MPs i.e. GF free 
which will be termed ‘dual blank’ scaffolds for the remainder of this study. 
Scaffolds were crosslinked to enhance their mechanical properties under an 
ultra-violet (UV-subtype C) lamp (365 nm λ) for 15 min and were turned half way 
through. Given the intended purpose of the composite scaffolds as GF delivery systems, 
traditional scaffold cross-linking and sterilization techniques used within our laboratory 
are not feasible due to the sensitivity of GFs exposed to high temperatures incurred 
during for example dehydrothermal (DHT) treatment. Soaking scaffolds in EtOH as a 
method of sterilization also poses the challenge of loss of GF via its release in the 
sterilisation fluid. Similarly, chemical crosslinking techniques results in release of the 
GF into the crosslinking solution before its use in culture. For this reason, physical 
crosslinking in the form of exposure of scaffolds to UV-C irradiation was opted for. 
UVC irradiation has previously been shown to enhance the mechanical and enzymatic 
resistance properties of scaffolds. It does so by physically inducing collagen scaffold 
polymerization via the modification of amine and carboxyl groups within the collagen 
molecules allowing for their covalent modification [214].  
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3.2.2 Effect of microparticle incorporation on scaffold mechanical and structural 
properties  
3.2.2.1 Scanning Electron Microscopy (SEM)  
The distribution of MPs within the scaffold pores was examined by SEM 
imaging. Scaffolds were mounted onto metallic studs coated with thermoplastic 
adhesive and later sputtered with gold. Scaffold surface and cross sections were 
examined using a scanning electron microscope (SMU SEM, Japan) and an optical 
microscope (Olympus CX-41). Images were captured as outlined in Chapter 2. 
3.2.2.2 Confocal microscopy 
To determine the presence of fluorescently labelled protein (BSA-FITC in 
alginate and BSA-Rhodamine in PLGA) distributed throughout the CHA scaffolds, the 
use of a confocal laser scanning microscope was employed as described in Chapter 2 at 
original magnification 63X.  
3.2.2.3 Mechanical testing 
The effects of MP incorporation on the mechanical properties of scaffolds was 
assessed and compared with MP-free CHA scaffolds. Scaffolds 6 mm in diameter (n=9) 
were obtained using a biopsy punch and employed for the analysis. Compressive 
modulus was determined using a Z050 mechanical testing machine (Z050, Zwick/Roell) 
fitted with a 5-N load cell. Unconfined wet compression testing was performed on 
constructs that were immersed in PBS and tested at a rate of 10 % strain/min. The 
modulus was calculated from the slope of the stress-strain curve over the range 2-5 % 
strain (n=4).   
3.2.2.4 Pore structure and pore diameter analysis 
To examine the effects of MP incorporation on the porous structure of the 
scaffolds, they were embedded (n=3) in JB-4-glycolmethacrylate® (Polysciences, Inc, 
UK) using a previously established method [91] and then sectioned into 10 µm slices 
using a microtome. Scaffold sections were mounted on glass slides and stained with 
Toludine blue. To examine pore diameters the images were evaluated using 
MATLAB® pore topology analyser software, where original images were transformed 
into binary images. The pore size was defined as the diameter of a circle with a cross-
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sectional area equivalent to that of the best fit ellipse generated by the software (at least 
50 pores/section were considered for each analysis).  
3.2.2.5 Assessment of scaffold porosity 
The effect of MP incorporation on the porosity of the scaffolds was assessed by 
first weighing the scaffolds. The scaffolds were photographed and the pictures imported 
into Image J. The height and diameter of the scaffolds were measured to calculate their 
volume (n=9). Porosity was then calculated from the following equation; 
 
Equation 3.1 
 
Where  sample is the density of the sample and  material is the density of the material the 
scaffold is made from.  
3.2.3 Growth factor release kinetics from scaffolds 
To examine protein release kinetics from scaffolds, 6 mm diameter scaffolds, 
obtained using a biopsy punch, were placed in 2 mL of PBS (20mM sodium phosphate 
and 150 mM sodium chloride, pH 7.4) in a shaking water bath at 37º C. The release 
medium was replenished with fresh PBS at the following timepoints; 4 h, 1, 3, 7, 14, 21, 
28 and 32 days for analysis of protein content using a BMP-2 and VEGF enzyme-linked 
immunosorbent assay (ELISA) as described in Chapter 2.  
3.2.4 Bioactivity of growth factor released from microparticle-loaded scaffolds  
3.2.4.1 Analysis of BMP-2 bioactivity 
Cell culture & seeding 
To analyse osteogenesis, MC3T3-E1 cells, a pre-osteoblastic cell line, were 
cultured to confluence and then seeded directly onto the scaffolds where they were 
cultured in α-MEM with osteogenic supplements as described in Chapter 2. In a 24 well 
plate, each scaffold was seeded drop-wise with 25 µL of the cell suspension and then 
placed in the incubator for 15 min, the discs were then turned over and another 25 µL of 
the cell suspension was added drop-wise (total number of cells per scaffold = 5 x 10
5
 
cells). After 15 min, 1 mL of media was added to each well and the scaffolds returned to 
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the incubator. At day 3 and day 7, constructs were rinsed twice in PBS, flash frozen in 
liquid nitrogen and stored at -80
o 
C until analysis.  
 
DNA quantification 
To analyse the influence of the GF-releasing scaffold on the number of cells 
present on the scaffold over time and therefore their ability to proliferate, DNA was 
quantified as a surrogate measure of cell number. The PicoGreen assay was employed 
as previously outlined in Chapter 2 however, the 3D cell seeded constructs were 
homogenised in lysis buffer using a rotor-stator homogeniser (Omni International, 
Germany) and the cell/scaffold suspension was centrifuged at 2500 X g for 10 min at 4º 
C. The supernatant was collected and used for DNA analysis in the PicoGreen assay and 
the same sample was used to quantify ALP as described below. 
 
Alkaline phosphatase quantification 
As a measure of the ability of BMP-2 released from scaffolds to enhance 
osteogenesis, ALP, an early osteogenic marker, was quantified from MC3T3 cells 
cultured in direct contact with the scaffolds after 7 days. Scaffolds were homogenised in 
lysis buffer according to the manufacturer’s protocol (SensoLyte pNPP Alkaline 
Phosphatase Assay Kit) and the ALP assay carried out as previously described in 
Chapter 2. 
3.2.4.2 Analysis of VEGF bioactivity  
Cell culture and seeding 
To analyse angiogenesis HUVECs were cultured to confluence and seeded in a 
Matrigel tubule formation assay similar to Chapter 2. All scaffolds were sterilised under 
a UV-C germicidal lamp (254 nm) for 2 h in a laminar flow cabinet and were turned 
half way through [215]. The sterility of the composites was confirmed by incubating 
scaffolds in antibiotic-free cell culture medium at 37º C following exposure to UV 
irradiation and assessing for any changes in colour or turbidity daily which would 
denote infection. 
 
Matrigel tubule formation assay 
As a measure of the ability of VEGF released from scaffolds to enhance vascular 
activity in vitro, a Matrigel™ tubule formation assay was performed as previously 
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described in Chapter 2 using GF reduced Matrigel™ under the same conditions [216]. 
However, VEGF was first released from the VEGF-releasing scaffolds and the 
concentration quantified by ELISA as described in section 3.2.3 and diluted to 50 
ng/mL. VEGF-free media was employed as a negative control and non-encapsulated 
rhVEGF (50 ng/mL) added directly to the media was employed as a positive control. 
3.2.5 Statistical analysis 
The data are represented as means ± standard error of the mean (SEM). Statistics 
were carried out using GraphPad Prism software using a general linear model ANOVA 
with Tukey’s post hoc tests performed for multiple comparisons. All experiments were 
performed with a sample size of 3 per treatment group unless otherwise stated. 
Statistical significance was taken at P≤0.05 unless otherwise stated. 
3.3 Results 
3.3.1 Scaffold fabrication 
A number of preliminary experiments were carried out to optimise the 
fabrication process used to produce functionalized scaffolds. The liquid suspension of 
MPs was first mixed by homogenisation with the CHA slurry and the final suspension 
was degassed under vacuum to remove air bubbles which would affect scaffold pore 
structure. However, in order to minimise the time spent in the acidic environment of the 
slurry, the degassing step was removed and the slurry was degassed prior to the addition 
of a liquid suspension of MPs. Finally, the homogenization step was removed in order 
to minimise shearing of the MPs in the blender. The MP/slurry suspension was mixed 
briefly by vortexing. The final process involved adding the MP suspension to the 
primary slurry in an iterative manner, typically in aliquots, and ideally drop-wise. The 
suspension was subsequently freeze-dried initially at a final freezing temperature of -
40° C however, in order to achieve increased pore sizes a final freezing temperature of -
10° C was ultimately deemed optimal. Figure 3.2 shows the morphology and MP 
distribution throughout alginate and PLGA MP-loaded CHA scaffolds as determined by 
SEM achieved using the final optimised process of degassing prior to freeze-drying at -
10° C. 
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Fig. 3.2 Scanning electron micrographs of the cross section of CHA scaffolds showing the 
incorporation of alginate and PLGA microparticles. Various concentrations (0.5 % w/v, 1.1 % 
w/v and 2.2 % w/v) of microparticles were incorporated. Inset is the microparticle-free scaffold 
control. Images were taken at 1600X magnification. Scale bar represents 5 µm. 
 
Fluorescently labeled BSA-FITC was encapsulated in MPs in order to determine 
the distribution of the polymeric MPs throughout the composite scaffolds. Confocal 
microscopy indicated homogenous distribution of fluorescent alginate MPs within the 
scaffolds following the freeze-drying process (Fig. 3.3A-C). A more intense fluorescent 
signal was seen with increasing MP concentrations. PLGA was uniformly distributed 
throughout the scaffolds; however some aggregates were observed at the lowest 
concentration of MPs incorporated (Fig. 3.3D-F). 
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Fig. 3.3 Confocal Laser Scanning Microscopy (CLSM) images of CHA scaffolds incorporating 
BSA-FITC (green) loaded alginate (A-C) and PLGA (D-F) microparticles at various 
concentrations (0.5-2.2 % w/v). Microparticles are uniformly dispersed throughout the scaffolds 
with less uniformity observed with PLGA. 
 
3.3.2 Effects of microparticle incorporation on scaffold mechanical and structural 
properties 
3.3.2.1 Scaffold mechanical properties 
The mechanical properties of the scaffolds varied with the different MP 
concentrations incorporated. As shown in Figure 3.4, the incorporation of PLGA MPs 
did not significantly affect the compressive modulus of the scaffolds at any of the 
concentrations examined. Similarly the inclusion of low and medium concentrations of 
alginate MPs did not affect scaffold compressive modulus compared to the MP-free 
control. However, the inclusion of higher amounts (2.2 % w/v) yielded stiffer scaffolds 
compared to the control (1.8 kPa versus 1kPa). Taken together, the results indicated that 
alginate MPs promoted enhanced mechanical properties when compared with PLGA 
owing to the different affinities of these polymers to water present during testing.  
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Fig. 3.4 Influence of microparticle incorporation on scaffold compressive modulus. ***P<0.001 
denotes a significant increase in alginate scaffold compressive modulus compared to PLGA at 
0.5 and 2.2 % microparticles as well as an increase in alginate at 2.2 % microparticles compared 
to all other groups and the microparticle-free control. 
 
3.3.2.2 Porous architecture and pore diameter of scaffolds 
 Figure 3.5 displays the effects of MP incorporation on scaffold porous 
architecture. Scaffolds containing both PLGA and alginate (Fig.3.5A-C) maintained a 
homogenous pore structure similar to MP-free scaffolds (inset). The pore diameters of 
the scaffolds decreased depending on the concentration of alginate and PLGA MPs 
loaded in the scaffolds (Fig.3.5G). In scaffolds containing the lowest concentration of 
MPs, pore diameters were similar to that of the control (100 µm).  
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Fig. 3.5 Effects of microparticle incorporation on porous architecture and pore diameters of 
scaffolds. Bright field images of Toludine blue stained scaffold sections displaying the effect of 
alginate (A-C) and PLGA (D-F) microparticle incorporation at concentrations ranging from 0.5-
2.2 % w/v on scaffold porous structure. Scaffolds displayed a homogenous and interconnected 
pore structure. Inset is the MP-free control scaffold (CHA only). Scale bar indicates 100 µm. 
(G) Scaffold mean pore diameter (µm) as a result of MP incorporation. The graph indicates 
average pore sizes of 110 µm for MP-free scaffolds and significantly lower pore sizes of <100 
µm for MP-loaded scaffolds (***P<0.001) at the median and high MP loading.  
 
Porosity of the scaffolds as a result of incorporation of MPs was reduced at the 
highest concentrations for both alginate and PLGA however; high porosity was still 
maintained at high levels above 96 % (Fig. 3.6). Although the most concentrated PLGA 
and alginate scaffolds show a significant decrease in porosity, all the samples are above 
the level which has previously shown to be beneficial for cell and vascular infiltration 
into the scaffold (95 % porosity). 
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Fig. 3.6 Porosity of scaffolds incorporating polymeric microparticles. Scaffold porosity was 
maintained above 97 % for all scaffolds. *P<0.05 denotes significantly lower porosity in the 
most highly loaded scaffolds compared to those containing the lowest concentration of 
microparticles.   
 
Taken together, the data demonstrated that the lowest concentration of alginate 
MPs (0.5 % w/v) incorporated into the scaffold was optimal and the other 
concentrations were excluded from further studies. For PLGA, the MP loading finally 
chosen was 2.2 % w/v since the median or high concentrations did not detrimentally 
affect scaffold mechanical properties, pore size and maintained porosity values at 
beneficial levels (above 97 %). Additionally, a preliminary GF release study suggested 
that these MP loadings would allow for the release of therapeutically relevant GF 
concentrations which was further assessed below. Based on the previous findings, all 
subsequent scaffolds were fabricated containing GF-loaded alginate MPs at 
concentrations of 0.5 % w/v (corresponding to 355 ng GF/cm
2
) and GF-loaded PLGA 
MPs at concentrations of 2.2 % w/v (740 ng GF/cm
2
). 
3.3.3 In vitro growth factor release kinetics from microparticle-loaded scaffolds 
Figure 3.7 displays the pattern of protein released from alginate and PLGA MP-
loaded scaffolds over time (Fig. 3.8A-C). The protein release rate from alginate MP 
scaffolds was characterised by an initial burst release of 7.5 % BMP-2 within the first 
24 h and release was sustained at high levels up to 7 days (2-4 % at each timepoint). 
Protein release was lower from day 14 onwards (Fig. 3.7B). The cumulative release 
from the scaffold at the endpoint of the study was 15 % (135 ng/cm
2
) of the initial 
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amount incorporated (Fig.3.7A). In contrast, the release of BMP-2 from PLGA showed 
a double release profile characterised by an increase in GF release until day 7 (2 % peak 
corresponding to 15 ng/cm
2
), followed by a slower release which again peaked at day 
28 (Fig. 3.7C).  
 
Fig. 3.7 Release kinetics of rhBMP-2 from microparticle-loaded scaffolds. (A) In vitro 
cumulative release of BMP-2 from scaffolds as a percentage of the amount of BMP-2 loaded 
into alginate and PLGA microparticles. (B) BMP-2 release from alginate at the respective 
timepoints indicating high burst release of 7.5 % relative to day’s 1-7 (**P<0.01) and all other 
timepoints (***P<0.001) followed by a fluctuation in the release pattern and a low release from 
day 7 onwards. (C) BMP-2 release from PLGA displayed a double release profile indicated by a 
peak at days 7 and 28. 
 
The total percentage of GF delivered from the scaffold was similar to alginate at 
13 % (96 ng/cm
2
) of the initial amount incorporated however BMP-2 was released in a 
more sustained, prolonged manner from PLGA compared to its release from alginate. 
The concentration of BMP-2 released from PLGA at each timepoint was within the 
lower limits shown to induce ALP expression in preosteoblast cells whereas the 
concentration released from alginate after 7 days was well below the lower limits [193]. 
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The VEGF release kinetics, shown in Figure 3.8A, revealed that VEGF was 
released from alginate MP scaffolds at a higher rate relative to BMP-2 (26 % 
cumulative VEGF release versus 15 % BMP-2) although the kinetics of release were 
similar. This corresponds to 351 ng/cm
2
 of the initially incorporated VEGF (Fig.3.8A). 
A high burst release of 10 % of the total loaded protein was recorded followed by a low 
release of 5 % at day 1 and a burst again of 7 % at day 4 (Fig. 3.8B). After 4 days the 
release was sustained at 1 % (13.5 ng per scaffold) per timepoint thereafter.  
 
 
Fig. 3.8 Release kinetics of rhVEGF from microparticle-loaded scaffolds. (A) In vitro 
cumulative release, as a percentage of the amount of VEGF loaded into the alginate and PLGA 
microparticles within the scaffolds. (B) VEGF release from alginate at the respective timepoints 
showing high early release indicated by a burst release of 10 % at 4 h followed by lower release 
at days 1 and 3 and a sustained release profile from day 7 onwards (***P<0.001). (C) VEGF 
release from PLGA at the respective timepoints indicating low concentrations released at early 
timepoints relative to alginate but significantly high concentrations released at days 1 and 3 
(*P<0.05) which decreased thereafter. 
 
97 
 
Overall, VEGF was released from alginate in therapeutically relevant concentrations 
shown to increase neovascularisation in vitro and in vivo and with kinetics shown to 
promote enhanced EC proliferation and sprouting (high early concentrations >20-30 ng 
up to 7 days) [191, 192]. The cumulative release of VEGF from PLGA (7.8 %) was 5-
fold lower than VEGF from alginate (Fig. 3.8A) at the endpoint of the study. In contrast 
to alginate, this corresponds to 58 ng/cm
2
 of VEGF achieved with PLGA as opposed to 
the higher dose achieved with alginate (Fig. 3.8C). In addition no burst release was 
reported at 4 h as seen with alginate. A significant high peak in release from PLGA 
occurred at days 1 and 3 (>2 % release per timepoint) corresponding to a VEGF 
concentration of >15 ng/cm
2
 per timepoint. This was followed by a 2.5-fold decrease 
from day 3 to day 7 and the subsequent sustained release of low levels of VEGF 
thereafter (>4.4 ng/cm
2
) corresponding to the lower limits of VEGF reported to induce 
angiogenesis in vivo (4 ng/mL) [191]. 
3.3.4 Bioactivity of growth factor released from microparticle-loaded scaffolds 
3.3.4.1 Analysis of osteogenesis 
Having determined the release kinetics of proteins from the alginate and PLGA 
MPs in the scaffolds, the next step was to examine how the scaffold fabrication process 
affected BMP-2 protein bioactivity (Fig. 3.9A-B). The ability of cells to undergo 
osteogenesis whilst in direct contact with the scaffolds was examined. Figure 3.9A 
depicts cell numbers after 3, 7 and 14 days post-seeding on the various scaffolds, with 
significantly higher cell numbers observed at days 3 and 7 in the PLGA-BMP-2 group 
relative to the BMP-free control scaffolds. At day 14 in culture cell numbers were still 
higher than the control but not significantly so. Similarly, alginate-BMP scaffolds 
enhanced cell proliferation at days 3 and 7 with significantly higher cell numbers 
reported at day 14 (***P<0.001). Taken together, the results indicated that BMP-2 
retained its activity after fabrication and during the course of the study as indicated by 
higher levels of ALP activity from cells in contact with the BMP-2 eluting scaffolds 
compared with cells in contact with the BMP-free scaffolds (Fig. 3.9B). Specifically, 
ALP was significantly enhanced in the PLGA-BMP-2 group compared to all other 
groups in the absence of BMP-2 (***P<0.001) as well as to a lesser extent alginate-
BMP-2 scaffolds (**P<0.01). Importantly, this result demonstrates the pro-osteogenic 
effect of the PLGA-BMP-2 functionalised scaffolds and to a lesser extent alginate-
BMP-2 scaffolds.  
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Fig. 3.9 Effect of BMP-2-releasing scaffolds on osteogenesis. (A) Cell numbers of MC3T3 cells 
cultured in direct contact with the scaffold for 3, 7 and 14 days at an original seeding density of 
5x10
5
 cells/scaffold. **P<0.01 denotes a significant increase versus CHA control at 3 and 7 
days. ***P<0.001 denotes an increase vs CHA control at day 41. (B) ALP activity of cells 
cultured on scaffolds for 7 days. ***P<0.001 denotes significance in the BMP releasing PLGA 
group vs all groups and **P<0.01 denotes very significantly higher ALP in the BMP-2-
releasing alginate MP loaded scaffolds. A mild increase in ALP activity was shown in the 
alginate-BMP-2 groups relative to BMP-2 free scaffolds. 
3.3.4.2 Analysis of angiogenesis 
As a measure of the bioactive potential of encapsulated VEGF within the 
scaffolds, the tubule formation potential of endothelial cells (ECs), which is normally 
stimulated by VEGF (Fig. 3.10A), was determined after 6, 12 and 24 h in three different 
conditions including; media containing VEGF released from scaffolds (50 ng/mL) and 
controls (media alone and media containing non-encapsulated rhVEGF at the same 
concentration). It was observed that ECs cultured with VEGF released from alginate 
MP scaffolds (**P<0.01) and to a lesser extent PLGA MP scaffolds (*P<0.05) 
displayed enhanced vascular tubule formation compared to ECs in the absence of 
VEGF. When added directly to EC media at the same concentration, the VEGF control 
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similarly enhanced tubule length (2-fold increase) relative to ECs alone after 6 h (Fig. 
3.10B).  
VEGF encapsulated and released from alginate and PLGA MPs incorporated 
within scaffolds thus retains its bioactivity and enhances tubule formation. Interestingly, 
after 24 h tubules were longer in the presence of VEGF released from MP-loaded 
scaffolds than for the VEGF control (not previously encapsulated in MPs) at the same 
concentration suggesting the beneficial effects of controlled release on protein 
bioactivity. 
 
 
Fig. 3.10 Effect of VEGF-releasing scaffolds on angiogenesis. (A) Tubule formation by human 
endothelial cells cultured in VEGF from different sources after 6 h. Scale bar represents 100 
µm. (B) Quantification of tubule length after 6, 12 and 24 h cultured in the same conditions. 
Increased tubule length was recorded in the presence of 50 ng/mL rhVEGF (control) compared 
to ECs alone (***P<0.001), as well as the presence of VEGF released from alginate and PLGA-
VEGF scaffolds (**P<0.01,*P<0.05 respectively) after 6 h. After 24 h ECs exhibit increased 
tubule length relative to controls when cultured in the presence of VEGF released from alginate 
and PLGA-VEGF scaffolds only (*P<0.05 denotes significant increase versus ECs alone).  
 
Taken together, the GF release data and bioactivity tests suggest that PLGA is 
more suited for BMP-2 encapsulation while alginate is more effective for VEGF 
delivery. This finding is based on a number of comparisons including: GF release 
kinetics from scaffolds, the concentration of GF released and level of GF bioactivity 
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following release. BMP-2 released from PLGA was within the lower limits shown to 
induce ALP production in pre-osteoblasts at all timepoints and alginate released 
therapeutically relevant concentrations of VEGF. In addition, BMP-2 released from 
PLGA was more bioactive than BMP-2 released from alginate. Consequently, the 
effects of combining both MP/GF sets within a single ‘dual’ scaffold, to more closely 
resemble the conditions present in the repair sequences of a bone fracture, were also 
investigated below.  
3.3.5 Assessment of the in vitro potential of dual growth factor-releasing scaffolds 
3.3.5.1 Scaffold fabrication 
The effects of simultaneously incorporating VEGF and BMP-2 loaded alginate 
and PLGA MPs respectively within a dual scaffold on material and structural properties 
was investigated. The presence and distribution of MPs within the dual scaffolds was 
similarly confirmed as with single loaded scaffolds via SEMs of the scaffolds taken at 
three different magnifications shown from left to right in Figure 3.11A. SEMs 
demonstrated the incorporation of individual MPs throughout the scaffold walls as well 
as confirming the highly porous nature of the dual scaffolds similar to the single loaded 
scaffolds.  Fluorescently labeled BSA (BSA-FITC) (green) was once again encapsulated 
in alginate MPs and used as a model to determine MP distribution and PLGA was 
loaded with fluorescent rhodamine (red). Confocal microscopy indicated good 
distribution of both polymers throughout the dual scaffold as with the single loaded 
scaffolds. These scaffolds are individually displayed in Figure 3.11B from left to right 
and showed a homogenous distribution of MPs following the freeze-drying process. 
Although the MP loading in the dual scaffold (merged image on the right) is much 
denser (2.7 % w/v) than scaffolds incorporating either alginate or PLGA MPs alone (0.5 
and 2.2 % w/v respectively), the former still maintained a homogenous MP distribution 
throughout the matrix.  
 
101 
 
 
 
Fig. 3.11 Scanning electron micrographs and confocal images of dual growth factor-releasing 
scaffolds. (A) Micrographs of the surfaces of dual microparticle loaded scaffolds showing their 
homogenous incorporation throughout the matrix. Images were taken at 10,000, 5,000 and 1,000 
X magnification. Scale bar represents 5, 10 and 50 µm respectively. (B) Confocal images of 
BSA-FITC (green) loaded alginate and BSA-Rho (red) labelled PLGA microparticles and an 
overlay of both fluorescent signals in the dual loaded scaffold. Scale bar represents 200 µm. 
 
3.3.5.2 Effects of microparticle loading on scaffold mechanical and structural 
properties 
 
Scaffold mechanical properties and pore diameters 
The compressive modulus of the dual scaffolds decreased with the inclusion of 
both PLGA and alginate MPs compared to the MP-free CHA scaffold (control), as 
shown in Figure 3.12A. Images of control and dual loaded scaffolds show homogenous 
pore structures with a decrease in pore size (Fig. 3.12B) similarly to the single polymer 
loaded scaffold. This decrease in pore size was further corroborated by the pore 
diameter quantification analysis (Fig. 3.12C) which was shown to be 100 µm for the 
control and 90 µm for the dual loaded scaffold. 
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Fig. 3.12 Effect of PLGA and alginate microparticle incorporation on the compressive modulus 
(A), porosity (B) and pore sizes (C) of scaffolds. Influence of PLGA and alginate microparticle 
incorporation on scaffold compressive modulus. *P<0.05 denotes significantly higher modulus 
in the absence of particles. (B) Bright field microscopy images of Toludine blue stained control 
and dual scaffold sections indicating a homogenous pore structure with reduced pore size 
following microparticle incorporation. (C) Scaffold pore diameter variations as a result of 
microparticle incorporation. A significant reduction in pore size was observed following 
microparticle incorporation (*P<0.05). 
 
3.3.5.3 Growth factor release from dual scaffolds     
Figure 3.13 depicts the GF release kinetics from the dual loaded scaffolds with 
the optimised polymer-GF combination from the earlier studies. Cumulatively, the 
release of BMP-2 from PLGA and VEGF from alginate was 24 % and 41 % 
respectively (Fig. 3.13A). This corresponds to a 0.8-fold and 0.5-fold increase in the 
rate of BMP-2 and VEGF release respectively from PLGA and alginate MPs when 
combined in a dual scaffold in comparison to the single loaded scaffolds (13 % and 26 
% GF respectively). VEGF release from alginate was delayed in the dual loaded 
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scaffold at the initial timepoints compared to its release from single loaded scaffolds. 
Nonetheless, the scaffolds still delivered effective in vitro concentrations at days 1 and 3 
(>22 ng). VEGF delivery from the scaffold was characterized by low release early on 
until a peak in the release was seen at day 14 and 21 corresponding to 20 % (71 ng/cm
2
) 
and 12 % (43 ng/cm
2
) VEGF delivered respectively (Fig. 3.13B).  
 
Fig. 3.13 Release of rhVEGF and rhBMP-2 from dual scaffolds. (A) In vitro cumulative release 
of VEGF and BMP-2 from scaffolds as a percentage of the theoretically loaded amount of GFs 
in alginate and PLGA microparticles respectively. (B) VEGF release showing an initial low 
release followed by an increased release from day 10 onwards (***P<0.001 at 14 days vs 4 h to 
day 10, ***P<0.001 at 21 days vs 4 h to day 10). (C) BMP-2 release from scaffolds showing a 
sustained release of low levels of BMP-2 with respect to protein release from alginate and a 
peak in release at days 10 (**P<0.01) and 21 (***P<0.001) vs earlier timepoints. 
 
In contrast, the kinetics of BMP-2 release from PLGA was similar in the single 
and dual loaded scaffolds. BMP-2 release from the dual scaffolds was sustained at 2 % 
per timepoint until day 10 corresponding to a concentration of 15 ng/cm
2
 of BMP-2 per 
timepoint. A double release profile was observed thereafter, characterised by a 4 % peak 
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(corresponding to 29 ng/cm
2
) at day 10, followed by a slower release, which again 
peaked to 8.5 % at day 28 (corresponding to 63 ng/cm
2
) (Fig. 3.13C). 
3.3.5.4 Bioactivity of growth factor released from dual scaffolds 
Having determined the release kinetics of proteins from the dual loaded 
scaffolds the next step was to examine how the process of incorporating BMP-2 and 
VEGF loaded MPs into the scaffold followed by freeze-drying affects protein 
bioactivity. Cells were cultured in direct contact with the scaffolds. The dual loaded 
scaffolds were shown to increase the number of cells growing on it after 3 days relative 
to the control although this was not significant (Fig. 3.14A). By day 7 there was no 
difference between the control and dual scaffolds. However, when ALP activity was 
assessed, there was an increase (*P<0.05) in cellular activity of the enzyme in the 
presence of the dual loaded scaffold demonstrating the ability of the functionalized 
scaffold to induce cellular differentiation down the osteogenic lineage and thus release 
of bioactive GF (Fig. 3.14B).  
               
Fig. 3.14 Effect of dual scaffolds on osteogenesis. (A) Cell numbers of MC3T3 cells cultured in 
contact with the scaffold for 3 and 7 days at a seeding density of 5x10
5
 cells/scaffold. MC3T3 
cell number on dual and BMP-free scaffold (CHA control) remained constant between groups 
and timepoints. (B) ALP activity of cells cultured on the dual scaffolds for 3 days was 
significantly enhanced (*P<0.05) compared to the BMP-2 free scaffolds (CHA control).  
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In comparison to the single GF loaded scaffolds, ALP activity peaked at an 
earlier timepoint in the dual scaffolds. Additionally, the ALP concentration was lower 
compared to the former group suggesting a more moderate induction of osteoblast 
differentiation. Importantly, the dual scaffold maintained the potential to induce 
osteoblast differentiation and thus the BMP-2 was shown to retain sufficient bioactivity.  
VEGF released from the dual scaffold also retained its integrity. As a measure of the 
bioactive potential of the encapsulated VEGF from dual scaffolds, the tubule formation 
potential of endothelial cells (ECs) in response to released VEGF was determined. 
Compared to the group without VEGF, cells exposed to VEGF released from the dual 
scaffolds for 4 h were more effective at forming tubules but to a lesser extent than 
rhVEGF control (not previously encapsulated in MPs) after 6 and 12 h of exposure (Fig. 
3.15B). This suggests that VEGF released from dual scaffolds is still efficiently 
bioactive despite the processes of spray-drying, incorporation into the CHA slurry, 
freeze-drying and the added presence of the byproducts of degradation and release from 
PLGA (BMP-2) MPs.  
 
Fig. 3.15 Effect of dual scaffolds on angiogenesis. (A) Tubule formation by human endothelial 
cells cultured in VEGF from different sources. Scale bar represents 100 µm. (B) Quantification 
of tubule length after 6, 12 and 24 h. Increased tubule length was recorded in the presence of 50 
ng/mL VEGF (positive control) compared to ECs alone (**P<0.01) after 6 h. VEGF released 
from the dual scaffold induced an increase in tubule formation of ECs also although this was 
non-significant. (**P<0.01 denotes significant increase vs ECs alone).  
106 
 
3.4 Discussion 
A major field of research has emerged to fill the requirement for GF release 
profiles from scaffolds for tissue engineering which mimic in vivo tissue regeneration or 
morphogenesis. To this aim the delivery of GFs from a depot system which mimics the 
native ECM and releases a programmed concentration of GFs at a controlled rate is a 
desirable strategy. The fabrication process detailed in this chapter has led to the 
successful development of a functionally activated CHA scaffold capable of the 
sustained release of both BMP-2 and VEGF, the frontline GFs in bone repair. 
Furthermore, the incorporation of MPs maintained the inherent material and structural 
properties of the scaffold compared to MP-free scaffolds in terms of their compressive 
modulus, porosity and pore size which were sufficient to support cell infiltration, cell 
growth and enhance cell differentiation.  
The element of encapsulation which was investigated in this study is the 
incorporation of the GF loaded spray-dried alginate MPs as well as PLGA MPs 
fabricated by double emulsion (as described in Chapter 2), within a CHA scaffold 
optimised previously for bone repair. The result was a novel MP-loaded bioactivated 
CHA scaffold. Given the short half-life of BMP-2 and VEGF which, like many other 
GFs, are uptaken and catabolised by the liver, encapsulation and retention in the CHA 
matrix may serve to delay the otherwise rapid dispersal of the water-soluble protein. 
This composite matrix may also further promote osteogenesis via its innate 
osteoinductivity [57] as well as by providing a sustained release of BMP-2 or VEGF to 
cells thereby increasing the duration of exposure of cells in the defect site to the protein. 
Initially we confirmed the feasibility of the fabrication process, which was demonstrated 
by the homogenous distribution of MPs within the matrix following lyophilisation of 
the combined components. This is important since distribution of MPs will affect the 
protein release and local effects at a defect site. Overall the absence of aggregates is a 
positive result since the aggregation of MPs within scaffolds may not serve the purpose 
of controlled spatial delivery of therapeutics [121, 217, 218]. MPs were further shown 
to be well distributed throughout the collagen-HA fibrils of the scaffolds and in some 
instances in the scaffold walls. Furthermore, individual MPs retained their spherical 
structure following incorporation into the scaffold and were shown to be within the size 
range previously reported (< 10 µm) according to SEM which is less than the pore size 
of the scaffolds.  
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Optimal scaffolds developed for tissue regeneration should provide an 
appropriate environment for cell proliferation, differentiation and tissue synthesis. Since 
core degradation in scaffolds is of major concern resulting from the lack of 
vascularisation and waste removal throughout scaffolds, a porous, interconnected pore 
structure is vital for cell infiltration, nutrient and waste diffusion [44]. The architecture 
of the scaffold is critical to this aim. Freeze-drying is one of the most common methods 
of scaffold fabrication and results in the rapid formation of inter/intra connected ice 
crystals inside the polymer solution during freezing leading to the formation of pores 
during sublimation [93]. However, the introduction of MPs for GF release into its 
structure may influence the micro architecture of the scaffolds by changing the pattern 
of ice crystal formation. Herein, the results showed a homogenous scaffold pore 
structure irrespective of MP concentration as well as highly porous materials (≥ 97 %) 
with interconnected pores, which would facilitate vascular infiltration thereby reducing 
the possibility of avascular necrosis [41]. Additionally, pore size is a key component of 
scaffolds for TE. Cell interaction with the scaffold is dependent on ligands on the 
material surface which is influenced by the surface area, a property dependant on 
material porosity [47, 48]. Therefore, there exists a delicate balance which must be 
achieved, with materials having large enough pores to facilitate cell infiltration and 
small enough pores to allow for high ligand density which promotes sufficient levels of 
cell attachment on the material [47-50]. The minimum pore size range for significant 
bone growth has been reported as 75-100 µm while the optimal range is 100-135 µm 
[50].  The scaffolds produced herein had pore diameters in excess of 100 µm when MPs 
were loaded at low concentrations which decreased with higher concentrations. This 
result may be attributed to the MPs acting as nucleation sites for ice crystal formation 
during lyophilisation from which pores are formed resulting in smaller more compact 
porous architecture. These data indicate that the low concentration of alginate MPs led 
to scaffolds with an optimal pore size of >100 µm whereas for PLGA the low and high 
concentrations led to scaffolds with mean pore sizes >90 µm both sufficient for cellular 
attachment and infiltration. For PLGA the interaction of water with the hydrophobic 
surface of PLGA may affect the final pore size since water molecules in contact with 
PLGA do not form inter-molecular hydrogen bonds with the hydrophobic surface [219]. 
The result is the formation of highly connected intra-molecular hydrogen bonds with 
other water molecules. Since PLGA aggregations were reported in the lowest particle 
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dose the occurrence of these bonds may have increased resulting in higher pore 
diameters with respect to scaffolds with more homogenous PLGA distribution.  
The mechanical properties of a scaffold are of great importance particularly 
when regenerating hard tissue such as bone and play a role in affecting cell behaviour, 
including the angiogenic and osteogenic activity of incorporated cells [78, 220, 221]. 
The incorporation of PLGA did not affect the scaffold mechanical properties over MP-
free scaffolds. On the other hand, the increased scaffold compressive moduli in the 
alginate scaffolds with increasing concentrations of MPs may be attributed to the 
hydrophilic MPs reinforcing the scaffolds in a hydrophilic environment. Additionally, 
the porous architecture of the scaffold may have influenced this result since high MP 
concentrations reduced scaffold pore size resulting in a denser and tightly packed 
material. Following on from this, alginate MPs were subsequently loaded at a low 
concentration while PLGA MPs were loaded at the higher concentration. This regime of 
MP inclusion led to optimal pore sizes. Additionally the increased collagen to polymer 
content in these constructs could also encourage osteoblastic function by increasing the 
availability of ligands for osteoblast integrin binding [47, 48].  
Having confirmed that the MP-loaded scaffolds fabricated fulfilled the specific 
requirements of scaffolds for tissue engineering in terms of their micro structural 
properties, the GF release kinetics from the materials was examined. GF release from 
the scaffolds was different depending on the polymer of choice. BMP-2 release from 
alginate scaffolds followed a pattern of high initial burst release followed by a lower 
sustained release representing 15 % of the cumulatively loaded amount at the endpoint 
of the study. The high burst release is likely a result of protein being released from MPs 
at first contact with the acidic environment of the CHA slurry prior to freeze-drying. 
The cumulative amount of BMP-2 release from PLGA was similar to alginate; however 
the burst release effect was lost for PLGA loaded scaffolds. Interestingly, PLGA 
exhibited a double release pattern for BMP-2, an incremental increase from 4 h to 7 
days followed by a decrease which subsequently increased incrementally after day 21. It 
is hypothesised that the remaining protein is being retained within the scaffold, by the 
HA particles themselves [222, 223] or by the alginate and PLGA MPs still present at the 
end of the study.  Thus, the scaffold loaded with BMP-2 MPs is capable of further 
delaying the protein release kinetics and achieving a sustained steady state drug release 
profile not observed with MPs alone. Since the normal BMP-2 expression during bone 
repair shows an upregulation that peaks at/after 21 days, the results suggested that 
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PLGA loaded scaffolds may be more beneficial than alginate loaded scaffolds for BMP-
2 elution. Additionally, the PLGA scaffolds were capable of releasing bioactive 
concentrations of BMP-2 at all timepoints up to 28 days well within the lower limits 
shown to induce ALP expression in preosteoblast cells whereas the concentration 
released from alginate after 7 days was below the lower limits [193]. 
VEGF released from alginate followed a different release profile compared to 
BMP-2 released from alginate whereby protein was released at high concentrations for 
up to 3 days after which time a steady state sustained release profile for 28 days was 
observed. This result may be attributable to the different molecular weights of the 
proteins as previously described.  Encouragingly, the slow release of VEGF for a period 
of up to 7 days has been shown crucial for angiogenesis [102, 224]. Overall, the 
incorporation of 355 ng/cm
2
 of VEGF was released from scaffolds in therapeutically 
relevant concentrations and kinetics which have been shown to increase 
neovascularisation in vitro and in vivo, promoting enhanced EC proliferation and 
sprouting [191, 192]. During normal bone healing, VEGF expression shows an early 
peak in expression whereas BMP-2 expression peaks at later stages, a process which 
can be mimicked using the specific polymer-GF combinations optimised herein [225]. 
Collectively this data indicates that alginate MPs are effective for the release of VEGF 
from our scaffolds based on the high initial release profiles obtained and PLGA may be 
more effective for BMP-2 delivery based on the late stage peaks in delivery observed. 
This was backed up by analysis of protein bioactivity.  
The success of this scaffold-based delivery system depends largely on its ability 
to present BMP-2 and VEGF in an active form at the required continuous concentration 
to induce a bioactive response from cells. The scaffold also should protect the protein 
from denaturation via proteases as well as oxidative stresses from the surrounding 
environment [174]. With this in mind, GF bioactivity was assessed. The alginate-BMP-
2 scaffold displayed moderately enhanced ALP activity when cells were in direct 
contact with the scaffold. It is likely that the high burst release of BMP-2 reported for 
this polymer resulted in faster degradation when compared to PLGA-BMP-2 or 
inactivation in the culture medium by molecules such as serum proteins a result which 
was previously reported from BMP-2 released from MPs alone in Chapter 2. On the 
other hand, the PLGA-BMP-2 scaffold was shown to significantly enhance ALP 
activity indicating a bioactive protein and maintenance of protein activity following the 
fabrication process. Furthermore, the presence of PLGA-BMP-2 led to enhanced cell 
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numbers. Taken together, these results indicate the suitability of PLGA for the release 
of bioactive BMP-2 from CHA scaffolds at relevant in vivo concentrations but suggest 
that the BMP-2 released from alginate MPs within the scaffold may be less effective in 
stabilizing BMP-2 bioactivity compared to PLGA.  
The bioactivity of VEGF released from the scaffolds was also assessed. 
According to Bikfalvi et al, VEGF typically has a half-life of 2-3 h when exposed to 
ECs [226]. Herein, VEGF released from both PLGA and alginate-loaded scaffolds 
showed enhanced ability to stimulate ECs in culture suggesting preservation of 
bioactivity. Furthermore, released VEGF was shown to be not only functional at 
inducing EC tubule formation to a similar extent as rhVEGF not previously 
encapsulated in MPs (at the same concentration), but at later timepoints, more potent 
than the control. Hence, these results demonstrate preservation of VEGF bioactivity and 
a greater ability to preserve tubule formation at later timepoints. The results suggest that 
VEGF activity is possibly being enhanced via an alginate-protein ionic interaction 
stabilising VEGF from degradation compared to its direct addition to the cells as 
previously reported [203]. It has been suggested that alginate dissolving from particles 
into the release media may be altering the binding of VEGF to VEGF receptors on ECs 
thereby prolonging the effects, a result which was previously seen in Chapter 2.  
Delivery strategies thus far have yielded limited success in the formation of 
functional and stable vessel networks likely relating to the poorly controlled 
concentrations of VEGF delivered and its rapid depletion [123, 227, 228]. In this 
system, cumulative release data suggested a controlled release profile from the alginate 
MP scaffolds with a high initial burst release (135 ng/scaffold) followed by a lower 
release for up to 4 days after which time a steady state sustained VEGF release profile 
was observed. Although there is little conclusive information regarding the specific 
VEGF concentration required to elicit an in vivo biological response, it has been 
demonstrated that higher concentrations of VEGF for a period of up to 7 days followed 
by lower concentrations as well as a distributed spatial pattern of delivery, as achieved 
with this scaffold, is more effective at permitting perfusion and neovascularisation [102, 
119, 192]. Several previous studies using a bolus delivery method have demonstrated 
that doses of 10-30 ng/g resulted in increased neovascularisation in vivo. Other studies 
have shown that a lower dose of 4 ng/g of VEGF released from PLGA microparticles in 
an alginate gel was sufficient to induce angiogenesis in vivo [191]. The delivery system 
developed in this study is thus desirable since the kinetics achieved enabled the release 
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of therapeutically relevant VEGF concentrations from alginate-MP loaded scaffolds 
which may promote enhanced vasculogenesis [225]. This system could therefore 
potentially improve VEGF efficacy without a need to change the total dose as 
previously suggested [192, 205]. This may promote enhanced vasculogenesis in vivo 
given that during the course of fracture healing the rat isoform of VEGF165 is highly 
expressed early on and is constantly expressed after day 5 [225, 229, 230].  
Having optimised each system for the incorporation and release of individual 
GFs, the dual release of both GFs was then investigated in an attempt to mimic the 
conditions present in the repair sequences of bone fracture in vivo. This involves the 
complex, temporal and coordinated action of a myriad of signalling molecules, of which 
BMP-2 and VEGF play the most prominent role. Since VEGF participates in 
ossification [102] and angiogenesis precedes bone formation in vivo, the early release of 
VEGF is desired to re-establish the vasculature as well as the continuous release of 
BMP-2 for bone formation and remodelling [69, 119, 171-173]. A reduction in the 
mechanical properties of the dual scaffold was observed owing to the increased MP 
content. More importantly, both MP compositions were successfully incorporated in a 
similar manner as single polymer scaffolds and uniformly distributed throughout the 
scaffold. Pore size decreased relative to the controls as a result of the dual scaffold 
containing an increased MP load compared to single loaded scaffolds. Nonetheless, the 
dual scaffolds supported cell growth and differentiation while bioactivity studies 
demonstrated maintenance of VEGF and BMP-2 function following their dual 
incorporation into and release from the scaffold. Furthermore, the dual loaded scaffolds 
were capable of the sustained released of VEGF and BMP-2 in therapeutically relevant 
concentrations and at higher concentrations than those achieved with single loaded 
scaffolds. Additionally, the ratio of BMP-2 released from the dual scaffolds was higher 
than VEGF at all timepoints examined with a cumulative release ratio of 1:5 of BMP-2 
to VEGF until day 7. This is beneficial since it has been reported that the ratio of BMP 
to VEGF is critical to ensure synergistic effects in healing. Specifically, the delivery of 
a high ratio of BMP to VEGF can accelerate healing to a greater extent than high VEGF 
to BMP ratios in vivo. Moreover, excessive VEGF in relation to BMP can impair bone 
formation by driving cells down the endothelial lineage thus reducing the number of 
available MSCs for osteogenic differentiation [231]. Collectively, those studies 
accentuate the immense potential of dual loaded scaffolds fabricated herein. The ability 
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of these functionalised CHA scaffolds to enhance bone repair and angiogenesis was 
assessed in the study presented in Chapter 4.  
3.5 Conclusion 
The findings in this chapter report a multi-step process for combining the growth 
factor loaded polymeric particles fabricated in Chapter 2 with a CHA scaffold 
previously optimised for bone repair using well established and mild processing 
conditions to enhance the functionality of the scaffold. The resulting functionalised 
scaffolds possessed desirable pore structures and mechanical properties for tissue 
engineering applications. Furthermore the scaffold was capable of the sustained release 
of bioactive concentrations of VEGF from alginate and BMP-2 from PLGA 
microparticles within the matrix over 28 days with kinetics resembling the in vivo 
condition that is; the early expression of VEGF followed by later more sustained release 
of BMP-2, enhancing the functionality of the CHA scaffold. This fabrication process for 
scaffold functionalisation has the potential to be readily scalable to industrial levels and 
easily tailored in terms of not only the microarchitectural properties of the material but 
also the kinetics of release of a variety of different proteins from the scaffold. Taken 
together, these data indicate that alginate (VEGF) microparticles and PLGA (BMP-2) 
microparticles entrapped in CHA scaffolds, may offer an ideal platform to promote 
vasculogenesis and osteogenesis respectively of bone defects in vivo.  
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Chapter 4: In vivo evaluation of a series of BMP-2/VEGF releasing 
collagen-hydroxyapatite scaffolds for bone repair 
 
A patent has been filed based on this work which is also the subject of manuscripts in 
submission: 
 
Patent: O'Brien, F.J., Lopez-Noriega, A, Quinlan, E, Partap, S, Kelly, H, Cryan, S.A, 
A composite scaffold for use as a tissue engineering implant, 2014, WO2014060443 
A2: Royal College of Surgeons in Ireland.  
 
E. Quinlan, A. López-Noriega, E. Thompson, A. Hibbitts, S-A. Cryan and F.J. 
O’Brien, Controlled release of VEGF from spray-dried alginate microparticles in a 
collagen-hydroxyapatite scaffold for promoting vascularisation and bone repair, Journal 
of Tissue Engineering and Regenerative Medicine, Under Review. 
 
E. Quinlan, A. López-Noriega, E. Thompson and F.J. O’Brien, Development of 
collagen-hydroxyapatite scaffolds incorporating PLGA and alginate microparticles for 
the controlled delivery of rhBMP-2 for bone tissue engineering, In Preparation. 
 
4.1 Introduction 
The efficient repair and regeneration of bone following injury depends strongly 
on angiogenic and vasculogenic responses. Thus the long-term success of tissue 
engineered grafts post implantation requires rapid neo-vascularisation [33, 232, 233]. 
As such, the critical role played by the vasculature in supporting and nourishing the 
mesenchymal stem cells (MSCs) and osteoblasts necessary for endochondral 
ossification and fracture repair is well documented with several reports pertaining to the 
fact that neovascularisation increases bone mass following fracture [234]. Scaffolds 
have previously been employed to release GFs which enhance the regenerative capacity 
of bone although this approach required supraphysiological doses [235-237]. The short 
half-lives, slow tissue penetration, and potential toxicity at high doses suggest the 
conventional routes of delivery are unlikely to be successful, not only for VEGF, but for 
all growth factors (GFs). Consequently, materials which act as a depot system for the 
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controlled delivery of proteins, mimicking in vivo GF concentrations during tissue 
regeneration, such as those developed in Chapter 3, are desirable [138, 238, 239].  
In recent years, devices developed for the controlled release of BMP-2 have 
been tested in both ectopic and orthotopic sites for bone regeneration in different animal 
models such as rabbits [240], rats [241] or mice [242]. Similarly, encapsulation and 
incorporation of VEGF into three-dimensional (3D) matrices stimulated blood vessel 
formation in animal models in which the materials were implanted resulting in 
stimulation of fracture healing [137, 243]. Efforts to improve on the shortfalls of 
conventional GF delivery strategies have also led to the emergence of scaffolds capable 
of releasing or expressing osteogenic and angiogenic factors simultaneously. In some 
studies, these dual releasing scaffolds have been shown to enhance bone regeneration in 
comparison to treatment with either GF alone [171, 244, 245].  
In this thesis, collagen-hydroxyapatite (CHA) scaffolds which have been shown 
to facilitate bone regeneration of critical sized defects in two pre-clinical models (rat 
calvaria [57] and rabbit radii [59]), were utilised. The term ‘critically-sized defect’ 
defines the size limit of a defect which, if exceeded, may not regenerate without 
appropriate intervention in the form of bone grafts or another substitute [246]. Chapter 3 
sought to enhance the regenerative capacity of these CHA scaffolds via the inclusion of 
PLGA and alginate microparticle-based delivery systems which control the release of 
BMP-2 and VEGF respectively, embedded within this biomaterial platform. It is 
hypothesised that these functionalised scaffolds may reduce systemic exposure to GFs, 
maintaining GFs at the defect site resulting in bone healing and regeneration of a 
critically sized defect in vivo either alone or when delivered simultaneously due to (i) 
induction of angiogenesis by VEGF which lays down a vascular bed via the 
proliferation and recruitment of endothelial cells (ECs) as well as recruiting osteoblasts 
and (ii) induction of osteogenesis by BMP-2 leading to the recruitment of ECs and the 
indirect production of VEGF by osteoblasts. Furthermore, the scaffold would harness 
cell proliferation and differentiation, cell and vascular infiltration, guide bone 
regeneration and be well-resorbed and replaced by de novo bone.  
4.1.1 Objectives 
The overall objective of this chapter was to assess the in vivo potential of 
functionalised VEGF and/or BMP-2 eluting collagen-hydroxyapatite scaffolds to 
promote vascularisation and bone repair in a critically sized cranial defect rat model. 
115 
 
With this purpose in mind, neovascularisation and bone healing were assessed after 
implantation of a series of optimised GF-releasing scaffolds from Chapter 3 which are 
depicted in Figure 4.1.  
 
The specific aims were: 
1) To comparatively assess the potential of GF-releasing scaffolds to enhance 
osteogenesis over GF-free scaffolds and an empty defect containing no scaffold 
as a negative control 
2) To comparatively assess the potential of the GF-releasing scaffolds to enhance 
angiogenesis over GF-free scaffolds and an empty defect 
3) To assess whether the dual delivery of BMP-2 and VEGF further enhanced bone 
healing compared to the delivery of either GF alone. 
 
 
 
Fig. 4.1 Schematic of scaffolds used for in vivo implantation. These include a GF-free CHA 
scaffold and functionalised CHA scaffolds incorporating various GF eluting microparticles 
including: alginate (VEGF), PLGA (BMP-2) microparticles, a dual blank scaffold incorporating 
blank PLGA and alginate microparticles as a control and a dual loaded scaffold incorporating 
both polymer/protein combinations  
4.2 Materials and Methods 
4.2.1 Scaffold fabrication  
Collagen-hydroxyapatite (CHA) scaffolds and functionalised CHA scaffolds 
were fabricated using patented freeze-drying processes developed by the RCSI Tissue 
Engineering Research Group [57, 213]. Briefly, VEGF was encapsulated in alginate 
MPs and BMP-2 was encapsulated in PLGA MPs using methods optimised and detailed 
in Chapter 2. In order to incorporate the protein-loaded MPs into the scaffold for the 
fabrication of a functionalised CHA scaffold a suspension of MPs in water was 
dispersed within the CHA slurry prior to freeze-drying as outlined in Chapter 3. 
Alginate and/or PLGA MPs loaded with BMP-2 and VEGF respectively were 
incorporated at final concentrations of 0.5 and 2.2 % w/v equating to 1.3 and 3.2 µg of 
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protein respectively. Scaffolds were crosslinked and sterilised by UV irradiation as 
detailed in Chapter 3. The resulting materials were cut into 7 mm diameter discs under 
sterile conditions using a surgical punch  in order to fit into the in vivo defect site which 
was a critically sized 7 mm defect (outlined below). 
4.2.2 Surgical procedure 
To assess whether the functionalised scaffolds had the ability to promote bone 
repair in a critical size defect, young adult male Wistar rats (mean weight 375 g, range 
360-395 g) (Harlan, UK) were selected as an animal model and a 7 mm critically sized 
calvarial defect was generated. This rat model is used in 38 % of all critical size cranial 
defects in bone research [247] and is well established within our research group [41-43]. 
An animal license was granted by the Irish Government Department of Health (Ref. 
B100/4416) for carrying out this study and in vivo studies were conducted in accordance 
with protocols approved by the Research Ethics Committee of the Royal College of 
Surgeons in Ireland (REC Approval No. 662).  
The following groups (Fig. 4.1) were analysed with euthanasia occurring at 
either 4 or 8 weeks post-implantation (8 animals per group): 1) empty defect containing 
no scaffold 2) CHA scaffold alone (no MPs or GF) denoted ‘empty scaffold’, 3) CHA 
scaffold containing alginate MPs encapsulating VEGF denoted ‘Alginate-VEGF 
scaffold’, 4) CHA scaffold containing PLGA MPs encapsulating BMP-2 denoted 
‘PLGA-BMP-2 scaffold’, 5) CHA scaffold containing blank alginate and blank PLGA 
MPs denoted ‘Dual Blank scaffold’, 6) CHA scaffold containing PLGA MPs 
encapsulating BMP-2 and alginate MPs encapsulating VEGF ‘Dual Loaded scaffold’.  
The generation of a 7-mm-diameter critical-size cranial defect (Fig.4.2), the 
implantation of the composite materials in the defect site and the procedures for 
postoperative animal care were performed using methods established in the RCSI 
Tissue Engineering Research Group [41]. Anaesthesia was induced with an 
intraperitoneal injection of medetomidine hydrochloride (Sedastart) 0.3 mg/kg and 
ketamine hydrochloride (Narketan) 70 mg/kg and maintained with inhalational 
isoflurane (Forane) and oxygen (0.5-2 % isofluorane). The rats were then given a pre-
operative subcutaneous injection of the non-steroidal anti-inflammatory drug (NSAID) 
carpofen (Rimadyl) 5 mg/kg and the antibiotic Marbofloxacin (Marbocyl) 2 mg/kg 
before being placed in prone position on the operating table. The skin over the head was 
shaved from the top of the nuchal fold, between the ears to just above the eyes and 
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painted with 7.5 % povidone-iodine antiseptic surgical scrub (Promed, Ireland) prior to 
draping. A trephine burr drill (Fig.4.2) was used to create a 7 mm circular transosseous 
defect in the left side of the rat parietal calvarium lateral to the sagittal suture. The 
drilling was performed under constant irrigation with 0.9 % NaCl saline solution. The 
dura was identified to confirm that a transosseous defect had been created at surgery.  
 
A B
C D
 
 
Fig. 4.2 Creation of the critical size defect. (A) Schematic diagram of the defect model 
representing the location of the 7 mm defect (B) Image of the trephine used to create the circular 
transosseous defect. Macroscopic images of (C) the 7 mm circular defect being resected and (D) 
the surgical site prior to scaffold implantation.  
 
The scaffolds were implanted into the defect and the periosteum was oversewn 
with 3-0 absorbable monofilament sutures (Monocryl™). Firstly, the connective tissue 
superficial to the skull was closed to secure the scaffold in place. This was followed by 
a deep skin stitch and a fine subcuticular stitch. The wound was then closed with a 
topical skin adhesive (n-butyl cyanoacrylate) (3M™ Vetbond™ Tissue Adhesive) and 
the rats were given a subcutaneous injection of atipemazole (Sedastop) 1.2 mg/kg and 
placed in an incubator at 27º C until their recovery from anaesthesia. Animals were 
housed (2 per cage) in the Biomedical Research Facility at the RCSI. All surgeries were 
carried out in association with a clinical collaborator and surgeon, Dr. Emmet 
Thompson. At 4 or 8 weeks post-implantation, the animals were euthanized by CO2 
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asphyxiation. A 20 mm x 20 mm segment of calvarium containing the defect was 
resected using a dental saw (Dentalfarm, Torino, Italy) and the explants retrieved were 
stored in 10 % formalin for 4 days and then transferred to PBS prior to analysis. 
4.2.3 In vivo assessment of the ability of the growth factor-releasing scaffolds to 
enhance bone repair 
4.2.3.1 Microcomputed tomography analysis 
The three dimensional (3D) structure of the new bone produced within the 
cranial defect was analysed using micro computed tomography (microCT). Scans were 
performed on a Scanco Medical 40 MicroCT system (Scanco Medical, Bassersdorf, 
Switzerland) with 70 kVP Xray source and 112 µA (resolution of ~12µm). Two-
dimensional (2D) projection images were compiled to reconstruct 3D tomograms using 
the standard Scanco software package using a threshold of 140 in a scale from 0–1000. 
Although a 7mm defect was created surgically, when measuring new bone formation a 
6mm region of interest (ROI) was selected to ensure only new bone within the defect 
was accounted for and any old bone on the peripheries was excluded. Furthermore, 
some remnant bone on the dural aspect of the defect was detected in all experimental 
groups so these particular areas of the defect were excluded from ROI image 
reconstructions and bone volume analysis of the defects. Bone formation was expressed 
as a percentage of bone volume over total volume (% BV/TV) within the ROI.  
4.2.3.2 Histological analysis 
After microCT analysis, the implants were decalcified for a period of 4 to 5 
weeks depending on their level of mineralisation by immersing them in a solution of 
ethylenediaminetetraacetic acid (EDTA) 14 % (w/v) at pH 7.4 with replenishment of the 
solution 3-4 times per week. Following decalcification, specimens were dehydrated in a 
graded series of ethanol solutions using an automated tissue processor, bisected and 
embedded in single paraffin wax blocks. At least three 7 µm sections were cut from 
each sample using a rotary microtome (Microsystems GmbH, Germany) and sections 
were mounted on L-polysine coated glass slides (Thermo Scientific, Menzel & Co KG, 
Germany).  
Qualitative and quantitative histological examinations were performed on 
explants in order to assess the levels of bone formation in the defect site. Each section 
was stained with Haematoxylin and Eosin (H&E). Haematoxylin stains cell nuclei 
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purple, eosin stains ECM pink and bone appears dark pink/red. Images of each 
specimen were acquired and digitized using transmitted light and epifluorescence 
microscopic visualisation (Nikon Microscope Eclipse 90i with Nis Elements software 
v3.06, Nikon Instruments Europe, The Netherlands). Quantitative analysis was 
performed on n=4 sections from each specimen (n=2 per half of each defect) and 
representative images of each section were acquired. Histomorphometrical analysis 
(blind) was carried out in order to quantify the healing response from the H&E-stained 
samples. The defect margin was identified and any new bone was quantified by 
measuring the area of bone nucleation sites (BNS) in each section and calculating the 
mean total area of these sites per group. The area of new bone formation was calculated 
using Nis Elements software v3.06 (Nikon Instruments Europe B.V, The Netherlands).  
4.2.4 In vivo assessment of the capability of growth factor-releasing scaffolds to 
enhance angiogenesis 
4.2.4.1 Immunohistochemical analysis of explanted scaffolds 
The endothelial cell marker platelet endothelial cell adhesion marker 
(PECAM/CD31) was analysed to assess vessel formation. CD31 is a commonly used 
endothelial marker for quantifying angiogenesis by calculation of Microvessel Density 
(MVD) as it is highly expressed in endothelium [248, 249]. In order to carry out the 
analysis samples were first deparaffinized as outlined above and washed in PBS. They 
were then surrounded by a PAP pen and incubated in blocking buffer consisting of 
horse serum and 1 % BSA in PBS (Vectastain Elite Kit, Vector laboratories, CA, USA) 
for 1 h. The specimens were subsequently washed in PBS/Tween 20 and incubated in 
mouse anti-rat primary CD31 antibody (BD Biosciences, UK) at a dilution of 1:650 in 1 
% BSA in PBS for 1 h at room temperature and then mounted with Vectashield 
(Vectastain Elite Kit) containing 4’,6-diamidino-2-phenylindole (DAPI; 100 ng/mL).  
4.2.4.2 Quantitative assessment of vessel density and maturity 
Images of CD31 stained sections were captured from an epifluorescence 
microscope (Olympus IX51-AnalySIS imaging system). Fluorescent ECs in the sample 
sections were visualised using a FITC filter. Nuclei were stained with DAPI to identify 
the presence of vessel forming ECs. The size and density of vessels from these images 
were quantified using ImageJ software. 
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4.2.5 Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). Statistics 
were performed in GraphPad Prism using a general linear model analysis of variance 
(ANOVA) with Tukey post-hoc analysis. Statistical significance was taken at P≤0.05 
unless otherwise stated. 
4.3 Results 
4.3.1 In vivo assessment of the capability of growth factor-releasing scaffolds to 
enhance bone repair 
4.3.1.1 Micro computed tomography analysis 
An entire reconstruction of the excised calvarium was performed for each 
specimen using microCT in order to investigate the ability of the functionalised 
scaffolds to promote accelerated bone formation (Figure 4.3). Qualitatively this analysis 
determined that at 4 and 8 weeks post-implantation the alginate-VEGF group induced 
the most pronounced bone healing. The critical nature of the empty defect was 
confirmed with no new bone evident in the defect site at either 4 or 8 weeks. The 
PLGA-BMP-2, dual blank and dual loaded groups displayed low levels of healing by 
comparison to the empty defect at both timepoints although the level of tissue 
regeneration appeared to be higher than the empty defect.  
Following microCT reconstruction of the entire defect, quantification of new 
bone was performed on the 6 mm ROI. Figure 4.3 (B) displays the bone volume (BV) 
calculated from microCT reconstructions as a percentage of total volume (BV/TV %) 
after 8 weeks. These results corroborate the qualitative microCT results demonstrating 
that the alginate-VEGF group displayed the most advanced bone repair. Although the 
alginate-VEGF scaffold did not statistically augment bone volume in the defect site 
relative to the empty scaffold, it did produce statistically higher BV than the empty 
defect (**P<0.01).  
As expected, the BV/TV % in the alginate-VEGF group was also higher than the 
GF-free dual blank (*P<0.05). Surprisingly, healing was also more advanced in the 
alginate-VEGF groups containing VEGF alone compared to the dual loaded group 
containing both GFs (*P<0.05) and the PLGA-BMP-2 group. Bone formation in the 
PLGA-BMP-2 group was higher than the empty defect after 8 weeks but this scaffold 
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displayed a reduced capacity to enhance healing compared to the empty scaffold (non-
significant).  
 
 
 
Fig. 4.3 Qualitative (A) and quantitative (B) microCT analysis of new bone formation in a 6 
mm region of interest (ROI). Representative micro computed tomographical images 
demonstrating bone healing in the defect site following implantation of an empty scaffold, 
alginate-VEGF, PLGA-BMP-2, dual blank and dual loaded scaffolds at 4 or 8 weeks post-
implantation. Images demonstrate poor healing in the empty defect, dual blanks and BMP-2 
containing scaffolds at 4 weeks with greater healing evident in the alginate-VEGF group at 8 
weeks. (B) Quantitative microcomputed tomographical analysis demonstrated at 8 weeks the 
analysis corroborated the microCT images showing the greatest level of healing in defects 
implanted with the alginate-VEGF group compared to the empty defect (**P<0.01), dual blank, 
dual loaded (*P<0.05) as well as the empty scaffold and PLGA-BMP-2 (non-significant).  
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As a method of further characterising bone healing, histological staining was 
performed on samples explanted at 4 and 8 weeks post-implantation as shown in Figure 
4.4. H&E stained sections of the empty defect after 4 weeks showed that the defect 
space was primarily occupied by thin fibrotic tissue and very little bone formation had 
occurred. In addition, limited healing occurred after 8 weeks in the empty defect 
although healing was more evident at the defect boundaries in some explants. In the 
empty scaffold after 4 weeks considerably more bone formation was seen in the defect 
space and at the defect edges compared to the empty defect. In addition, a large amount 
of scaffold was still present. After 8 weeks thicker bone was evident with large areas of 
deeply stained bone nucleation sites deposited throughout the defect space as well as 
osteoid present at the defect boundaries.  
The alginate-VEGF group displayed the most pronounced healing in support of 
the microCT results (Fig. 4.4B) after 4 and 8 weeks. Partial bridging of the defect space 
and areas of thick bone formation were seen after 8 weeks in the form of deeply stained 
osteoid. Healing was more pronounced in this group compared to PLGA-BMP-2 which 
displayed low levels of healing after 4 weeks (Fig. 4.4B). After 8 weeks more enhanced 
bone formation was observed in the latter group at the defect boundaries and within the 
defect space when compared to the empty defect. However, healing appeared to be 
reduced compared to the empty scaffold. The level of healing was low in the dual blank 
and dual loaded groups after 4 weeks. Healing increased after 8 weeks where enhanced 
staining indicative of bone nucleation sites was observed especially in the dual loaded 
groups (Fig. 4.4C). In addition, the degree of scaffold degradation was considerably 
lower in both dual groups as well as the PLGA-BMP-2 group. Furthermore, these 
PLGA-containing scaffolds integrated poorly with the surrounding native tissue 
although good cellular infiltration was observed in both after 8 weeks (Fig. 4.4C). Table 
4.1 provides a summary of the results obtained by H&E staining indicating the level of 
healing that occurred in all groups. 
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Fig. 4.4 Representative histological images of scaffold sections demonstrating bone defect 
healing at 4 or 8 weeks post-implantation. Images of (A) empty defect and empty scaffold, (B) 
alginate-VEGF and PLGA-BMP-2 scaffold and (C) the dual blank and dual loaded scaffold are 
shown. (A) The empty defect was occupied by thin fibrous tissue after 4 and 8 weeks. At 4 
weeks the empty scaffold displayed some bone formation in the centre of the defect space which 
was more pronounced after 8 weeks. (B) the most advanced healing was observed in the 
alginate-VEGF group after 4 and 8 weeks and to a lesser extent the PLGA-BMP-2 group. (C) In 
the dual blank and dual loaded groups after 4 weeks bone healing was low. More pronounced 
healing was observed after 8 weeks particularly in the dual loaded group. The level of scaffold 
degradation was poor in both groups compared to the other groups (black arrows). 
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Table 4.1 Table detailing the level of healing occurring in each group at 4 and 8 weeks 
post-implantation. 
 
 4 weeks 8 weeks 
 
Empty Defect 
Primarily occupied by thin fibrotic 
tissue. No defect bridging.  
Thicker fibrotic tissue. Some 
bone at the defect edges. No 
defect bridging. 
 
Empty Scaffold 
Thin areas of bone formation at 
defect edges. Cell infiltration 
throughout the scaffold. Poor 
scaffold degradation.  
 
Thicker bone formation at the 
defect edges and in the centre 
of the defect. Good cell 
infiltration. Increased scaffold 
degradation. Defect bridging 
in some areas but not all 
samples. 
 
Alginate-VEGF 
Some bone at defect edges and 
some bone nucleation sites in the 
centre. High levels of 
mineralisation. Some scaffold 
present. No defect bridging 
 
Large areas of thick bone 
distributed throughout the 
centre of the highly 
mineralised defect site. 
Deeply stained osteoid. 
Increased ECM deposition. 
Less scaffold present than at 4 
weeks. Defect bridging in 
some groups. 
 
PLGA-BMP-2 
Low level of mineralised tissue. No 
bone formation. Poor cell 
infiltration and acellular regions 
evident. Poor scaffold degradation. 
No defect bridging. 
Thin areas of bone formation 
throughout defect space and 
within boundaries. Better cell 
infiltration. Some areas of 
ECM deposition. Less 
scaffold present. No defect 
bridging. 
 
Dual Blank 
Low level of mineralisation. Some 
acellular regions. Poor scaffold 
degradation. No defect bridging 
 
 
Some areas of ECM 
deposition and thin bone 
formation at defect edges. 
Good cell infiltration. Poor 
scaffold degradation. No 
defect bridging. 
 
Dual Loaded 
Some areas of mineralised tissue. 
Large amount of scaffold present. 
Large amount of remodelling still 
to occur. Poor scaffold degradation. 
No defect bridging. 
 
Thicker bone formation at 
defect edges in some but not 
all groups. Good cell 
infiltration. Higher degree of 
scaffold degradation but 
scaffold still present. No 
defect bridging. 
 
 
Histomorphometrical analysis of cellular infiltration and bone formation 
Figure 4.5 shows the results of the quantitative analysis of the area of new bone 
formed in all groups obtained from histomorphometry on the H&E stained section. 
Overall, there was no significant difference in bone area observed between any of the 
groups at 4 weeks post-implantation. A significant increase in new bone formation was 
observed in the alginate-VEGF group after 8 weeks compared to the empty defect 
(***P<0.001) and empty scaffold (**P<0.01) controls. The results show that after 8 
weeks only limited healing was observed in the empty defect group compared to all 
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other groups. In addition these data show that the presence of GFs within the CHA 
scaffold led to increased bone formation compared to the growth factor-free empty 
scaffold. The PLGA-BMP-2 group showed a similar trend of higher bone formation but 
at a reduced level compared to the alginate-VEGF group (**P<0.01, *P<0.05 vs the 
empty defect and empty scaffold respectively). Low levels of healing were observed in 
the GF-free dual blank control compared to the enhanced healing observed in the dual 
loaded group. In summary, the level of healing achieved was higher in the GF-loaded 
groups compared to the GF-free scaffolds and the highest healing compared to the 
empty defect was achieved with the alginate-VEGF group - consistent with the 
microCT results.    
 
 
Fig. 4.5 Quantitative histomorphometry showing the area of new bone formed in each group at 
8 weeks post-implantation. A significant increase in new bone formation was observed in the 
alginate-VEGF group after 8 weeks compared to the empty defect (***P<0.001) and empty 
scaffold (**P<0.01) controls. The level of healing in the PLGA-BMP-2 group was significantly 
enhanced compared to the empty defect (**P<0.01) and empty scaffold (*P<0.05) at 8 weeks. 
Low levels of healing were observed in the GF-free dual blank control compared to the 
enhanced healing observed in the dual loaded group containing both BMP-2 and VEGF which 
was significantly higher than the empty defect (*P<0.05) and empty scaffold (**P<0.01).  
    
4.3.2 In vivo assessment of the capability of growth factor-releasing scaffolds to 
enhance angiogenesis 
Once the osteogenic potential of the scaffolds had been analysed, the potential of 
these scaffolds to enhance local angiogenesis was then assessed by 
immunohistochemical analysis by characterising newly formed vessels at 4 or 8 weeks 
post-implantation. Figure 4.6 displays CD31 positively stained vessels in all of the 
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groups after 4 or 8 weeks. There was no discernable difference in the size or number of 
vessels formed in any of the scaffolds at 4 weeks post-implantation. However, more 
vessels were visible in the empty scaffold group compared to the empty defect at 8 
weeks post-implantation. The alginate-VEGF group (Fig. 4.6C) induced considerable 
growth of microvessels relative to the empty defect, empty scaffold, PLGA-BMP-2 and 
dual scaffolds after 8 weeks as evidenced by significantly higher numbers and size of 
positively stained vessels. After 4 weeks there were more vessels seen in the dual 
loaded scaffolds (Fig. 4.6E) compared to the dual blank whereas after 8 weeks these 
vessels degraded. Vessel formation was lower in the dual scaffolds compared to the 
controls at this timepoint.  
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Fig. 4.6 Immunohistochemical staining of anti-rat CD31+ in empty defect (A) and empty 
scaffold groups (B), alginate-VEGF (C), PLGA-BMP-2 (D), dual blank (E) and dual loaded (F) 
groups after 4 or 8 weeks. CD31+ cells are shown to be at the site of neo-vessel formation. 
Yellow arrows demonstrate CD31+ cells in close proximity to vessels. After 8 weeks the 
alginate-VEGF group displayed the highest vessel numbers and size in comparison to all other 
groups. Inset are DAPI stained nuclei indicating the presence of endothelial cells. Scale bar 
represents 50 µm. 
A
B
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Quantification of vessel density and size 
The potential of the scaffolds to enhance angiogenesis was quantified by 
counting the number of microvessels formed in defect sections at 4 and 8 weeks post-
implantation as depicted in Figure 4.7.  After 8 weeks vessel formation was higher in 
the empty scaffold and to a greater extent the alginate-VEGF scaffold when both groups 
were compared to the empty defect. Moreover, the number of vessels in the alginate-
VEGF group was significantly enhanced compared to the PLGA-BMP-2, dual blank 
and dual loaded groups (***P<0.001) after 8 weeks. However, after 8 weeks vessel 
density in the PLGA-BMP-2 group and empty defect were similar. The alginate-VEGF 
and dual loaded groups displayed the highest and lowest number of vessels respectively 
compared to all of the groups examined.  
 
Fig. 4.7 Quantitative assessment of microvessel density (MVD) as a marker of neoangiogenesis. 
Vessel density was higher in the empty scaffold compared to the empty defect (*P<0.05), with 
even greater vessel numbers in the alginate-VEGF group compared to the empty defect 
(***P<0.001). The number of vessels in the alginate-VEGF group was extremely significantly 
higher (***P<0.001) than the PLGA-BMP-2, dual blank and dual loaded groups also. The 
PLGA-BMP-2 group displayed a similar vessel numbers to the empty defect and the dual 
groups were below that of the empty defect displaying the lowest vessel number of all the 
groups examined. 
 
Figure 4.8 shows the vessel area calculated from images of CD31 positively 
stained vessels in defect sections at 4 or 8 weeks post-implantation. Vessel area is used 
to determine maturity by quantifying size distribution of the newly formed vessels at 4 
or 8 weeks post-implantation. After 4 weeks vessels were larger in the defects implanted 
with GF-loaded scaffolds compared to the defects containing GF-free scaffolds 
although this was not significant (Fig. 4.8A). Also, after 4 weeks the largest vessels 
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were observed in the dual loaded groups (non-significant) relative to all other groups. 
However, after 8 weeks vessel size increased signiﬁcantly in the alginate-VEGF group 
which had the largest vessels compared to all other groups (Fig. 4.8B). Although the 
PLGA-BMP-2 group did not induce statistically larger vessels than the empty defect 
after 8 weeks, larger vessels were observed compared to the empty scaffold 
(***P<0.001). After 8 weeks, the smallest vessels were recorded in the dual blank and 
dual loaded groups.  
In summary, after 8 weeks the alginate-VEGF groups displayed the most 
prominent vasculature in terms of vessel size and number in comparison to all other 
groups.  
 
Fig. 4.8 Assessment of vessel size by quantification of size distribution of newly formed vessels 
at (A) 4 weeks post-implantation or (B) 8 weeks post-implantation. (A) The dual loaded group 
had larger vessels than all other groups after 4 weeks, although this was not significant. (B) The 
alginate-VEGF group promoted the growth of significantly larger vessels compared to all other 
groups after 8 weeks. (**P<0.01 versus empty defect and dual loaded, ***P<0.001 versus 
empty scaffold, PLGA-BMP-2 and dual blank).  
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4.4 Discussion 
Therapeutic approaches to enhance bone regeneration are increasingly using 
biomaterial scaffolds which mimic the extracellular matrix as platforms for the delivery 
of growth factors (GFs) to the defect site while suitably accommodating these 
coordinated actions. In this sense, while the delivery of bone morphogenetic protein-2 
(BMP-2) from scaffolds for bone repair and regeneration is favorable, there is no 
consensus concerning the benefits of combined release of BMP-2 and vascular 
endothelial growth factor (VEGF) at bone defect sites. The primary objective of this 
chapter was to assess whether a functionalised scaffold containing GF-loaded polymeric 
microparticles (MPs) for the controlled release of VEGF and/or BMP-2 had the ability 
to enhance bone regeneration in a rat critically-sized cranial defect. Results from this 
study show that a scaffold eluting both VEGF and BMP-2, did not promote a synergistic 
increase in bone formation in a critically-sized defect as some studies suggest [172], 
however, the delivery of VEGF alone from the alginate-VEGF scaffold offered an 
excellent platform for promoting blood vessel formation resulting in increased bone 
repair. 
Three GF-releasing scaffolds were investigated in this work including PLGA-
BMP-2, alginate-VEGF and, dual loaded scaffolds containing a combination of both. 
Among them, the highest level of de novo bone formation within a critically sized bone 
defect was observed when alginate-VEGF scaffolds were implanted for 8 weeks. The 
ability of VEGF to promote chemotaxis and differentiation of osteoblasts is known 
[171] and is consistent with previous studies which showed that the release of VEGF 
from biomaterials can enhance bone regeneration in critically sized defects [101, 250-
252]. Furthermore, VEGF release from biomaterials indirectly increases bone formation 
as a consequence of incrementing blood flow in the defect site by laying down a 
supportive vascular network and increasing vascular permeability [119]. The extensive 
characterisation carried out in this chapter confirmed these studies, as VEGF released 
from alginate-VEGF scaffolds promoted enhanced bone healing. The results 
demonstrate that the scaffold sustained sufficient VEGF concentration gradients across 
the scaffold-tissue interface to elicit an enhanced biological response. Additionally, the 
size of newly formed vessels was shown to be larger in the defects treated with alginate-
VEGF scaffolds compared to GF-free scaffolds. Furthermore, VEGF released from the 
material enhanced vessel maturity as shown by the increased size of the newly formed 
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vessels in the defects treated with alginate-VEGF scaffolds. Taken together, these 
results demonstrate the potential of alginate-VEGF functionalised scaffolds for 
facilitating bone growth and vascular infiltration. This bioactivated material provided a 
sustained and localised release of VEGF, permitting robust cellular infiltration 
throughout the matrix whilst degrading at appropriate rates.  
The results in this chapter also confirm that the level of bone healing in the 
defects treated with PLGA-BMP-2 scaffolds was higher than the empty defect (non-
significant) but not as high as expected given that the osteoinductive effect of BMP-2 
released from PLGA is well established [163, 164, 253, 254]. There are a number of 
factors which may have led to this outcome.  Firstly, BMP-2 releasing scaffolds that 
display initial burst release followed by a sustained release of BMP-2 have been shown 
to promote more significantly enhanced bone regeneration in some studies compared to 
a sustained release alone. This can be attributed to the burst release of BMP-2 
promoting the recruitment of osteoprogenitors into the matrix [255]. However this burst 
release effect was not observed in the BMP-2 releasing scaffolds fabricated in this 
study. Secondly, the dose of BMP-2 released in vivo (2 µg per 7 mm scaffold) may have 
been insufficient. A dose of 20 µg has been shown to induce defect bridging when 
delivered from an 8 mm diameter matrix to the defect site. Finally, the degradation rate 
of PLGA-BMP-2 scaffolds was slower in this study compared to MP-free scaffolds. 
Ideally, carrier systems should biodegrade within a short time frame so the slower 
resorption may have interfered with the innate healing response. This may have affected 
cellular infiltration and proliferation. This may also explain the lower healing rate 
compared to alginate-VEGF scaffolds which degraded at a faster rate. In an attempt to 
address these limitations, an alternative experimental approach is currently being 
explored in our Tissue Engineering Research Group at RCSI whereby BMP-2 is added 
directly to the CHA slurry  prior to freeze-drying i.e. no microparticles at all are used. 
Preliminary results obtained to date have shown that approach leads to enhanced in vivo 
healing compared to the BMP-2 MP encapsulation approach developed in this thesis. In 
contrast to the materials described here, this MP-free scaffold provides an initial burst 
release of BMP-2 followed by a sustained delivery of appropriate BMP-2 doses. This is 
most likely due to the surface adsorption of BMP-2 to hydroxyapatite (HA) most likely 
by covalent and electrostatic interactions. HA can also attract and concentrate the hosts 
endogenous BMPs [256]. The presence of PLGA in the CHA scaffold may have 
interfered with this interaction accounting for some of the discrepancies in the results 
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with this group. Following this MP-free approach, the alginate-VEGF scaffolds may 
also act as a platform for the development of a dual releasing scaffold with directly 
incorporated BMP-2 to promote enhanced bone repair with the added benefit of 
promoting vascularisation of defects in vivo.  
Having confirmed the ability of VEGF and to a lesser extent BMP-2 
individually released from scaffolds to enhance bone formation in the defect site, the 
effect of the simultaneous release of both GFs on the quantity of new bone was also 
examined. The extent of new bone formed in the defect treated with dual scaffolds was 
significantly higher than the GF-free scaffolds but was not notably enhanced compared 
to single-GF delivery. This is in agreement with a recent study by Hernandez et al 
which suggests the absence of a beneficial long term effect in combining BMP-2 and 
VEGF over BMP-2 alone [257]. On the other hand, a number of studies by Peng et al, 
Kanczler et al and Kakudo et al suggest a synergistic effect of combining VEGF and 
BMP-2 in enhancing the osteogenic potential of bone tissue engineered constructs [172, 
231, 245]. However, a number of experimental variables were different in this study 
compared to those performed previously including the animal model used (e.g. muscle 
pouch models [245], mouse models [231] and femoral defect models [172]) and the 
timepoints studied post-implantation (e.g. 3 [245] and 12 weeks [249]). The discrepancy 
between the in vivo results in this work in comparison to these studies may also have 
their origin in the lower BMP-2 doses used here and the lack of burst release of BMP-2 
outlined in the previous section. In addition, it has been shown that the synergistic 
interplay between VEGF and BMP-2 is dependent on the ratio of these factors [231, 
244]. A lower VEGF: BMP ratio shows enhanced bone repair compared to higher 
VEGF: BMP ratios. Although this low ratio was achieved until day 7 with the dual 
scaffolds used in this study, the lack of long-term delivery of low VEGF: BMP-2 
concentrations, as reported in Chapter 3, may have contributed to the reduced efficacy. 
Also, the scaffold degradation rate might have had an influence on this outcome. The 
amount of polymer loaded in the dual scaffolds was considerably higher than the 
incorporation of either PLGA or alginate MPs in the scaffolds. As a result, the 
degradation of the scaffold is further delayed. As a consequence of this restrained 
resorption, subsequent tissue growth within the defect site is impaired. Ultimately, this 
may have interfered with the deposition of mineral throughout the defect site. This 
phenomenon is confirmed by the in vivo response of the dual blank group which had 
similarly low levels of scaffold resorption.  
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A key hurdle inhibiting innovation in TE is the difficulty in characterizing the 
final product to enable sufficient development of meaningful quality controls and 
product release specifications. However, given that these materials are cell-free their 
complexity from a regulatory perspective may be reduced. Reduced complexity may 
offer the advantage of ease of control over the manufacturing consistency as well 
predictability to developers. Furthermore, combination products which consist of more 
than one component, often straddle existing classifications of regulated products 
complicating the determination of the appropriate regulatory process [258]. However, in 
the context of the alginate-VEGF scaffolds, the incorporation of single GFs into the 
cell-free matrix reduces the complexity of the material. In this sense, this biomaterial 
delivers a single GF similar to Medtronic’s INFUSE® which has been approved by the 
FDA since 2002 for rhBMP-2 delivery but importantly, in a controlled manner unlike 
the latter. Ultimately this simplicity in biomaterial design in the alginate-VEGF scaffold 
may therefore make the regulatory evaluation process for this product easier in the 
future when compared with the dual loaded scaffolds.  
The scaffolds releasing VEGF alone resulted in an increased angiogenic 
response. This scaffold not only induced significant increases in microvessel density in 
the defect area relative to controls but also increased the size of the vessels thus giving 
an indication of the enhanced level of maturity of the vessels as a result of VEGF 
release. It is likely that some of these large vessels were derived from newly formed 
capillaries resulting from increased vessel density. In contrast, the dual scaffold 
containing the same concentration of VEGF displayed a higher angiogenic response 
after 4 weeks which was however lower than the alginate-VEGF scaffold after 8 weeks. 
It is known that the presence of VEGF for relatively long periods of days to weeks is 
required to prevent regression of nascent vessels [259]. It is plausible that implantation 
of the dual scaffold led to the formation of large diameter vessels after 4 weeks which 
were subsequently degraded after 8 weeks due to insufficient GF release and suboptimal 
doses. In Chapter 3 it was shown that in contrast to the single loaded scaffolds, the dual 
loaded scaffolds released higher doses of GF which was also less bioactive and the 
scaffold pore diameters were smaller which may have interfered with vascular 
infiltration [44, 50]. In combination, these effects likely contributed to the reduced 
vessel formation compared to the elevated angiogenic response following implantation 
of the alginate-VEGF scaffold.   
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Taken together, results from this chapter have demonstrated the ability of the 
alginate-VEGF scaffolds to enhance vessel formation resulting in increased bone 
regeneration compared to all other groups. The functionalised scaffolds described herein 
represent a very promising approach for overcoming the associated problems of 
uncontrolled drug delivery for TE with the added benefit of off-the-shelf availability 
and lack of surgical manipulation and cell culture prior to implantation. Both the spray 
drying and the freeze-drying techniques, used for the fabrication of MPs and the 
scaffolds respectively, made from GRAS materials are reproducible processes which 
can be easily scaled up to industrial production [147, 260]. Another potential avenue for 
this system is the adaptability of this pro-angiogenic material to a wide range of other 
applications e.g. to enhance vascularisation in ischemic tissues. As such, freeze-dried 
collagen-based scaffolds are currently being used for the regeneration of a wide range of 
tissues, such as cartilage [261], cornea [262] and blood vessels [263]. For example the 
inclusion of VEGF-loaded alginate MPs within a collagen-glycosaminoglycan scaffold 
optimised for angiogenesis [264] may allow for a more enhanced angiogenic response. 
These VEGF-eluting scaffolds may be applied to the treatment of critical limb ischemia, 
wound healing and myocardial repair. Thus, this system has an enormous potential in 
regenerative medicine, as it could be tuned in terms of the composition of the collagen-
based scaffold and released therapeutic to be optimized for the healing of very diverse 
organs.  
4.5 Conclusions 
The ability of a series of VEGF, BMP-2 and dual VEGF/BMP-2-eluting 
functionalised scaffolds to promote vascularisation and bone repair was assessed and 
among them the VEGF-eluting scaffold demonstrated the most accelerated vessel 
formation and bone healing when implanted in a rat calvarial defect model for 4 or 8 
weeks. However, the expected osteoinductive effect of BMP-2 eluting scaffolds as well 
as the synergistic effect of delivering both GFs was not observed, an inconsistency 
which may have its origin in the BMP-2 dose and release kinetics, VEGF/BMP-2 ratios 
and degree of scaffold degradation. Ultimately, the alginate-VEGF scaffold offers an 
excellent platform for enhancing neovascularisation and bone repair. In addition, the 
process developed to functionalise theses scaffolds, may offer an ideal platform to 
promote angiogenesis and tissue regeneration for a wide variety of applications in 
addition to bone. 
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Chapter 5: Development of a collagen-glycosaminoglycan/bioactive 
glass composite scaffold for the release of pro-angiogenic cobalt ions to 
enhance in vitro angiogenesis and osteogenesis 
 
 
The study presented in this chapter is the subject of the below manuscript. 
E. Quinlan, S. Partap, M.M. Azevedo, G. Jell, M.M. Stevens and F.J. O’Brien, 
Hypoxia-mimicking collagen-glycosaminoglycan/bioactive glass composite scaffolds to 
enhance angiogenesis and bone repair, Biomaterials, In Review. 
 
5.1. Introduction 
Ideal scaffolds provide sites for cell attachment, mechanical stability within 
the defect site and a porous and interconnected pore network for interaction with the 
host (cell migration and nutrient and waste removal) [40]. In our laboratory, we have 
developed a series of scaffolds from collagen (Type I) and the abundant 
polysaccharide, glycosaminoglycan (GAG), to produce a highly porous collagen 
GAG (CG) scaffold by way of a controlled freeze-drying process [48, 51, 91]. These 
scaffolds have an optimised composition to facilitate osteogenesis [265] and have 
been shown to enhance bone repair in vivo in minimally loaded calvarial defects [41]. 
The traditional role of the scaffold to simply serve as a template for tissue formation 
has evolved and the new generation of scaffolds are increasingly being used as 
delivery vehicles for therapeutic molecules such as drugs, genes and the previously 
described osteogenic and angiogenic proteins that initiate biological events leading to 
the regeneration of tissue as outlined in Chapter 3 [51].  However, the scaffold 
fabrication method must be compatible with the drug stability and is often restricted 
by conditions of high temperature, free radical generation, pressure and use of organic 
solvents that may affect organic drug incorporation, release and bioactivity. Therefore 
the use of inorganic metallic ions as therapeutic agents in tissue engineering is an 
attractive path to explore. This chapter proposes a drug/GF-free alternative strategy 
employing the use of therapeutic ions as an attractive, cost-effective, safer approach 
to tissue regeneration which would be more preferable from a regulatory perspective 
than GF delivery. 
A variety of ions have been suggested for use in regenerative medicine due to 
their pro-angiogenic and pro-osteogenic potential as well as their antibacterial and 
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wound healing capacity (Fig. 5.1). These inorganic ions are increasingly being 
considered as potential alternatives to growth factors and gene-based approaches in 
tissue engineering due to their stability at high temperatures, ease of processing, and 
controllable release kinetics [12]. Ions have been classified as therapeutics; for 
instance, it has been shown that silicon (Si) and calcium (Ca) ions initiate 
osteogenesis when released in biologically relevant ranges as reviewed by Hoppe et al 
(15-30 ppm for Si and 60-90 ppm for Ca)[6, 266]. However, although the use of ions 
is economical and they remain stable under typical scaffold processing techniques, 
the potential cytotoxic affects of local delivery of metallic ions has to be considered.  
 
Fig. 5.1 Overview of some common targets of therapeutic metallic ions during bone repair 
taken from Mouriño et al 2011 [12]. Critical concentrations of soluble ions such as silica (Si), 
calcium (Ca), phosphate (P) and sodium (Na) leads to intracellular and extracellular signalling 
between the bioactive glass and the cellular environment resulting in induction of genes related 
to the processes involved in bone metabolism,  promoting osteogenesis. The incorporation of 
metallic ions such as copper, zinc, silver and strontium into scaffolds are also commonly studied 
for their bacteriostatic and angiogenic effects leading to devices capable of inhibiting bacterial 
colonisation and/or promoting vascularisation respectively following implantation. 
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To overcome this limitation the controlled release of ions from matrices is 
desirable. One method of delivery is to bind ions to a suitable substrate such as 
bioactive glasses (BG), which are defined as inorganic surface active bioceramics. 
Controlled rates of dissolution of the BG provide the physiologically relevant 
concentrations of the biologically active ions to the cells when exposed to body fluids 
[6]. Bioglass 45S5 is one of the most important formulations of bioactive silica glasses 
many of which are based on this formula consisting of 45 wt. % of SiO2 and 5:1 ratio of 
CaO to P2O5. Lower Ca/P ratios do not bond to bone [267]. Bioglass particles, 
NovaBone and PerioGlas are examples of commercially available products that are used 
in the treatment of a wide range of dental and orthopaedic applications [268]. A 
hydroxyl carbonate apatite (HCA) layer is capable of forming on BG when exposed to 
biological fluids. Once the apatite layer is formed, osteoblasts can preferentially 
proliferate over fibroblasts on its surface. This layer then forms a bond between the 
bioactive glass and bone imparting pro-regenerative, osteoconductive ability to the BG 
as it allows for bone ingrowth without the intervention of fibrous tissue [6, 62]. An 
approach to further enhance the therapeutic potential of the BG is to introduce these 
therapeutic ions such as strontium [269], magnesium or zinc [270] which are known to 
have anabolic responses in bone metabolism.  
It is obvious that vascularisation is essential for the clinical success of tissue 
engineered constructs for bone repair [103]. Lack of vascularisation can lead to graft 
failure due to avascular necrosis as discussed in previous chapters. Methods of initiating 
angiogenesis include using recombinant pro-angiogenic vascular endothelial growth 
factor (VEGF) proteins (Chapter 2-4) and genes encoding for VEGF. An alternative 
strategy is to target the cellular Hypoxia Inducible Factor (HIF-1α) cellular pathway 
which responds to low oxygen concentration (hypoxia) and results in the activation of 
pro-vasculogenic genes involved in angiogenesis – including VEGF [131]. Cobalt is an 
ion that has the potential to mimic hypoxia stabilising the transcription factor HIF-1α, 
which then moves into the nucleus to stimulate upregulation of pro-vasculogenic genes 
such as VEGF [271] and has been adopted as a potential neovascularisation strategy in a 
number of studies [128, 272] as previously discussed in Chapter 1. Since cobalt can be 
toxic at high concentrations (>20 ppm) [273], a controlled released mechanism is 
essential for applications of cobalt. Recently, cobalt-eluting BG has been developed as a 
delivery system allowing for the sustained release of the pro-angiogenic cobalt ion 
[132] with the potential for the controlled release of numerous ions involved in bone 
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metabolism outlined in detail in Chapter 1. Mesoporous bioactive glass scaffolds have 
successfully been used to control the release of cobalt ions combining the osteogenic 
properties of the matrix with the angiogenic properties of cobalt [273, 274]. The focus 
of this study was to incorporate hypoxia-mimicking BGs loaded with cobalt [132] into 
CG scaffolds previously optimised for bone repair [50, 85, 92, 265]. This approach 
offers an alternative to GF incorporation to enhance the angiogenic and osteogenic 
potential of the scaffold in order to facilitate bone repair.  
5.1.1 Objectives 
The overall objective of this chapter was to develop and characterise a collagen-
glycosaminoglycan (CG) scaffold functionally enhanced with bioactive glass 
microparticles for the sustained release of pro-angiogenic cobalt ions to promote 
vascularisation and bone repair.  
 
The specific aims were: 
1) To combine cobalt-eluting and non-eluting bioactive glass microparticles at 
different concentrations with the CG scaffold. 
 
2) To characterise the resulting scaffold in terms of material properties in order to 
determine if the addition of bioactive glass affected pore structure, compressive 
moduli and porosity of the scaffold 
 
3) To determine the kinetics of cobalt ion release from the bioactive glass 
microparticles within the scaffold in order to assess the optimal microparticle 
loading to achieve therapeutically relevant cobalt release. 
 
4) To assess the in vitro biological activity of the resulting scaffold to induce 
angiogenic and osteogenic responses from cells. 
5.2. Materials & Methods 
5.2.1 Synthesis of bioactive glass 
Bioactive glasses (BG) were synthesised in the Steven’s laboratory in Imperial College 
London in collaboration with Prof. Molly Steven’s. A series of BG with cobalt (Co2+) 
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contents of 0 and 4 mole % were prepared by a melt-quench route as described 
elsewhere [132, 275]. The BG compositions were designed using the inorganic polymer 
model of soda-lime–phosphosilicate glasses with the general formula of 
3SiO2·0.07P2O5·(1.4-X)CaO·1.6Na2O·XAO (A = Co). Cobalt oxide was added to the 
glass composition at a concentration of 4 mole % where each mole of SiO2 was replaced 
with one mole of CaO. Once the compositions were prepared they were transferred to a 
platinum–rhodium crucible and placed into the pre-heated furnace (1400º C) for 90 
mins and the molten contents of the crucible were then quenched into deionised water. 
The granular glass frit was collected and dried in an oven at 100º C. Finally, the glass 
frit was ground into a powder and sieved to obtain particles smaller than 100 and 38 
µm. Glass powders were stored in a desiccator until used.  
5.2.2 Scaffold fabrication 
A CG slurry was produced by mixing type I collagen (1.8 g) isolated from 
bovine tendon (Integra, New Jersey, USA) in 300 mL aqueous 0.5 M glacial acetic acid 
solution as previously described in Chapter 3, followed by the addition of 0.32 g 
chondroitin-6-sulphate sodium salt (Sigma-Aldrich, Ireland) in 60 mL of 0.5 M aqueous 
acetic acid solution [91]. The slurry was degassed prior to the addition of the BG. Three 
different BG particles were investigated; (1) cobalt-free BG with a particle size of < 38 
m, (2) BG containing 4 % cobalt with a particle size of < 38 m and (3) BG containing 
4 % cobalt with a particle size of < 100 m. The BG was suspended in distilled water at 
a concentration of 0.14 g/mL. Various concentrations (0.5, 0.2 and 0.1 mL) of the BG 
suspension was added drop wise to 20 mL of the CG slurry to fabricate a range of 
slurries incorporating final BG concentrations of 0, 1.4, 2.8 and 7 mg per scaffold. The 
slurries were homogenised at a low speed to ensure a homogeneous distribution of the 
BG, while also ensuring not to introduce excess air during the addition.  
A series of preliminary experiments were conducted to establish the optimal 
scaffold fabrication process in order to successfully introduce BG into the CG scaffolds. 
A number of approaches were taken, one of which was to immediately freeze the slurry 
in a controlled manner. Another was to add the BG after the collagen slurry had been 
degassed (as the degassing process could take up to a few hours); in this approach the 
slurry was not degassed a second time to eliminate any air that may have been 
introduced whilst incorporating the bioactive glass. The slurry (2 mL) was pippetted 
immediately into each well of a 24 well plate and lyophilised (Advantage EL, VirTis 
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Co., Gardiner, NY) for 24 h using a final freezing temperature of -40 °C at either 1 
o
C/min or 4
o
C/min. A number of different freezing parameters were varied including 
both controlled and immediate cooling of the samples in the freeze-dryer, varying 
cooling rates of 1 
o
C/min and 4 
o
C/min and degassing under vacuum both pre- and post-
slurry fabrication to eliminate air bubbles. Scaffolds were sterilised after fabrication 
using a dehydrothermal (DHT) treatment for 24 h at 105°C and further chemically 
crosslinked using 14 mM N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride) and 5.5 mM N-Hydroxysuccinimide (Sigma -Aldrich, Ireland) in 
distilled water for 2 h followed by 2 x 30 min rinses in PBS [85]. For the remainder of 
the chapter, the different scaffold groups will be denoted as CG (BG-free CG scaffold- 
negative control), CGBG (38 µm) (cobalt-free CG/BG scaffold) and the two cobalt-
doped CGBG scaffolds containing 38 m and 100 m BG particles respectively i.e. 
CGBG (38 µm) 4Co or CGBG (100 µm) 4Co. 
5.2.3 Physical characterisation of collagen-glycosaminoglycan/bioactive glass 
scaffolds 
5.2.3.1 Analysis of cobalt release from scaffolds 
The scaffolds were incubated in 5 mL TRIS buffer which was completely 
replaced at 24 h and then again at 7 days. The samples were frozen at -80
o
C until 
analysis. To determine the cobalt ion concentration released from the scaffolds Ion 
Chromatography Plasma Mass Spectrometry (ICP-MS) was employed. ICP-MS was 
performed on a Varian 8200 machine. All samples were run in triplicate. 
5.2.3.2 Effect of bioactive glass incorporation on scaffold mechanical properties  
Compressive modulus of the scaffolds was determined using a Z050 mechanical 
testing machine (Z050, Zwick/Reoll) fitted with a 5-N load cell as previously described 
in Chapter 3. Unconfined wet compression testing was performed on disc shaped 9 mm 
constructs that were immersed in PBS and tested at a rate of 10 % strain/min. The 
modulus was calculated from the slope of the stress-strain curve over the range 2-5 % 
strain (n=4).   
5.2.3.3 Effect of bioactive glass incorporation on scaffold pore structure 
The mean pore size of the scaffolds was determined by embedding scaffolds in 
JB4 glycomethacrylate resin according to manufacturer’s instructions and as outlined in 
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Chapter 3. The embedded scaffolds were sectioned at 10 m thicknesses (Leica RM 
2255, Leica, Germany microtome), mounted on slides and then stained with an aqueous 
1 wt % Toludine Blue solution for 5 min. They were rinsed in distilled water and left to 
dry, the slides were mounted with coverslips using DPX mountant. The sections were 
imaged using a Nikon microscope (Optimphot2, Nikon, Japan) and pore diameters 
recorded from the images. Scanning electron micrographs of the scaffolds were 
obtained as previously described in Chapter 3. 
5.2.4 Effect of bioactive glass incorporation on biological response in the scaffolds 
5.2.4.1 Cell culture & seeding 
In order to assess the angiogenic and osteogenic response of the scaffolds, two 
commonly used cell lines were used. Human Umbilical Vein Endothelial Cells 
(HUVECs) and MC3T3-E1 cells, a pre-osteoblastic cell line were cultured to 
confluence as previously described in Chapter 2 and 3. Briefly, in a 24 well plate, each 
scaffold was seeded drop-wise with 25 µL of the cell suspension and then placed in the 
incubator for 15 min, the scaffold discs were then turned over and another 25 L of the 
cell suspension was added drop-wise (total number of cells per scaffold = 5 x 10
5
 cells) 
to produce a cell seeded construct. After 15 min, 2 mL of endothelial media (HUVECs) 
or osteogenic media supplemented as previously described was added to each well and 
the scaffolds returned to the incubator. The constructs were cultured for 24 h, 3 and 7 
days in the case of HUVECs while MC3T3-E1 cells were cultured for up to 21 days to 
allow for mature osteogenesis to take place. At each timepoint, constructs were removed 
as before flash frozen using liquid nitrogen and stored at -80
o
C for analysing the DNA 
and RNA content, whilst 1 was fixed in 10 % formalin for histological analysis. 
Additionally, 1 mL of media was collected and stored at -80 
o
C for analysis by ELISA. 
5.2.4.2 Analysis of angiogenesis in collagen-glycosaminoglycan/bioactive glass 
scaffolds  
DNA quantification  
To analyse DNA content as an indicator for cell proliferation in response to the 
scaffolds, constructs were digested as in Chapter 3 and homogenised using a rotor-stator 
homogeniser (Omni International, Germany).  Cell lysates were centrifuged using QIA 
shredder columns (Qiagen, Ireland) to remove any scaffold material. The subsequent 
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sample was then analysed using the PicoGreen assay according to the manufacturer’s 
protocol (Quanti-iT TM PicoGreen dsDNA Molecular Probes, OR, USA). 
 
Quantification of VEGF gene expression 
In order to investigate the ability of BG to enhance angiogenic gene expression, 
RNA was extracted from endothelial cells seeded directly on scaffolds using the 
samples prepared as similarly described for PicoGreen analysis. Extraction was carried 
out using the RNeasy Mini Kit (Qiagen, Ireland) according to the manufacturer’s 
protocol. Expression levels of the angiogenic marker VEGF was investigated by 
quantitative Real-Time PCR (RT-PCR). Reverse transcriptions (20 μl) were performed 
on 100 ng of total RNA using the QuantiTect Reverse Transcription Kit according to 
the manufacturer’s instructions.  Real-time PCR reactions (15 μl) were performed in 
triplicate on a 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, 
USA) using the QuantiTect SYBR Green PCR kit (Qiagen, Ireland).  The following 
predesigned human primers from Qiagen (QuantiTect Primer Assays) were used: VEGF 
primer (Hs_VEGFA_6_SG) and 18s primer (Hs_RRN18S_1_SG) was used as the 
housekeeping gene.  Relative expression of VEGF was determined using the ΔΔCT 
method [276]. 
 
Quantification of VEGF protein production 
In order to quantify the protein production by ECs on scaffolds, media samples 
were removed as detailed above and analysed using a VEGF enzyme-linked 
immunosorbent assay (Quantikine ELISA kit, R&D Systems, Europe) according to the 
manufacturer’s instructions as outlined in Chapter 2.  
 
Matrigel assay 
In a related but separate experiment, in order to further assess the ability of 
cobalt eluted from the CGBG scaffold to enhance angiogenesis, a Matrigel™, assay was 
performed as described in Chapter 3. Plates were placed in an incubator for 20 min after 
which 1 mL of endothelial media (without VEGF supplement) was added. Well inserts 
consisting of CG and cobalt-eluting CGBG scaffolds were applied on top of the wells. 
A further 1 mL of media was then added. Matrigel cultures were imaged at 6h, 12h and 
24h post-seeding with a Leica DMIL microscope (10x objective, DFC420C digital 
camera) with 5 images taken and analysed for each group using ImageJ. The length of 
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tubule network formation by endothelial cells in response to the cobalt eluted from the 
scaffolds was used as a quantitative assessment of angiogenesis.   
5.2.4.3 Analysis of osteogenesis in collagen-glycosaminoglycan/bioactive glass 
scaffolds  
DNA and alkaline phosphatase quantification 
Alkaline phosphatase (ALP) activity was assessed in order to demonstrate the 
ability of the cobalt eluting and non-eluting BG composite scaffolds to enhance 
osteogenesis. At the endpoint of the study, constructs containing MC3T3-E1 cells were 
washed in PBS and lysed according to the manufacturer’s protocol (SensoLyte pNPP 
Alkaline Phosphatase Assay Kit) and as described in Chapter 3. Briefly, scaffolds were 
homogenised in the appropriate lysis buffer and incubated at 4 ºC. The media was 
collected for quantification of ALP or DNA.  
 
Assessment of cell-mediated mineralisation 
In order to assess cell-mediated matrix mineralisation on the scaffolds in 
response to BG and cobalt-BG, three different methods were applied; alizarin red and 
von kossa staining as well as calcium quantification. To examine the ability of the 
constructs to produce calcium phosphates, wax embedded scaffold sections (10 µm) 
were de-paraffinized to distilled water and stained with 2 % alizarin red (Sigma-
Aldrich, Ireland) for 2 mins and mounted with a coverslip or 2 % silver nitrate solution 
and exposed to UV light for 20 mins prior to mounting. Digital images were obtained as 
previously described (section 5.2.3.3). The ability of the CGBG scaffolds to induce 
mineralisation by the pre-osteoblast cells was further assessed using a calcium 
quantification technique used routinely in our laboratory [58]. Constructs were added to 
1 mL of 0.5 M hydrochloric acid (HCL), homogenised using a rotor-stator homogeniser 
and incubated overnight at 4 ºC whilst shaking to disassociate calcium from proteins. 
The samples were analysed according to the StanBio Calcium Liquicolour Kit 0150 
assay protocol. A standard curve was constructed from 0 to 1 µg/mL and from the 
equation of the trendline the concentration of calcium per sample was obtained.  
5.2.5 Statistical analysis 
These data are represented as means ± standard error of the mean (SEM). 
Statistics were carried out using GraphPad Prism software using a general linear model 
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ANOVA with Tukey’s post hoc tests performed for multiple comparisons. All cell 
cultures were performed with a sample size of 3 per treatment group. Statistical 
significance was taken at P≤0.05 unless otherwise stated. 
5.3 Results 
5.3.1 Scaffold fabrication 
Of the various scaffold fabrication parameters investigated, it was observed that 
the faster cooling rate (4
o 
C/min) produced a film on the scaffold surface which could 
potentially be problematic for cell attachment and infiltration; furthermore a 
heterogeneous pore structure was observed compared to the slower cooling rate of 
1
o
C/min (Fig. 5.2). Preliminary analysis showed that the length of time the bioactive 
glass was in contact with the acidic collagen slurry affected the resulting freeze-dried 
scaffold structure due to an increase in slurry pH causing it to precipitate. Following a 
series of preliminary experiments, the optimal scaffold fabrication process to reduce this 
effect and maintain the microstructural integrity was determined.  This involved the 
direct addition of BG into the pre-formed CG slurry, with degassing prior to BG 
addition to remove air bubbles followed by freeze-drying at a cooling rate of 1
o
C/min   
for 24 h using a final freezing temperature of -40°C. These studies eventually resulted in 
the development of a fabrication process which could consistently achieve homogenous 
CGBG scaffolds.      
  
Fig. 5.2 Toluidine Blue stained images of collagen-glycosaminoglycan (CG) scaffolds made 
with bioactive glass containing cobalt (particle size <100 m). Sections of scaffold fabricated at 
a controlled freezing rates of (A) 1
o 
C/min and (B) 4
o 
C/min. A more homogenous pore 
structure at 1
o 
C/min was demonstrated. Scale bar is 500 m at 20X magnification  
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5.3.2. Physical characterisation of collagen-glycosaminoglycan/bioactive glass 
scaffolds 
5.3.2.1 Analysis of cobalt release from scaffolds 
Only the scaffolds containing 2.8 and 7 mg of BG/scaffold  released cobalt ions 
in the biologically relevant range of above 3 ppm for activation of the HIF-1 pathway 
[130, 132]. The incorporation of the highest BG concentration of 7 mg/scaffold 
displayed optimal cobalt release kinetics and released >3 ppm of cobalt at each 
timepoint examined (day 3 and day 7) versus the addition of 2.8 mg/scaffold. It was also 
observed that BG particle size did not significantly affect the release behaviour of cobalt 
ions (Fig. 5.3) although smaller particles of <38 µm displayed a trend towards increased 
ion release at the respective timepoints. 
 
7
2.
8 7
2.
8
0
5
10
15
20
CGBG (38 m) 4Co
CGBG (100 m) 4Co
Day 1 Day 7
3-15ppm = limit for HIF-1 activation
Mass of bioactive glass (mg/scaffold)
C
o
b
a
lt
 c
o
n
c
e
n
tr
a
ti
o
n
 (
p
p
m
)
 
Fig. 5.3 Release of cobalt ions from the collagen glycosaminoglycan-bioactive glass scaffolds 
measured by using Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). The results 
show the release of cobalt after 24 h and the cumulative release at 7 days. Scaffolds 
incorporating 7 mg of bioactive glass/scaffold release cobalt in a biologically active range, 
delineated by the dashed red line. Scaffolds incorporating smaller diameter BG particles release 
cobalt at a faster rate than larger particles (100 m) although this difference is not significant. 
Error bars represent standard error of the mean (n=3). 
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5.3.2.2 Effect of bioactive glass incorporation on scaffold mechanical properties 
A series of tests were conducted to examine the effects of BG on the physical 
properties of the scaffolds. The compressive moduli of the scaffolds were significantly 
increased by the addition of BG when compared to the negative control (BG-free CG 
scaffold) (Fig. 5.4) showing that BG particles have the effect of reinforcing the 
scaffolds. It was also observed that the moduli increased with increasing bioactive glass 
concentration, the highest concentration of 7 mg/scaffold eliciting a 4–6 fold increase in 
scaffold mechanical properties over the scaffold alone. All further in vitro studies were 
carried out with the optimal BG concentration of 7 mg per scaffold based on 
combination of the cobalt release kinetics and improved mechanical properties 
achieved.  
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Fig. 5.4 Effect of bioactive glass incorporation on scaffold compressive modulus. 
Analysis of compressive moduli (kPa) of collagen-glycosaminoglycan (CG) bioactive glass 
composites made with varying particle sizes (100 and 38 m) at three different bioactive glass 
concentrations (1.4, 2.8 and 7 mg/scaffold).  ***P<0.001 indicates a significant increase vs the 
BG-free CG scaffold. 
 
5.3.2.3 Effects of bioactive glass incorporation on scaffold porosity 
BG incorporation reduced the porosity of the scaffolds compared to the control 
(P<0.001) but maintained porosities at levels beneficial for cell and vascular infiltration 
and tissue growth. When quantified all scaffolds maintained high degrees of 98 % 
porosity and above (Fig. 5.5A).  The scanning electron micrographs in Figure 5.5B 
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indicate the highly porous architecture of the scaffolds. An even distribution of BG was 
observed throughout the collagen matrix.  
 
 
 
Fig. 5.5 Effects of bioactive glass incorporation on scaffold porosity. (A) Porosity (%) of 
collagen-glycosaminoglycan (CG) bioactive glass composites made with varying particle sizes 
(100 and 38 µm) at one bioactive glass concentration (7 mg/scaffold).  ***P<0.001 vs the BG-
free CG control. (B) Scanning electron micrographs of CGBG composite scaffolds indicating 
pore structure.  Scale bar represents 50 µm. Images were taken at 1000X. 
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5.3.3 Effect of bioactive glass incorporation on biological response  
5.3.3.1 Analysis of angiogenesis  
In order to investigate the ability of the composite materials to support growth of 
ECs prior to assessing their ability to induce angiogenesis, HUVECs were seeded onto 
the optimised scaffolds (containing 7 mg BG/scaffold). An initial reduction in cell 
number was reported on scaffolds containing cobalt-free BG at day 1 and day 3 
compared with the control. However, during longer culture periods, cell numbers were 
relatively homogenous between the different composites examined (day 7). There was 
no significant reduction in cell number reported on scaffolds containing the pro-
angiogenic cobalt-eluting BG (Fig. 5.6).  
 
Fig. 5.6 Number of endothelial cells on collagen glycosaminoglycan-bioactive glass (CGBG) 
scaffolds at 1, 3 and 7 days post-seeding. An initial seeding density of 500,000 cells per scaffold 
was used. Cell numbers were initially higher in the BG-free CG controls (***P<0.001 and 
**P<0.01 vs the cobalt-free CGBG scaffold) but were maintained at similar levels in all groups 
by 7 days post seeding. 
 
VEGF gene expression was next analysed and shown to be enhanced in cells on 
scaffolds containing cobalt-BG particles (Fig. 5.7A). Initially, the smaller diameter 38 
µm cobalt-BG particles induced higher levels after 24 h and 3 days post-seeding but by 
day 7 the highest gene expression was seen in the presence of larger diameter cobalt-BG 
particles (100 µm) compared to all other groups. Furthermore, VEGF gene expression 
correlated with VEGF protein production (Fig. 5.7B) and also significantly increased in 
the CGBG (100 µm) scaffolds compared to the CG scaffold alone at day 7.  
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Fig. 5.7 Analysis of angiogenesis in collagen glycosaminoglycan-bioactive glass (CGBG) 
scaffolds. (A) Vascular endothelial growth factor (VEGF) gene expression in CG and CGBG 
composites seeded with HUVECs at day 1, 3 and 7 days in culture. Gene expression 
significantly increased (**P<0.01) in cells cultured on the CGBG (100 µm) – 4Co scaffolds 
versus the BG-free CG control and scaffolds with smaller cobalt-BG particles.  n=3. All data is 
normalized to the 24 h negative control. (B) Vascular endothelial growth factor (VEGF) protein 
concentration in CG composites seeded with HUVECs for 7 days indicating a significant 
increase (*P<0.05) vs CG control at the same timepoint. 
 
The ability of the CGBG scaffolds to promote tubule formation in human ECs 
was then assessed using a tubule formation assay (Fig. 5.8A-B). It was observed that 
ECs cultured with cobalt-releasing CGBG scaffolds displayed enhanced vascular tubule 
formation compared to the CG control (Fig. 5.8B) at 4 and 12 h further indicating a 
cobalt-induced angiogenic response. Tubule formation was more enhanced in the 
presence of larger diameter cobalt-BG particles of 100 µm compared with the smaller 
particles of <38 µm further corroborating the gene and protein data.   
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Fig. 5.8 Analysis of tubule formation in endothelial cells cultured with collagen 
glycosaminoglycan-bioactive glass (CGBG) scaffolds. (A) Bright field images of Matrigel™ 
tubule formation in CGBG scaffolds indicating enhanced tubule formation in endothelial cells 
on Matrigel™ exposed to CGBG scaffolds after 6, 12 and 24 h. Scale bar is 100 µm. (B) Tubule 
length quantification from Matrigel™ assay indicating cobalt-eluting CGBG scaffolds led to 
enhanced tubule formation by cells compared to the BG-free CG control at 4 h (**P<0.01, 
*P<0.05 vs the CG control at 4 h and **P<0.01 vs the CG control at 12 h).  
 
5.3.3.2 Analysis of osteogenesis  
When pre-osteoblastic cell number was assessed, there was no significant 
difference in the presence of BG (Fig. 5.9A) compared to the BG-free CG scaffold at 
day 3. At days 7 and 14 the CG scaffold alone had the highest cell numbers compared to 
the CGBG scaffolds which displayed a reduction in cell number at days 7 (**P<0.01, 
*P<0.05) and 14 (***P<0.001). Importantly, cell numbers increased to a similar extent 
as the control over time indicating cellular proliferation on the scaffolds in the presence 
of cobalt-BG. Having demonstrated the ability of these constructs to support cell 
proliferation, the osteogenic activity of these cells was then measured by monitoring 
ALP production at day 7 (Fig. 5.9B). Significant effects of cobalt-BG incorporation in 
the scaffolds was observed at day 7 (*P<0.05) at which point ALP activity was shown 
to be upregulated (2.6 and 2.2-fold) in the presence of cobalt-eluting BG particles 
compared to both the BG-free CG scaffold and the cobalt-free CGBG scaffold. No 
difference in ALP expression was seen between the scaffolds incorporating different 
sized BG particles (38 µm vs 100 µm).  
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Fig. 5.9 Analysis of osteogenesis in collagen glycosaminoglycan-bioactive glass (CGBG) 
scaffolds. (A) Increase in cell number of preosteoblasts on CGBG scaffolds at 3 and 7 days post 
seeding. An initial seeding density of 500,000 cells was used per scaffold. *P<0.05 denotes 
significant increase vs CG scaffold with 38 and 100 µm cobalt-BG particles and 
**P<0.01denostes an increase vs cobalt-free CGBG scaffold at 7 days. ***P<0.001 vs CG 
scaffold at 14 days. (B) Alkaline phosphatase activity increased in the presence of cobalt-
eluting CGBG scaffolds (*P<0.05) compared with the BG-free CG scaffold and cobalt-free BG 
scaffold (CGBG (38 µm). 
 
Similarly, alizarin red staining after 28 days revealed enhanced calcium 
deposition within the BG-containing scaffolds compared to the CG scaffold alone (Fig. 
5.10A). Von kossa staining revealed a comparable trend with more intense calcium 
phosphate deposition in the CGBG groups when compared to the BG-free CG control 
(Fig. 5.10B). Cell-mediated calcium production from cells seeded on the scaffolds for a 
period of 14 days was then quantified (Fig. 5.10C). The results corroborated the staining 
results. Enhanced calcium deposition was reported in scaffolds containing cobalt-free 
BG (***P<0.001 CGBG (38 µm)) and, to a lesser extent cobalt-eluting BG. A 
significant increase was observed in the scaffolds containing smaller cobalt-BG 
particles (38 µm) compared to the CG control.  Taken together cobalt-BG previously 
shown to enhance angiogenic activity was also shown to enhance the osteogenic 
potential of the scaffold. 
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Fig. 5.10 Analysis of calcium and calcium phosphate deposition and calcium production in 
collagen glycosaminoglycan-bioactive glass (CGBG) scaffolds. (A) Bright field images of 
alizarin red stained scaffolds demonstrating enhanced staining by cells in the CGBG groups at 
day 28. Staining was most intense in cobalt-free BG groups. (B) Von kossa staining 
demonstrated similarly enhanced deposition when BG was present in the scaffold. Scale bar is 
500 µm. Similarly, calcium quantification (C) demonstrated an increase in calcium levels in 
CGBG scaffolds (**P<0.01) with the highest levels seen when larger BG particles were 
incorporated into the scaffolds (***P<0.001) compared to the CG scaffold at day 28. 
    
5.4. Discussion 
One of the main limitations in regenerative medicine is achieving functionally 
vascularised constructs that can integrate fully with the host tissue upon implantation 
[103]. Conventional approaches aimed at initiating angiogenesis and osteogenesis [99] 
involve the delivery of therapeutic growth factors and are associated with limitations as 
a result of uncontrolled delivery leading to potential safety concerns within a clinical 
setting [115]. Previous studies have used BG derived scaffolds as a platform for cobalt 
delivery as a potential neovascularisation strategy [273]. The focus of this study was to 
combine resorbable bioactive glasses doped with hypoxia-mimicking cobalt ions with a 
collagen-glycosaminoglycan scaffold optimised for bone tissue regeneration. The 
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results of these studies confirmed the enhanced potential of CG scaffolds incorporating 
cobalt-BG as a biomaterials based approach for bone repair. Inclusion of the bioactive 
glass microparticles (cobalt-eluting and non-eluting) not only improved the compressive 
modulus of the resulting scaffolds whilst maintaining high degrees of porosity but also 
induced a dual angiogenic and/or osteogenic responses from cells. These scaffolds may 
have significant potential in bone tissue regeneration applications since they do not 
require the use of growth factor delivery.  
Developing a fabrication process which could consistently achieve homogenous 
cobalt-eluting CGBG scaffolds was a significant initial challenge in this study. 
Bioactive glass bonds bone because of the formation of a hydroxyl carbonate apatite 
layer (HCA) layer on the glass surface following contact with body fluid thereby 
ensuring osteoconduction. The first step in this sequence of events is the rapid exchange 
of Na
+
 and Ca
2+
 from the glass with H
+
 or H3O
+
 from the solution causing hydrolysis of 
the silica groups which creates silanols. A silica hydrogel layer forms on the surface of 
the glasses and provides sites for apatite nucleation. The apatite nuclei form and grow 
by consuming calcium and phosphate ions from the body fluid that surrounds them to 
form HA crystals [62]. Consequently, the pH of the solution increases as a result of the 
H
+
 ions in the solution being replaced by cations [277] and, in this study, this initial 
increase caused some difficulties in incorporating the BG into the collagen slurry. Thus, 
the challenges were to (1) incorporate the BG and (2) to minimise the length of time it 
spent in the slurry to prevent the pH increasing and the slurry subsequently separating. 
Immediate, controlled cooling at a rate of 1
o
C/min was successfully used to synthesise 
subsequent scaffolds as it produced a homogenous pore structure. Previous work has 
combined BG with collagen sponges via a soak loading method but did not investigate 
the effects on scaffold properties [278]. However, directly incorporating BG into a 
preformed collagen slurry followed by lyophilisation to yield a particle loaded scaffold 
has thus far never been successfully achieved to the best of our knowledge. Despite the 
aforementioned difficulties, we successfully developed a method whereby cobalt 
containing BG particles could be incorporated into collagen-based scaffolds fabricated 
using an immediate, controlled lyophilisation technique. 
The addition of BG to the CG scaffolds led to improved mechanical properties. 
Higher compressive moduli were observed with increasing amounts of BG due to the 
reinforcing effect of the particles with the scaffold framework. The mechanical 
properties of a scaffold are of great importance particularly when regenerating hard 
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tissue and play a role in affecting cell behaviour [220]. This reinforcing effect of 
particles has previously been demonstrated in our laboratory with the incorporation of 
ceramic particles into collagen-based scaffolds [57, 279].  Encouragingly, the addition 
of the BG whilst improving mechanical properties did not have a consequent major 
detrimental effect on the high porosity of the CG scaffold, all scaffolds had porosities 
above 97 %, a level which has been shown to be beneficial for cell and vascular 
infiltration in scaffolds [41].  
The majority of research pertaining to the ability of BG to induce an angiogenic 
or osteogenic response from cells has been carried out by analysis of the soluble 
dissolution products of BG as reviewed by Hoppe et al., 2010 [6]. However, we sought 
to investigate the effects of BG incorporation in scaffolds on cells cultured in direct 
contact with these materials. Previous work has shown that incorporating cobalt into 
mesoporous BGs represents a viable option for promoting enhanced angiogenesis in 
human bone marrow stromal cells [273]. Since cobalt ions at high concentrations may 
cause cell toxicity, the controlled release of cobalt from BG is therefore a desirable 
approach for achieving concentrations pertinent to HIF-1α activation. The scaffolds 
developed in this study containing 7 mg BG/scaffold demonstrated successful release of 
cobalt ions within a biologically active concentration range (3-15 ppm). This range was 
previously determined to promote angiogenesis in vitro in osteoblasts and endothelial 
cells [130, 271, 280] and in vivo [133], well below cytotoxic levels [273, 281].   
Scaffolds containing the optimal BG particle dose (7 mg BG per scaffold) which 
did not negatively affect scaffold microarchitecture were thus carried forward for 
further in vitro analysis. The ability of these materials to promote VEGF gene and 
protein production from ECs was initially higher in scaffolds containing smaller BG 
particles (CGBG (38 µm) 4Co) compared to the other groups but was significantly 
enhanced at the later timepoint of 7 days in the presence of the larger BG particles. 
Hypoxia mediates a broad genetic programme including pro-regenerative responses 
such as expression of VEGF via the HIF-1α pathway [129]. In hypoxic environments 
HIF-1α is stabilized from routine normoxic proteasomal degradation and is translocated 
to the nucleus where it undergoes dimerisation with HIF-1β to induce pro-regenerative 
genes. As cobalt ions have been shown to mimic this effect by artificially stabilising 
HIF-1α, the enhanced angiogenic response observed here is attributed to the activation 
of the HIF pathway via cobalt eluted from the scaffolds – thereby confirming our initial 
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hypothesis. The mechanism of angiogenesis is coordinated by genes encoding for 
cytokines and growth factors such as VEGF. VEGF has been implicated as a critical 
regulator of neo vascularisation [119] and is also fundamental to the osteogenic 
response in bone healing where it is essential for intramembranous and endochondral 
bone formation [244].  
Encouragingly, the VEGF gene expression results were further corroborated by 
enhanced protein secretion from cells cultured on CGBG scaffolds.  CGBG scaffolds 
containing 100µm sized particles were found to significantly upregulate VEGF protein 
production (360 versus ~620 pg/mL by day 7) compared with the smaller particles after 
7 days of culture. This was further corroborated by enhanced tubule formation by ECs 
compared to the CG control with more pronounced tubule length formed by the cells in 
the presence of CGBG scaffolds containing larger BG particles versus smaller particles 
at 4 h. The different pattern of VEGF gene and protein production between the different 
sized BG particles may be attributed to the cobalt release profiles achieved, with smaller 
particles (38 µm) eluting cobalt and other ions at a faster rate than larger BG particles 
(100 µm). Since cobalt concentration is critical in the angiogenic response, the lower 
cobalt concentrations released from the larger BG particles may be more beneficial than 
high concentrations eluted from smaller BG particles since, cells exposed to more cobalt 
exhibited levels of gene and protein expression comparable to the negative control. 
VEGF protein secretion by cells was shown to decrease with time in the CG scaffolds 
whereas enhanced protein secretion was recorded from day 3 to day 7 in the BG loaded 
scaffolds. The half-life of endogenous VEGF mRNA increases during hypoxia [282] 
and this may explain why VEGF protein accumulates with time in cells exposed to 
cobalt containing composite scaffolds. Taken together, these results indicate a cobalt 
induced pro-angiogenic response which is in agreement with previous studies since 
cobalt has been shown to promote in vivo angiogenesis in a rat remnant kidney model 
via the HIF pathway [134] and in a rat bladder model [133]. The incorporation of 
cobalt-BG into CG scaffolds is therefore a promising biomaterials based approach 
aimed at inducing the hypoxic cascade to promote neovascularisation of scaffolds for 
the regeneration of bone tissue. 
The osteogenic potential of the BG-containing scaffolds was assessed and was 
shown to have considerable potential in actively promoting osteoblast differentiation via 
the induction of ALP in agreement with previous studies [283-285].  CG scaffolds [48, 
91] have previously been developed to serve as analogs of native extracellular matrix 
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[41, 286] for bone repair and it was hypothesised that in addition to enhancing the 
angiogenic potential of the scaffolds as above, the osteogenic abilities of the scaffold 
may be amplified by incorporating BG given its excellent osteoinductive properties 
[277]. Microarray analysis has also confirmed that solutions containing phosphate, 
silicon and calcium, the primary ionic dissolution products of BG, are capable of 
directly inducing genes relevant to osteoblast metabolism and the maintenance of ECM 
[285]. Cell number was first assessed and shown to be significantly reduced in the 
presence of BG. Ion-induced cell death such as from calcium [287] may account for the 
reduced cell numbers due to initial ion release from BG changing the pH of the 
surrounding media, an effect which is reduced in the in vivo environment. Importantly, 
ALP induction was enhanced in the presence of cobalt-eluting BG particles compared to 
the BG-free CG control and the cobalt-free CGBG scaffold irrespective of BG particle 
size. The calcium quantification results further corroborated the observations that 
scaffolds containing bioactive glass were capable of promoting differentiation of 
preosteoblasts.  Calcium deposition was enhanced in the presence of BG and to a lesser 
extent with cobalt-BG. Thus, CG scaffolds containing cobalt-BG particles may 
potentially provide a better environment for bone tissue formation or biosynthesis 
compared with the traditional CG scaffold both in terms of enhancing cell-mediated 
osteogenesis as well as being stronger due to the reinforcement provided by the BG 
particles. 
The delivery of tissue inductive factors in the form of cobalt-BG, from an 
osteoconductive substrate such as collagen-glycosaminoglycan scaffolds, offers 
considerable potential for enhanced bone tissue repair and regeneration due to the 
additive effects of biomolecules and biomaterial substrate. The importance of the 
interplay between angiogenesis and bone formation has previously been reported with 
several studies suggesting the synergism between the two processes leads to increased 
bone healing [171]. The presentation of multiple regulatory signals is essential for many 
tissue regeneration processes and may thus be a prerequisite for the design of more 
advanced tissue engineered materials going forward. BG particles with controllable ion 
release kinetics may serve as valid platforms for the tailored release of numerous ions 
for specific cellular or tissue responses such as silver ions (Ag-BG) which have 
antibacterial effects [288], strontium ions (Sr-BG) for increasing osteoblast activity 
[269] and zinc ions (Zn-BG) which have beneficial anti-inflammatory effects [289]. 
This indicates the significant potential of such composite materials with dual 
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functionality. Taken together, the results indicate for the first time that BG is capable of 
promoting osteogenic differentiation when combined with CG scaffolds. The dual 
potentiality of this composite system in upregulating angiogenic markers as well as 
osteogenic markers offers significant potential for bone repair. 
5.5. Conclusions 
 In this study, we have successfully combined novel hypoxia-mimicking cobalt 
containing bioactive glasses with collagen-glycosaminoglycan scaffolds optimised for 
bone repair. The results have demonstrated that these scaffolds may create a 
microenvironment capable of stimulating both angiogenesis and vascularisation via the 
release of cobalt, a known hypoxia mimic, as well as osteogenesis via the incorporation 
of osteoinductive bioactive glass particles in collagen-glycosaminoglycan scaffolds. 
Overall, this study indicates that an angiogenic response may be achievable exclusively 
through a growth factor-free biomaterials based approach leading to the development of 
dual osteoinductive and angiogenic scaffolds with enhanced capacity for bone repair. 
Ultimately this delivery system may be adopted as a platform for the controlled release 
of an array of economically viable and biologically stable therapeutic ions depending on 
the intended application, making them attractive candidates for tissue engineering. 
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Chapter 6: Discussion 
6.1 Overview  
In tissue engineering (TE), the delivery of growth factors (GFs) to the defect site 
represents a therapeutically powerful approach which has been applied to skin 
restoration, neovascularisation and for enhancing bone tissue regeneration. Since the 
effective repair of tissues involves the action of GFs for durations of days to weeks, a 
simplistic yet ineffective way to achieve this has been to deliver supraphysiological 
doses of GFs. However, the conventional routes of administration using systemic bolus 
injections or infusions of aqueous formulations of recombinant human (rh) GFs to the 
target tissue [99, 123, 124] are associated with numerous limitations. The short half-
lives of GFs, slow tissue penetration, and potential toxicity in non-target tissues at high 
doses suggest these routes of GF delivery are unlikely to be successful [99, 121-124]. 
For bone TE, scaffolds are increasingly being designed to contain intrinsic bioactivity 
mediated by the release of GFs and other therapeutic biomolecules. The current gold 
standard of GF delivery from a matrix to enhance bone repair is Medtronic’s INFUSE® 
which delivers osteoinductive bone morphogenetic protein (rhBMP-2). However the 
inability to control BMP-2 delivery leads to insufficient local retention requiring high 
doses of costly GFs to exert a biological effect. These supraphysiological doses often 
result in undesired side-effects in off-target tissues [290]. Hence, a delivery system 
which controls the release of GFs in a spatiotemporal manner is a desirable therapeutic 
approach to achieve enhanced healing. As such, a vast array of scaffolds of various 
compositions have emerged to this aim, from ceramics to natural and synthetic 
polymers [44]. The overall goal of this research was to develop a new generation of 
scaffolds by functionally enhancing collagen-based scaffolds specifically optimised for 
bone repair in order to make them capable of coupling both angio- and osteogenesis and 
thus enhance their regenerative capacity.  
Collagen-based scaffolds have been utilised for bone TE specifically since 
collagen has been shown to influence osteoblast differentiation and bone formation [83, 
291, 292]. A series of collagen-based matrices have been optimised in our Tissue 
Engineering Research Group at RCSI, specifically collagen-hydroxyapatite (CHA) and 
collagen-glycosaminoglycan (CG) scaffolds and have proved to provide excellent 
platforms for bone repair [41, 57, 264, 293]. However, inherent limitations with 
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scaffold-based TE approaches include: 1) the requirement for an additional stimulus to 
enhance healing of large fractures and 2) the lack of vasculature within TE scaffolds to 
enable sufficient engraftment and integration within the host [103]. In the context of 
producing superior bone graft substitutes, the major objective of this thesis was to 
develop functionally enhanced collagen-based scaffolds overcoming these limitations 
by the controlled release of pro-osteogenic BMP-2 and pro-angiogenic vascular 
endothelial growth factor (VEGF). Consequently, the development of a controlled 
release delivery system for these specific GFs was explored as the major theme guiding 
this thesis. This was achieved by loading these GFs in polymeric microparticles (MPs) 
that were then incorporated into the scaffolds. As a viable alternative, the pro-
angiogenic and pro-osteogenic potential of a GF-free biomaterial was also investigated 
in this thesis. This was achieved by loading cobalt-doped bioactive glass (BG) MPs for 
the controlled release of pro-angiogenic cobalt ions, into a collagen-based scaffold. 
Chapter 2 of this thesis focuses on the fabrication of MPs for the sustained 
delivery of both rhBMP-2 and rhVEGF. This chapter established feasible preparation 
methods for GF-eluting MPs composed of non-cytotoxic, biodegradable carrier 
materials. It was shown that poly (lactic-co-glycolic acid) (PLGA) MPs fabricated by 
double emulsion and spray dried alginate MPs were capable of not only controlling the 
release of two of the main GFs pertinent to bone repair for up to 28 days but retaining 
their bioactivity following the various processing parameters. Additionally, these 
studies demonstrated that it is possible to tailor the release kinetics of GFs by using 
different polymers for encapsulation.   
The aim of Chapter 3 was to develop a functionalised CHA scaffold by the 
incorporation of the controlled release GF delivery systems optimised in Chapter 2 and 
to characterise the resulting scaffold in terms of microarchitecture, GF release kinetics 
and in vitro bioactivity. With this in mind, Chapter 3 explored the effect of the 
incorporation of the MPs over compressive modulus, pore diameters and porosity of the 
scaffolds. These studies demonstrated that, with an optimised fabrication process, it was 
possible to develop GF-releasing scaffolds containing MPs without interfering with the 
structural properties of the scaffolds which had already been optimised for bone repair. 
Additionally, sustained release of GFs from the scaffolds over an extended period of 
time was demonstrated with kinetics resembling the in vivo condition; that is the early 
expression of VEGF from alginate MPs followed by later more sustained release of 
BMP-2 from PLGA MPs [225]. Importantly, since the success of GF delivery systems 
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depends on the ability to present GFs not only at the required continuous concentrations 
to induce a bioactive response from cells but in an active form, it was shown that 
bioactivity of both BMP-2 and VEGF was maintained and scaffolds were capable of 
inducing pro-angiogenic and pro-osteogenic responses. 
Subsequently, Chapter 4 saw the in vivo assessment of GF-eluting scaffolds 
containing either VEGF or BMP-2 encapsulated in the optimal GF/MP formulations 
concluded from Chapter 3. Since some studies suggest that dual release of GFs leads to 
a synergistic effect on bone healing [172, 231, 245], this study attempted to recapitulate 
this biomimetic approach also by studying the regenerative capacity of a dual scaffold 
releasing both GFs. This study was carried out by implanting functionalised scaffolds 
into critical size defects in rat calvariae and assessing the level of healing 4 or 8 weeks 
post-implantation. The results showed that all scaffolds showed some degree of defect 
healing, but, somewhat unexpectedly, the alginate-VEGF scaffold explicitly 
demonstrated elevated angiogenic responses resulting in appreciable bone healing 
representing an excellent platform for bone repair.  
To complete this thesis, an alternative approach to enhancing bone repair was 
adopted. The aim was to develop and characterise a growth factor-free collagen-based 
scaffold incorporating pro-angiogenic and pro-osteogenic cobalt-bioactive glass 
microparticles and to assess the in vitro ability of the scaffold to promote osteogenesis 
and angiogenesis (Chapter 5). In order to achieve this pro-angiogenic and pro-
osteogenic cobalt-doped bioactive glass (BG) was incorporated into a collagen-
glycosaminoglycan (CG) scaffold. The slow dissolution rates of silica-based BG served 
to effectively control the delivery of ions negating any potential cytotoxic effects of 
their uncontrolled release. Consequently, it was shown that cobalt-releasing CG 
scaffolds promoted in vitro angiogenesis as well as stimulating osteogenesis via the 
release of ions from the dissolution of BG particles.  
The following sections will summarise the key findings and implications from 
each individual chapter and review the possible future directions which have arisen 
from this research. 
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6.2 Chapter 2: Polymeric alginate and PLGA microparticles as 
carriers for the controlled release of BMP-2 and VEGF in bone tissue 
engineering 
 
A growing body of evidence suggests that biodegradable polymeric 
microparticles (MPs) can be used to control the release of the otherwise rapidly 
degraded GFs. With this in mind, in this chapter, PLGA and alginate MPs were 
investigated as delivery vehicles for the most pertinent GFs in bone repair, BMP-2 and 
VEGF. These polymers have many possible applications in the area of drug delivery 
and controlled release since they are biocompatible, biodegradable and easily applied to 
a variety of in vivo locations [143]. In this chapter, the amenability of PLGA MPs 
prepared by double emulsion and alginate MPs fabricated by spraydrying to encapsulate 
high doses of GF while retaining their bioactivity, was firstly investigated. Secondly, 
the release kinetics of BMP-2 and VEGF from the MPs was examined, with the 
hypothesis that polymeric MPs may serve to sustain GF release and promote different 
release kinetics depending on the polymer used. 
An assessment of MP characteristics revealed the potential of spray-dried 
alginate MPs to effectively encapsulate BMP-2 and VEGF with efficiencies >45 %. 
PLGA MPs prepared by the double emulsion method were also shown to effectively 
encapsulate BMP-2 and VEGF with efficiencies >84 %. In addition, the size of alginate 
and PLGA MPs, distributed in the range of 1-10 and 1-8 µm respectively, facilitated 
better dispersion and incorporation into scaffolds compared to larger particles. It was 
shown that the kinetics of protein release varied depending on the polymer of choice. 
Alginate displayed high, early concentrations of GF release whereas PLGA displayed 
an initial burst release profile followed by a lower sustained pattern of delivery 
thereafter. These results show that PLGA can be used for the long-term, sustained 
release of bioactive concentrations of GF whereas alginate is more suited to achieving 
higher concentrations at early timepoints. Both polymers released GF concentrations 
above the lower limits required for in vitro differentiation of pre-osteoblasts [193] and 
endothelial cells (ECs) [191].  
Essentially successful formulations for encapsulating therapeutics must maintain 
the chemical and physical stability of GFs delivering them in an active form. The GF 
must remain active in a number of environments including: in chemical solvents often 
employed during the fabrication process, within the release system itself and within the 
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biological environment of the application site. Indeed some studies have reported that 
protein bioactivity can be compromised via a number of these stresses including but not 
limited to shear, interfacial, and thermal stresses. In this study, VEGF functionality 
following release from MPs was confirmed as it continued to act as a mitogen for 
endothelial cell (EC) proliferation as well as promoting tubule formation, a critical 
regulator of the angiogenic process. Furthermore, BMP-2 was shown to retain its 
integrity post-processing as it demonstrated bioactive potential to upregulate an early 
marker for osteogenic differentiation in preosteoblasts.  
In summary, this chapter showed that it is possible to encapsulate BMP-2 and 
VEGF in alginate and PLGA MPs respectively. Importantly, this chapter describes, for 
the first time, that spray-dried alginate MPs may effectively encapsulate and sustain the 
release of bioactive BMP-2 and VEGF, GFs pertinent to bone repair. These optimised 
carriers were then incorporated into CHA scaffolds for controlling the release of the 
GFs from the matrix (Chapter 3). 
6.3 Chapter 3: Functionalisation of a collagen-hydroxyapatite scaffold 
via the delivery of BMP-2 and VEGF from polymeric microparticles 
 
Several scaffold-based systems either naturally or synthetically derived have 
been developed to deliver GFs to target cells for bone TE [76, 145, 294]. A viable 
approach to achieve this controlled delivery system is by incorporating GF-eluting MPs 
within the scaffolds. These GF-releasing scaffolds have demonstrated functionality in 
previous studies effectively protecting the proteins from the chemical and physical 
extremes incurred during the manufacturing process as well as stresses incurred in vivo 
[145, 173, 295]. With this in mind, this chapter sought to functionalise and characterise 
a highly porous CHA scaffold, which facilitates bone regeneration in two pre-clinical 
models [57, 59] as well as promoting osteogenesis via its innate osteoinductivity [57], 
by including GF-eluting MPs detailed in Chapter 2.   
A series of experiments were carried out to ensure that the incorporation of the 
MPs led to a scaffold which would: a) maintain its structural properties following MP 
incorporation b) regulate GF release at required continuous concentrations to induce the 
specific bioactive responses from cells and c) maintain bioactivity of the therapeutic. 
With this in mind, following the successful optimization of a multi-step fabrication 
process for incorporating GF-loaded MPs over a range of concentrations (0.5-2.2 % 
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w/v), the structural properties of the scaffolds were analysed Analysis of scaffold 
microarchitecture showed that the materials remained highly porous (>97 %) with 
interconnected pore structures irrespective of MP concentrations. This feature is vital 
for cell infiltration, nutrient and waste diffusion and to prevent avascular necrosis [44]. 
In addition, the incorporation of the MPs led to scaffold pore sizes within the optimum 
range (>75 µm) reported to allow significant bone growth [50]. Consequently, from this 
chapter an optimal functionalised scaffold was obtained with a concentration of a) 0.5 % 
and/or b) 2.2 % w/v alginate and PLGA MPs respectively. 
The investigation of GF release kinetics determined that the delivery of BMP-2 
and VEGF from the functionalised scaffolds differed depending on the polymer in 
which the GFs were incorporated but the kinetics of release were relevant to bone 
healing in vivo. Specifically, alginate-VEGF scaffolds released high concentrations of 
VEGF for up to 7 days which has previously been shown to enhance neovascularisation 
[102, 119, 192]. Additionally, BMP-2 release from PLGA-BMP-2 scaffolds was shown 
to peak around day 21 which correlates with normal expression profiles during bone 
repair for this GF [201].  
It is essential that a scaffold-based GF delivery system maintains the bioactivity 
of the load, protecting the protein from denaturation via proteases as well as oxidative 
stresses from the surrounding environment [174]. The in vitro bioactivity studies 
demonstrated maintenance of VEGF integrity following its release from scaffolds. 
Interestingly, VEGF eluted from the alginate-VEGF scaffold was shown to be not only 
functional but more potent than the VEGF control, non-eluted VEGF. Similarly, BMP-2 
bioactivity studies demonstrated that released BMP-2 maintained its integrity post-
processing since it upregulated an early osteogenic differentiation marker in 
preosteoblasts. This study revealed that although both polymers maintained the 
bioactivity of the GF to some extent, alginate was less effective in preserving BMP-2 
bioactivity compared to PLGA within the scaffold.  
The biomaterials developed in this chapter, particularly the PLGA-BMP-2 
scaffold, present three main advantages when compared with the commercially 
available rhBMP-2-releasing sponge, INFUSE®: 1) it provides the spatiotemporal, 
controlled release of GFs. 2) It requires an equivalent of 20 times less GF to achieve 
bioactive concentrations at the defect site compared to the high doses in INFUSE® 
(50 μg per 7 mm) [9, 296]. 3) Furthermore, it is potentially an off-the-shelf sustainable 
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GF depot system which would not require surgical manipulation in comparison to 
INFUSE® which requires the surgeon to prepare the material prior to implantation.  
In summary, this study reports a multi-step process for combining the GF-loaded 
MPs fabricated in Chapter 2 with a CHA scaffold previously optimised for bone repair. 
The fabrication process for scaffold functionalisation uses well established techniques 
and mild processing conditions with the potential to be readily scalable to industrial 
levels and easily tailored. These scaffolds were shown to be highly porous, with suitable 
properties for bone TE purposes. Furthermore, the results revealed the suitability of the 
functionalised scaffolds to sustain bioactive VEGF or BMP-2 elution for up to 28 days 
with kinetics of release resembling their normal in vivo expression during bone repair. 
Overall, the functionalised scaffolds developed in this chapter suggest an ideal platform 
to promote vasculogenesis and osteogenesis within bone defects in vivo.  This was 
assessed in Chapter 4 of the thesis. Since bone repair involves the synergistic interplay 
of multiple GFs, a dual releasing scaffold was also investigated which combined the 
optimised polymer MP/GF combinations within the same matrix, i.e., PLGA (BMP-2) 
and alginate (VEGF) MPs.  
6.4 Chapter 4: In vivo evaluation of a series of BMP-2/VEGF releasing 
collagen-hydroxyapatite scaffolds for bone repair 
 
This chapter investigated the healing potential of the functionalised scaffolds 
developed in Chapter 3. With this aim in mind, a comparative in vivo assessment of the 
angiogenic and osteogenic potential of GF-eluting scaffolds (alginate-VEGF and 
PLGA-BMP-2) compared with non-eluting scaffolds and non-treated controls, was 
performed in a critically sized rat calvarial defect. Since fracture healing is under the 
regulation of multiple GFs, a biomimetic approach involving a dual scaffold eluting 
both GFs (dual loaded) was also investigated.  
Results from this chapter demonstrated that the alginate-VEGF scaffold 
successfully increased bone regeneration in comparison to an empty defect and GF-free 
scaffold at 4 and 8 weeks post-implantation. This result is consistent with previous 
reports which show enhanced bone repair in critically sized defects implanted with 
VEGF-releasing biomaterials [101, 250-252]. This outcome can be attributed to the role 
of VEGF in ossification by permitting neovascularisation of defects as well as by 
directly affecting bone cells. VEGF has a chemoattractive effect on osteoblasts and 
165 
 
mesenchymal progenitor cells and stimulatory effect on osteoblast differentiation [120, 
297, 298]. In addition, after 8 weeks an increase in de novo blood vessel formation, as 
well as maturity of vessels was recorded when defects were treated with alginate-VEGF 
scaffolds. As such, it was demonstrated that VEGF released from the scaffold is 
sustained at concentration gradients sufficient to lay down a vascular network which 
increments blood flow in the defect site thereby increasing vascular permeability [119]. 
In addition, the results showed that PLGA-BMP-2 scaffolds increased bone formation 
compared to the empty defect. However, this increase was not as significant as expected 
considering BMP-2 released from PLGA has been shown to be osteoinductive [163, 
164, 253, 254]. This inconsistency may have its origin in: 1) the BMP-2 dose which was 
lower than previous reports, 2) the lack of burst release of BMP-2 from the scaffold, 
considered beneficial in some studies to recruit osteoprogenitor cells and 3) the slow 
degradation rate of the scaffold. Interestingly, the results demonstrated that dual GF-
releasing scaffolds did not notably enhance bone healing compared to the single GF-
releasing scaffolds. These results corroborate a previous report which studied the pro-
osteogenic potential of a dual GF-releasing material which showed the absence of a 
synergistic long-term effect of the combination of BMP-2 and VEGF over single GF 
delivery [257]. 
Thus, controlled VEGF release led to increased vessel density and vessel 
maturation, increasing accessibility of osteoprogenitors to the defect site and osteogenic 
differentiation, the overall effect resulting in considerable de novo bone formation and 
early bone healing of a critically sized bone defect. This novel functionalised scaffold 
offers the primary advantage of off-the-shelf availability and lacks the need to for in 
vitro cell culture. In addition, the process optimised to functionalise these scaffolds may 
offer an ideal platform to promote angiogenesis and tissue regeneration for a wide 
variety of applications in addition to bone since it can be tuned and applied to any 
freeze-dried protein-based scaffold for TE. Thus, this system has an enormous potential 
in regenerative medicine, as it could be altered in terms of the composition of the 
collagen-based scaffold and released therapeutic to be optimized for the healing of very 
diverse organs. 
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6.5 Chapter 5: Development of a collagen-glycosaminoglycan/bioactive 
glass composite scaffold for the release of pro-angiogenic cobalt ions to 
enhance in vitro angiogenesis and osteogenesis 
 
Despite the significant advances in the development of controlled delivery 
systems for biomolecules such as those described in the present thesis, there are 
unresolved issues regarding the clinical use of GFs. Among them, the lack of 
confidence from surgeons, regulatory bodies and the wider community in the long-term 
in vivo safety and efficacy of these biomolecules represent hurdles for clinical 
translation of bone biomaterials [115]. Ions are being considered as possible alternatives 
to GFs and genetic approaches in TE because they remain stable under typical scaffold 
processing techniques and at high temperatures and they are easily processed as well as 
being more cost-effective [12]. The aim of this chapter was to develop and characterise 
a growth factor-free collagen-based scaffold incorporating pro-angiogenic and pro-
osteogenic cobalt-bioactive glass microparticles and to assess the in vitro ability of the 
scaffold to promote osteogenesis and angiogenesis.  
With this aim, cobalt ions were employed as the therapeutic biomolecule since 
they have the potential to mimic the Hypoxia Inducible Factor (HIF-1α) cellular 
pathway, artificially stabilising HIF-1, resulting in the activation angiogenesis-related 
genes including VEGF [131]. However, it is essential that the in vivo release of cobalt 
ions is controlled in order to negate any potential cytotoxic effects at high 
concentrations (>20 ppm) [273]. A well known platform for controlled delivery of ions 
is bioactive glass (BG) [6]. In this sense, cobalt-eluting BG has recently been developed 
for the sustained release of pro-angiogenic cobalt ions [132, 299]. In addition, BG has 
been shown to upregulate numerous osteogenic genes known to have anabolic responses 
in bone metabolism [269, 270, 285]. Due to their osteoconductivity and 
osteoinductivity, BGs have previously been incorporated with polymer scaffolds to 
enhance their mechanical properties as well as to guide bone regeneration [300]. With 
this in mind, it was thought that a novel collagen-based scaffold incorporating cobalt-
eluting BG may lead to dual angiogenic and osteogenic responses from cells. 
Specifically, a collagen-glycosaminoglycan (CG) scaffold previously optimized within 
our laboratory for bone repair was chosen as opposed to CHA scaffolds from Chapters 3 
and 4. CG scaffolds may better facilitate the purposes of this study as they lack a 
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ceramic HA phase which may potentially conceal the beneficial effects of 
osteoinductive BG within the matrix and fill the collagen material with excess ceramic.  
 Initially, a series of preliminary experiments were conducted to establish the 
optimal scaffold fabrication process to successfully introduce BG MPs into the CG 
scaffolds while maintaining their microstructural integrity. As such, several 
experimental variables were explored including: a) the scaffold lyophilisation technique, 
b) the optimal concentration of BG MPs and c) size of cobalt-eluting and non-eluting 
BG MPs to include. The effect of these variables over the pore structure, compressive 
moduli and porosity of the scaffolds was examined. Results showed that the addition of 
BG led to improved scaffold mechanical properties due to the reinforcing effect of the 
ceramic MPs, which has been shown previously [57, 279]. Furthermore, MP 
incorporation maintained the porosities of the scaffolds at levels which have been 
shown to be beneficial for cell and vascular infiltration in scaffolds [41].  
 Since cobalt ions may cause cell toxicity at high concentrations, a release study 
was performed to assess the optimal MP loading to achieve therapeutically relevant 
cobalt delivery. This concentration of BG incorporated into the CG scaffolds released 
cobalt ions within a non-cytotoxic [273, 281], biologically active concentration range of 
3-15 ppm (half maximal inhibitory concentration (IC50) = 20 ppm). This range has 
previously been shown to promote angiogenesis in osteoblasts and ECs in vitro [130, 
280, 301] and in vivo [133].  
 The bioactivity studies indicated that the cobalt-eluting scaffolds were capable 
of promoting VEGF gene expression and protein production from ECs cultured in direct 
contact with the materials while enhancing their tubule formation potential. In addition 
with their angiogenic potential, this chapter also reported on the ability of cobalt-eluting 
and non-eluting BG MPs to enhance the osteogenic properties of the CG scaffold. This 
was evidenced by increased differentiation of osteoblasts cultured on the cobalt-BG 
containing scaffolds compared to a BG-free CG control. In addition, the scaffolds 
containing BG and to a lesser extent cobalt-BG MPs were capable of promoting 
enhanced calcium production and deposition. Thus, cobalt-eluting CGBG scaffolds may 
potentially provide a better environment for bone tissue formation compared with the 
traditional CG scaffold given that they enhanced cell-mediated osteogenesis as well as 
providing a more structurally reinforced template for tissue formation. 
In summary, this study demonstrates that incorporation of cobalt-BG into CG 
scaffolds represents a promising approach aimed at inducing the hypoxic cascade to 
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promote neovascularisation of scaffolds for the regeneration of bone tissue. In addition, 
the inclusion of the BG particles not only improved the compressive moduli of the 
resulting scaffolds whilst maintaining high degrees of porosity but also induced an 
osteogenic response in vitro. This GF-free biomaterials based approach represents a 
promising alternative to the GF-eluting scaffolds investigated in Chapter 2-4 of this 
thesis. 
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Chapter 7: Final conclusions 
 
This work has led to the successful development of novel spray-dried alginate 
MPs and PLGA MPs fabricated by double emulsion capable of GF-elution by 
optimizing well established methods. The release of VEGF and BMP-2 from the MPs 
was controlled and sustained for prolonged periods of time and the integrity and 
bioactivity of both proteins were maintained following encapsulation and release from 
the MPs. Whatsmore alginate microparticles fabricated by spray-drying were shown for 
the first time to encapsulate and release BMP-2 and VEGF. A multi-step process was 
developed for combining GF-loaded MPs within CHA scaffolds to fabricate 
bioactivated matrices. A comparative assessment of scaffold structure, GF release 
kinetics and bioactivity showed that as well as possessing desirable pore structures and 
mechanical properties for TE, these scaffolds were capable of the sustained release of 
bioactive VEGF from alginate and BMP-2 from PLGA MPs from within the matrix 
over 28 days. The kinetics of release resembled the in vivo condition; early expression 
of VEGF and later, sustained release of BMP-2, thus enhancing the functionality and 
regenerative capacity of the CHA scaffold. These functionalised CHA scaffolds eluting 
VEGF and/or BMP-2 demonstrated enhanced healing compared to non-eluting scaffolds 
as well as non-treated animals when implanted in rat calvarial defects. VEGF-releasing 
CHA scaffolds accelerated healing to a greater extent than all other scaffolds offering an 
ideal, novel platform to promote vasculogenesis and osteogenesis of bone defects in 
vivo. In addition, a GF-free biomaterial alternative, a novel hypoxia-mimicking scaffold 
was successfully fabricated by the incorporation of cobalt-eluting bioactive glass 
particles into a CG scaffold. This material offers the benefits of economics as well as 
efficacy as it was capable of stimulating angiogenesis in vitro via the release of cobalt 
as well as osteogenesis via the dissolution of osteoinductive BG particles. This study 
indicated that an angiogenic and osteogenic response may be achievable exclusively 
through a growth factor-free biomaterials based approach leading to the development of 
dual osteoinductive and angiogenic scaffolds with enhanced capacity for bone repair.  
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7.1 Future work 
 An assessment of bone healing over a longer timepoint of 12 weeks may provide 
insights into the ability of the GF-releasing scaffolds to promote enhanced bone 
repair at longer timepoints. Additionally, this study would provide insights into 
the potential of these materials to promote bone remodeling which occurs at 
later stages during normal bone fracture repair. The level of bone healing 
achievable in larger animal models would provide insights into the translational 
capabilities of the functionalised scaffolds. Additional in vivo studies would be 
of interest particularly the potential of the alginate-VEGF scaffold to repair long 
bone defects such as in a femoral defect model. 
 
 This work has laid the foundation for a number of other studies relating to the 
direct incorporation of BMP-2 into the scaffold. Preliminary findings 
demonstrate the viability of this approach to achieve sustained release of BMP-2 
over extended periods via an interaction with HA present in the scaffold [302]. 
Results up to date show a significant enhancement in de novo bone formation. 
This MP-free approach to BMP incorporation into scaffolds has also been 
investigated in combination with VEGF-eluting MPs developed herein. The in 
vivo assessment on the pro-angiogenic and pro-osteogenic efficacy of this 
material is currently underway. 
 
 Chapter 2 of this thesis demonstrated the potential to release VEGF and BMP-2, 
GFs pertinent to bone repair. However, the functionalised scaffolds could be 
adapted for other applications through the encapsulation of other GFs. For 
example by exchanging VEGF or BMP-2 for pro-chondrogenic proteins TGF-β 
or IGF-1, this GF-releasing system could be applied for cartilage regeneration 
[303]. Additionally, this system could be further adapted to enhance 
angiogenesis by incorporating PDGF which functions to stabilize de novo 
vessels [304]. Freeze-dried collagen-based scaffolds are currently being used for 
the regeneration of a wide range of tissues in our lab for ocular, neural, 
respiratory and cardiovascular (critical limb ischemia, myocardial infarction and 
heart valves and blood vessels) applications. Thus, this system could be tuned in 
terms of the composition of the collagen-based scaffold as well as released 
therapeutic to heal other organs.  
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 Biodegradable polymers have been employed as carriers for the controlled 
delivery of a vast array of proteins and drugs [143]. The MP delivery system 
developed in this study therefore has the potential to be used in combination 
with other biomolecules such as GF-mimicking therapeutics in the form of short 
peptides or fragments of GFs representing a viable, cost-effective alternative to 
GFs. For instance, in the context of bone remodelling, a promising alternative 
approach would be the utilization of PTH 1-34. This fraction of protein has been 
shown to be effective in preventing fractures in postmenopausal women with 
osteoporosis due to its ability to stimulate bone formation and increase bone 
mass [305]. Also, the pentapeptide PTHrP 107-111, well known for its 
antiosteoclastic properties, has also been shown to increase the proliferation of 
osteoblasts and exert osteogenic activity [306, 307]. In essence, these peptides 
represent an economic alternative to the utilization of GFs and can have similar 
binding affinities to their respective receptors as GFs. An investigation into the 
utility of this system to release these peptides is currently ongoing in our labs. 
 
 The considerable potential of CGBG scaffolds to enhance in vitro angiogenesis 
or osteogenesis was demonstrated. An in vivo assessment of the potential of this 
scaffold to enhance bone repair when implanted in critically sized defects may 
provide insights into the therapeutic potential of a GF-free biomaterials based 
approach to bone healing. Furthermore, this GF-free material could be directly 
compared to GF-releasing scaffolds for their in vivo functionality given that the 
former is more preferable from a regulatory perspective.  
 
 Considering the risk of infection following implantation of a TE construct an 
alternative prophylactic strategy for sensitive biomaterials could be to deliver 
antibacterial ions from scaffolds for tissue regeneration. The composition of BG 
can be modified to contain silver, incorporated as a network modifier, which is 
known to have antibacterial properties [308, 309]. As shown in this thesis, by 
the incorporation of silver-doped BG particles into the scaffold, this ion would 
be released in a sustained fashion during cation exchange following glass 
dissolution, similar to cobalt. This approach may represent a promising 
alternative to the traditional utilization of antibiotics. 
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